-
曾紀(jì)洲主任醫(yī)師 北京潞河醫(yī)院 骨關(guān)節(jié)外科 激素使用對(duì)股骨頭骨壞死發(fā)生和進(jìn)展的影響:一項(xiàng)全國(guó)性巢式病例對(duì)照研究（2024）EffectofCorticosteroidUseontheOccurrenceandProgressionofOsteonecrosisoftheFemoralHead:ANationwideNestedCase-ControlStudy?KwonHM,HanM,LeeTS,JungI,SongJJ,YangHM,LeeJ,LeeSH,LeeYH,ParkKK.EffectofCorticosteroidUseontheOccurrenceandProgressionofOsteonecrosisoftheFemoralHead:ANationwideNestedCase-ControlStudy[J].JArthroplasty,2024轉(zhuǎn)載文章的原鏈接1：https://pubmed.ncbi.nlm.nih.gov/38830431/轉(zhuǎn)載文章的原鏈接2：https://www-clinicalkey-com-443.vpnm.ccmu.edu.cn/#!/content/journal/1-s2.0-S0883540324004595?AbstractBackgroundAlthoughitisverywellknownthatcorticosteroidscauseosteonecrosisofthefemoralhead(ONFH),itisunclearastowhichpatientsdevelopONFH.Additionally,therearenostudiesontheassociationbetweencorticosteroiduseandfemoralheadcollapseinONFHpatients.WeaimedtoinvestigatetheassociationbetweencorticosteroiduseandtheriskofONFHamongthegeneralpopulationandwhatfactorsaffectONFHoccurrence.Additionally,weaimedtodemonstratewhichfactorsaffectfemoralheadcollapseandtotalhiparthroplasty(THA)afterONFHoccurrence.雖然眾所周知，皮質(zhì)類固醇會(huì)導(dǎo)致股骨頭骨壞死(ONFH)，但目前尚不清楚哪些患者會(huì)發(fā)生ONFH。此外，沒(méi)有關(guān)于皮質(zhì)類固醇使用與ONFH患者股骨頭塌陷之間關(guān)系的研究。我們的目的是調(diào)查普通人群中皮質(zhì)類固醇使用與ONFH風(fēng)險(xiǎn)之間的關(guān)系，以及影響ONFH發(fā)生的因素。此外，我們旨在證明哪些因素影響ONFH發(fā)生后股骨頭塌陷和全髖關(guān)節(jié)置換術(shù)(THA)。?MethodsAnationwide,nestedcase-controlstudywasconductedwithdatafromtheNationalHealthInsuranceServicePhysicalHealthExaminationCohort(2002to2019)intheRepublicofKorea.WedefinedONFH(N=3,500)usingdiagnosisandtreatmentcodes.PatientswhohadONFHwerematched1:5toformacontrolgroupbasedonthevariablesofbirthyear,sex,andfollow-upduration.Additionally,inpatientswhohaveONFH,welookedforriskfactorsforprogressiontoTHA.使用韓國(guó)國(guó)民健康保險(xiǎn)服務(wù)機(jī)構(gòu)身體健康檢查隊(duì)列(2002年至2019年)的數(shù)據(jù)進(jìn)行了一項(xiàng)全國(guó)性的巢式病例對(duì)照研究。我們使用診斷和治療代碼定義ONFH(N=3,500)。根據(jù)出生年份、性別、隨訪時(shí)間等變量對(duì)ONFH患者進(jìn)行1:5匹配，形成對(duì)照組。此外，在患有ONFH的患者中，我們尋找進(jìn)展為THA的危險(xiǎn)因素。?ResultsComparedwiththecontrolgroup,ONFHpatientshadalowhouseholdincomeandhadmorediabetes,hypertension,dyslipidemia,andheavyalcoholuse(drinkingmorethan3to7drinksperweek).Systemiccorticosteroiduse(≥1,800mg)wassignificantlyassociatedwithanincreasedriskofONFHincidence.However,lipidprofiles,corticosteroidprescription,andcumulativedosesofcorticosteroiddidnotaffecttheprogressiontoTHA.與對(duì)照組相比，ONFH患者家庭收入較低，糖尿病、高血壓、血脂異常和重度飲酒(每周飲酒超過(guò)3至7天)的發(fā)生率更高。全身使用皮質(zhì)類固醇(≥1800mg)與ONFH發(fā)生率增加顯著相關(guān)。然而，脂質(zhì)譜、皮質(zhì)類固醇處方和皮質(zhì)類固醇累積劑量對(duì)進(jìn)展到THA沒(méi)有影響。?ConclusionsTheONFHriskincreasedrapidlywhencumulativeprednisoloneusewas≥1,800mg.However,oralorhigh-doseintravenouscorticosteroiduseandcumulativedosedidnotaffecttheprognosisofONFH.SincetheoccurrenceandprognosisofONFHarecomplexandmultifactorialprocesses,furtherstudyisneeded.當(dāng)累積使用潑尼松龍≥1800mg時(shí)，ONFH風(fēng)險(xiǎn)迅速增加。然而，口服或大劑量靜脈注射皮質(zhì)類固醇和累積劑量不影響股骨頭壞死的預(yù)后。由于股骨頭壞死的發(fā)生和預(yù)后是一個(gè)復(fù)雜的多因素過(guò)程，需要進(jìn)一步研究。?Osteonecrosisofthefemoralhead(ONFH)maycauseseverehippain,andcanultimatelyleadtocollapseofthefemoralheadandsubsequentrapiddestructionofthehipjointinrelativelyyoungpatients[1-3].Intractablepaincausedbyfemoralheadcollapseeventuallyleadstototalhiparthroplasty(THA)atayoungage[4,5].Althoughtrauma,theuseofcorticosteroid,andexcessivealcoholintakearewell-knownriskfactorsforONFH,theetiologyofONFHremainsmultifactorial,andnoconsensusexistsonthecommonpathophysiology[6-9].Impairedperfusionofbloodtobone,abnormalcellularreparativeprocesses,andgeneticpointmutationsarepresumedtoaffectONFHoccurrence,butithasnotyetbeenclarified[10-12].股骨頭壞死(Osteonecrosisoffemoralhead,ONFH)可引起嚴(yán)重的髖關(guān)節(jié)疼痛，在相對(duì)年輕的患者中，最終可導(dǎo)致股骨頭塌陷并隨后迅速破壞髖關(guān)節(jié)[1-3]。股骨頭塌陷引起的頑固性疼痛最終導(dǎo)致在年輕時(shí)進(jìn)行全髖關(guān)節(jié)置換術(shù)(THA)[4,5]。雖然創(chuàng)傷、皮質(zhì)類固醇的使用和過(guò)量飲酒是眾所周知的ONFH的危險(xiǎn)因素，但ONFH的病因仍然是多因素的，對(duì)共同的病理生理尚未達(dá)成共識(shí)[6-9]。據(jù)推測(cè)，骨血流灌注受損、細(xì)胞修復(fù)過(guò)程異常以及基因點(diǎn)突變可能影響ONFH的發(fā)生，但尚未明確[10-12]。AlthoughitisverywellknownthatcorticosteroidscauseONFH,itisunclearastowhichpatientsdevelopONFH.Thereareseveralstudiesreportingthathigh-dosecorticosteroiduseof2grams(g)ormorewithin3monthsisassociatedwithONFHdevelopment[8,13-15].However,thesewerestudieswitharelativelysmallnumberofpatients,andthereareheterogeneitiesinpatientdemographicsandepidemiologicvariabilities.OnceONFHoccurs,theprognosisisknowntobepoor,andtherearestudiesstatingthatfemoralheadcollapseprogressesfromabout24.6to42.8%withnaturalevolutionwithin2years[16,17].Inparticular,whenfemoralheadcollapseoccurs,manypatientsoftenreceiveTHAatayoungage,sopredictingtheprognosisforfemoralheadcollapseisasimportantaspredictingtheoccurrenceofONFH.SeveralstudieshavedemonstratedthatfemoralheadcollapseinONFHpatientsisassociatedwithsize,volume,locationofnecroticlesions,andanatomicalparameters[1,2,18,19].However,therearenostudiesontheassociationbetweencorticosteroiduseandfemoralheadcollapseinONFHpatients.雖然眾所周知，皮質(zhì)類固醇會(huì)引起ONFH，但尚不清楚哪些患者會(huì)發(fā)生ONFH。有幾項(xiàng)研究報(bào)道，在3個(gè)月內(nèi)使用2克或更多的高劑量皮質(zhì)類固醇與ONFH的發(fā)生有關(guān)[8,13-15]。然而，這些研究的患者數(shù)量相對(duì)較少，并且在患者人口統(tǒng)計(jì)學(xué)和流行病學(xué)變異方面存在異質(zhì)性。一旦發(fā)生ONFH，預(yù)后很差，有研究表明股骨頭塌陷在2年內(nèi)自然演化，從24.6%發(fā)展到42.8%[16,17]。特別是股骨頭塌陷發(fā)生時(shí)，許多患者往往在年輕時(shí)接受THA，因此預(yù)測(cè)股骨頭塌陷的預(yù)后與預(yù)測(cè)ONFH的發(fā)生同樣重要。多項(xiàng)研究表明，ONFH患者股骨頭塌陷與壞死灶的大小、體積、位置和解剖學(xué)參數(shù)有關(guān)[1,2,18,19]。然而，目前還沒(méi)有關(guān)于ONFH患者使用皮質(zhì)類固醇與股骨頭塌陷之間關(guān)系的研究。TheNationalHealthInsuranceService(NHIS)ofSouthKoreaisanationalinsurancecoverageservicethatcoversabout97%ofcitizensinSouthKorea,includingdemographicdataandaclaimdatabaseincludingdiagnosesandprescriptions[20].Additionally,theNHISoffershealthscreeningexaminationsforinsuredKoreansaged40yearsorolder,includingbasicbloodtests,smoking,drinking,andphysicalactivitiesusingself-reportedquestionnaires.BecausetheNationalHealthInsuranceService–NationalSampleCohort(NHIS-NSC)isahighlyrepresentativepopulation-basedcohortoftheentireKoreanpopulation,itcanbeusedasapopulation-based,nationwidestudyforepidemiologicresearchonvariousdiseases[20-22].韓國(guó)國(guó)民健康保險(xiǎn)服務(wù)(NationalHealthInsuranceService,NHIS)是一項(xiàng)覆蓋韓國(guó)約97%公民的國(guó)民保險(xiǎn)服務(wù)，包括人口統(tǒng)計(jì)數(shù)據(jù)和包括診斷和處方在內(nèi)的索賠數(shù)據(jù)庫(kù)[20]。此外，國(guó)民健康保險(xiǎn)制度還為40歲或40歲以上的參保韓國(guó)人提供健康檢查，包括基本的血液檢查、吸煙、飲酒和使用自我報(bào)告問(wèn)卷的體育活動(dòng)。由于國(guó)民健康保險(xiǎn)服務(wù)-國(guó)民樣本隊(duì)列(NationalHealthInsuranceService-NationalSampleCohort,NHIS-NSC)是韓國(guó)人口中極具代表性的基于人群的隊(duì)列，因此可以作為一項(xiàng)基于人群的全國(guó)性研究，用于各種疾病的流行病學(xué)研究[20-22]。Therefore,inthepresentstudy,weaimedtoinvestigatetheassociationbetweencorticosteroiduseandtheriskofONFHdevelopmentamongthewholegeneralpopulationandwhatfactorsaffectONFHdevelopmentusinganationwidelargesamplefromlongitudinalnestedcase-controldatainalong-termcohortstudy.Inaddition,weaimedtodemonstratewhichfactorsaffectTHAafterthedevelopmentofONFH.因此，在本研究中，我們旨在通過(guò)一項(xiàng)長(zhǎng)期隊(duì)列研究，在全國(guó)范圍內(nèi)采用縱向嵌套病例對(duì)照數(shù)據(jù)的大樣本，調(diào)查皮質(zhì)類固醇使用與整個(gè)普通人群中ONFH發(fā)生風(fēng)險(xiǎn)之間的關(guān)系，以及影響ONFH發(fā)生的因素。此外，我們旨在證明哪些因素會(huì)影響ONFH發(fā)展后的THA。?MaterialsandMethodsStudyPopulationWeuseda2002to2019datasetfromtheNHISPhysicalHealthExaminationCohort(NHIS-NSC)2.0databaseintheRepublicofKorea[23].TheNHIS-NSC2.0databasewascomprisedofatotalof1,137,861participantswhowerestratifiedandrandomlysampledsuchthattheage,sex,region,healthinsurancetype,andhouseholdincomesofthesamplesremainedproportionaltothoseofthe2006Koreanpopulationof50million.Weexcluded223,474participantswhowerealreadyprescribedintravenous(IV)ororalcorticosteroidstoreducethebiasintheanalysisoftheeffectoftheprescribedcorticosteroiddoseonONFH.Fromtheremainingcohort,weexcluded241participantswhowerealreadydiagnosedwithONFHin2002toobtainthenewdevelopmentofONFH(washoutperiod).Therefore,theindexdatewasthedatethatthepatientwasdiagnosedwithONFH.Weincluded914,146participantsinthefinalanalysis.Theinformationinthedatasetincludedallinpatientandoutpatientmedicalclaimsdata,includingprescriptiondruguse,diagnosticandtreatmentcodes,primaryandsecondarydiagnosticcodes,andhealthexaminationdata.AlltheindividualsincludedintheNHIS-NSCwerefolloweduntil2019,unlesstherewasadeathordisqualificationforNationalHealthInsurance,suchasemigration.TheprotocolofthisstudywasapprovedbytheInstitutionalReviewBoardofourinstitution(4-2022-0304)andtheNHIS(NHIS-2022-2-232).我們使用了2002年至2019年的數(shù)據(jù)集，這些數(shù)據(jù)集來(lái)自韓國(guó)NHIS身體健康檢查隊(duì)列(NHIS-nsc)2.0數(shù)據(jù)庫(kù)[23]。國(guó)民健康保險(xiǎn)制度-國(guó)家安全保障制度2.0數(shù)據(jù)庫(kù)共包括1137861名參與者，這些參與者的年齡、性別、地區(qū)、健康保險(xiǎn)類型和家庭收入與2006年韓國(guó)5000萬(wàn)人口的比例保持一致，并進(jìn)行了分層和隨機(jī)抽樣。我們排除了223,474名已經(jīng)靜脈注射或口服皮質(zhì)類固醇的參與者，以減少處方皮質(zhì)類固醇劑量對(duì)ONFH影響分析的偏倚。從剩余隊(duì)列中，我們排除了241名在2002年已經(jīng)診斷為ONFH的參與者，以獲得ONFH的新進(jìn)展(洗脫期)。因此，索引日期為患者被診斷為ONFH的日期。我們?cè)谧罱K分析中納入了914146名參與者。數(shù)據(jù)集中的信息包括所有住院和門診醫(yī)療索賠數(shù)據(jù)，包括處方藥使用、診斷和治療代碼、初級(jí)和二級(jí)診斷代碼以及健康檢查數(shù)據(jù)。納入國(guó)家健康保險(xiǎn)制度-國(guó)家安全保障制度的所有個(gè)人都被跟蹤到2019年，除非死亡或喪失參加國(guó)家健康保險(xiǎn)的資格，例如移民。本研究的方案經(jīng)我院機(jī)構(gòu)審查委員會(huì)(4-2022-0304)和NHIS(NHIS-2022-2-232)批準(zhǔn)。?CaseandControlSelectionWeusedtheInternationalStatisticalClassificationofDiseasesandRelatedHealthProblems,10thRevision(ICD-10)toidentifycasepatients.WedefinedONFH(N=3,500)usingthediagnosticcodeandtreatmentcodeICD-10codesforosteonecrosisofthefemur(SupplementaryTable1).Toavoidlengthbias,anestedcase-controlanalysiswasdesignedtoinvestigatetheeffectoftheprescribedcorticosteroiddoseonONFH.PatientswhohadONFHwerematched1:5toformacontrolgroupbasedonthevariablesofbirthyear,sex,andfollow-upduration.Identicalexclusioncriteriawereappliedtothecontrolgroup(N=12).Finally,casepatients(N=3,488)andcontrolpatients(N=17,440)werematchedbasedonsexandageattheindexdateandcompared(Figure1).我們使用國(guó)際疾病和相關(guān)健康問(wèn)題統(tǒng)計(jì)分類第十次修訂版(ICD-10)來(lái)確定病例患者。我們使用股骨骨壞死的診斷代碼和治療代碼ICD-10來(lái)定義ONFH(N=3,500)(補(bǔ)充表1)。為避免長(zhǎng)度偏倚，設(shè)計(jì)了巢式病例對(duì)照分析，以調(diào)查處方皮質(zhì)類固醇劑量對(duì)ONFH的影響。根據(jù)出生年份、性別、隨訪時(shí)間等變量對(duì)ONFH患者進(jìn)行1:5匹配，形成對(duì)照組。對(duì)照組(N=12)采用相同的排除標(biāo)準(zhǔn)。最后，根據(jù)索引日期的性別和年齡對(duì)病例患者(N=3,488)和對(duì)照患者(N=17,440)進(jìn)行匹配和比較(圖1)。??Fig.1Studyflow:selectionofparticipantsofcasesandmatchedcontrolsONFH,osteonecrosisoffemoralhead.??DefinitionofParametersFromthehealthexaminations,participantswereclassifiedinto4groupsbasedonthebodymassindex(BMI)accordingtotheWorldHealthOrganizationWesternPacificRegionguidelineandtheKoreanpracticalguidelineasfollows:low(<18.5),normal(18.5to23),overweight(23to25),andobese(>25).UnderlyingcomorbiditiesweredefinedbyatleastoneadmissionoroutpatienttreatmentupontheprimaryorfirstsecondarydiagnosisusingtheICD-10codeforthepastyear(hypertension:I10-I15,diabetesmellitus:E10-E14,dyslipidemia:E78).Thefrequencyofdrinkingalcoholwascategorizedas“non-alcoholuse”(drinkinglessthan1drinkperweek),“mildalcoholuse”(drinking1to2drinksperweek),or“heavyalcoholuse”(drinkingmorethan3to7drinksperweek).Smokingstatuswascategorizedasnonsmoker,pastsmoker,orcurrentsmoker.Afterovernightfasting,bloodsampleswereobtained,andserumhigh-densitylipoproteincholesterol,low-densitylipoprotein(LDL)cholesterol,andtriglyceride(TG)resultscouldbeobtained.根據(jù)健康檢查結(jié)果，根據(jù)世界衛(wèi)生組織西太平洋地區(qū)指南和韓國(guó)實(shí)踐指南，將參與者的身體質(zhì)量指數(shù)(BMI)分為4組:低(<18.5)、正常(18.5~23)、超重(23~25)和肥胖(>25)。潛在的合并癥是在過(guò)去一年中使用ICD-10代碼進(jìn)行原發(fā)性或首次繼發(fā)性診斷時(shí)至少進(jìn)行一次住院或門診治療(高血壓:I10-I15，糖尿病:E10-E14，血脂異常:E78)。飲酒頻率分為“不飲酒”(每周飲酒少于1杯)、“輕度飲酒”(每周飲酒1至2杯)或“重度飲酒”(每周飲酒超過(guò)3至7杯)。吸煙狀況分為不吸煙者、過(guò)去吸煙者和現(xiàn)在吸煙者。禁食過(guò)夜后采集血樣，得到血清高密度脂蛋白膽固醇、低密度脂蛋白膽固醇和甘油三酯(TG)結(jié)果。?SystemicCorticosteroidPrescriptionWedefinedsystemiccorticosteroidprescriptionsasoralcorticosteroidprescriptionsandIVcorticosteroidprescription.Systemiccorticosteroidusewasdefinedastheprescriptionofmedicationcodesduringadmissionsandoutpatientvisitsfrom2003totheindexdate(Table1).Bothgroupshadidenticalobservationperiods.Allcorticosteroidformulationswereconvertedintoadailydosebasedonprednisoneequivalentdoses[24](1mgprednisolone=4mghydrocortisone=0.8mgmethylprednisolone=0.8mgtriamcinolone=0.16mgbetamethasone=1.2mgdeflazacort),andwecalculatedcumulativedosesofexposureforcorticosteroidswiththesumofthedosesforalltheprescribeddays,whichwasexpressedasthecumulativedefineddailydose(cDDD)accordingtotheWorldHealthOrganizationdefinition.我們將系統(tǒng)性糖皮質(zhì)激素處方定義為口服糖皮質(zhì)激素處方和靜脈糖皮質(zhì)激素處方。系統(tǒng)性糖皮質(zhì)激素使用定義為從2003年到基線日期（見(jiàn)表1）的住院和門診就診期間的藥物代碼處方。兩組觀察期相同。將所有糖皮質(zhì)激素制劑轉(zhuǎn)換為基于潑尼松等效劑量（1毫克潑尼松龍等于4毫克氫化可的松等于0.8毫克甲基潑尼松龍等于0.8毫克曲安奈德等于0.16毫克倍他米松等于1.2毫克德夫氯喹）的每日劑量，并根據(jù)世界衛(wèi)生組織的定義計(jì)算糖皮質(zhì)激素的累積暴露劑量（累積定義每日劑量，cDDD），即將所有處方天數(shù)的劑量相加。?Table1PrescriptionDrugCodesandDosageofSystemicCorticosteroidBasedontheHealthInsuranceClaimsPaymentCodingSystem.Drug???????Code??????CorticosteroidandDosageOralcorticosteroids116401ATB???betamethasone0.5mg116501ATB???betamethasonesodiumphosphate0.5mg296900ATB???betamethasone0.25mg140801ATB???deflazacort6mg140802ATB???deflazacort30mg141901ATB???dexamethasone0.5mg141903ATB???dexamethasone0.75mg141904ATB???dexamethasone4mg170901ATB???hydrocortisone10mg170905ATB???hydrocortisone20mg170906ATB???hydrocortisone5mg193301ATB???methylprednisolone16mg193302ATB???methylprednisolone4mg193303ATB???methylprednisolone8mg193304ATB???methylprednisolone2mg193305ATB???methylprednisolone1mg217001ATB???prednisolone5mg243201ATB???triamcinolone1mg243202ATB???triamcinolone2mg243203ATB???triamcinolone4mgHigh-doseIVcorticosteroids?171201BIJ???????hydrocortisonesodiumsuccinate100mg171202BIJ?????hydrocortisonesodiumsuccinate250mg171203BIJ?????hydrocortisonesodiumsuccinate40mg193601BIJ?????methylprednisolonesodiumsuccinate125mg193602BIJ?????methylprednisolonesodiumsuccinate250mg193603BIJ?????methylprednisolonesodiumsuccinate40mgmethylprednisolonesodiumsuccinate500mg193604BIJ?????methylprednisolonesodiumsuccinate1000mg193605BIJ?????prednisolonesodiumsuccinate1000mg217301BIJ?????prednisolonesodiumsuccinate250mg217302BIJ???????SubgroupAnalysisATHAafteranONFHdiagnosiswasusedasasurrogateforfemoralheadcollapse.Therefore,wedividedallcasesinto2groups:agroupthatreceivedTHAandanothergroupthatdidnotreceiveTHAusingtreatmentcodes(N0711.N7020).Amongatotalof3,430patients,weexcluded70patientswhohadaTHAtreatmentcodepriortodiagnosis,1,175patientswhoreceivedTHAduringtheobservationperiod,and2,255patientswhodidnot.Wecomparedthe2groupsandanalyzedthemusingtheCoxproportionalhazardsmodel,whichfactorsaffectdiseaseprogressionleadingtoTHA(Figure2).診斷為ONFH后進(jìn)行THA作為股骨頭塌陷的替代。因此，我們使用治療代碼(N0711)將所有病例分為兩組:接受THA治療的組和未接受THA治療的組。N7020)。在總共3430例患者中，我們排除了70例在診斷前有THA治療代碼的患者，1175例在觀察期間接受THA治療的患者和2255例未接受THA治療的患者。我們對(duì)兩組患者進(jìn)行比較，并使用Cox比例風(fēng)險(xiǎn)模型進(jìn)行分析，分析影響THA病情進(jìn)展的因素(圖2)。??Fig.2Studyflow:comparisonofpatientswhoreceivedanddidnotreceivetotalhiparthroplastyafterdiagnosisONFH,osteonecrosisoffemoralhead;THA,totalhiparthroplasty.??DataAnalysisChi-squaredtestsforcategoricalvariableswereperformedtocomparethebaselinecharacteristicsbetweencaseandcontrolpatients.AconditionallogisticregressionanalysiswasperformedtoevaluatetheassociationbetweensystemiccorticosteroiduseandtheriskofONFH.Forsubgroupanalysis,weusedCoxproportionalhazardmodelstoestimateadjustedhazardratios(aHRs)and95%confidenceintervals(CIs).APvalue<.05wasconsideredsignificant.AllstatisticalanalyseswereperformedusingSASEnterpriseGuideversion7.1(SASInstitute,Cary,NorthCarolina).?ResultsDemographicDataforONFHCasesandMatchedControlsTable2showsthebaselinecharacteristicsofcasesandmatchedcontrols.The2groupshadevendistributionsinthematchingvariables,includingsexandbirthyear.Subjectswerepredominantlymen(61.1%),andthemostcommonagegroupwasthoseborninthe1950s(age63to72asof2022).Comparedwiththecontrolgroup,ONFHcasepatientshadlowhouseholdincomeandhadmorediabetes,hypertension,dyslipidemia,andheavyalcoholuse(drinkingmorethan3to7drinksperweek).Inaddition,thecasepatientshadnormalserumLDLlevels(<100mg/dL),butconversely,thereweremanycasesofhypertriglyceridemiawithserumTGlevelsof200mg/dLormore.??Table2BaselineCharacteristicofOsteonecrosisofFemoralHeadCasesandMatchedControls.totalN=20,928(%)?????CasesN=3,488(%)ControlsN=17,440(%)?????PSex????????????????????????Men12,792(61.1)?2,132(61.1)???10,660(61.1)?Women???8,136(38.9)???1,356(38.9)???6,780(38.9)???????Birthyear??????????????????????????????<1930????852(4.1)142(4.1)710(4.1)1930to1939?3,024(14.4)???504(14.4)??????2,520(14.4)?????1940to1949?4,074(19.5)???679(19.5)??????3,395(19.5)?????1950to1959?5,112(24.4)???852(24.4)??????4,260(24.4)?????1960to1969?3,786(18.1)???631(18.1)??????3,155(18.1)?????1970to1979?2,184(10.4)???364(10.4)??????1,820(10.4)?????1980to1989?1,080(5.2)?????180(5.2)900(5.2)1990to1999?558(2.7)93(2.7)??465(2.7)2000to2009?210(1.0)35(1.0)??175(1.0)2010to2019?48(0.2)??8(0.2)????40(0.2)??Age(atindexdate)55.2±16.9????55.2±16.9???????55.2±16.9????Householdincome????????????????????????Low4,535(21.7)???896(25.7)??????3,639(20.9)???????<.001Middle???6,500(31.0)???1,090(31.2)???5,410(31.0)???????High???????9,893(26.5)???1,502(43.1)???8,391(48.1)???????Comorbidities????????????????????????Hypertension?6,631(31.7)???1,301(37.3)???5,330(30.6)?????<.001Diabetesmellitus???4,567(21.8)???908(26.0)???????3,659(21.0)???<.001Dyslipidemia??5,555(26.5)???1,120(32.1)???4,435(25.4)?????<.001Frequencyofdrinkingalcohol??????????????????????????????<1d/wk??10,044(48.0)?1,613(46.2)???8,431(48.3)???????<.0011to2d/wk?????3,987(19.1)???560(16.1)??????3,427(19.7)?????3to7d/wk?????2,794(13.3)???621(17.8)??????2,173(12.5)?????Missing??4,103(19.6)???694(19.9)??????3,409(19.5)???????Smokingstatus?????????????????????????????Non-smoker???9,455(45.2)???1,539(44.1)???7,916(45.4)?????.199Ex-smoker?????2,865(13.7)???462(13.3)??????2,403(13.8)?????Currentsmoker??????4,488(21.4)???790(22.6)???????3,698(21.2)???Missing??4,120(19.7)???697(20.0)??????3,423(19.6)???????BMI,kg/m2??24.0±3.3??????23.9±3.4??????24.0±3.3??.547<18·5?????608(2.9)113(3.2)495(2.8).09018·5to22·9???6,126(29.3)???1,029(29.5)???5,097(29.2)?????23·0to24·9???4,239(20.3)???651(18.7)??????3,588(20.6)?????≥25·0?6,113(29.2)???1,049(30.1)???5,064(29.0)???????Missing??3,842(25.1)???646(18.5)??????3,196(18.3)???????HDL,mg/dL??54.2±20.5????55.2±22.7????54.0±20.0.015<40?2,113(10.1)???339(9.7)1,774(10.2%).03340to59??8,856(42.3)???1,411(40.5)???7,445(42.7%)??≥60???????4,700(22.5)???830(23.8)????3870(22.2%)???????Missing??5,259(25.1)???908(26.0)??????4,351(24.9%)??LDL,mg/dL???114.8±77.2??110.6±56.9??115.7±80.6<.001<100??????5,627(26.9)???1,045(30.0)???4,582(26.3)???????<.001100to159?????8,493(40.6)???1,297(37.2)???7,196(41.3)?????≥160?????1,528(7.3)?????234(6.7)1,294(7.4)?????Missing??5,280(25.2)???912(26.1)??????4,368(25.0)???????TG,mg/dL?????144.5±108.7154.8±125.0142.5±105.1??????<.001<150??????10,395(49.7)?1,651(47.3)???8,744(50.1)???????<.001150to199?????2,447(11.7)???390(11.2)??????2,057(11.8)?????≥200?????2,829(13.5)???540(15.5)??????2,289(13.1)???????Missing??5,257(25.1)???907(26.0)??????4,350(24.9)???????BMI,bodymassindex;HDL,highdensitylipoprotein;LDL,lowdensitylipoprotein;TG,triglyceride.??Table3showsthecomparisonofprescribedsystemiccorticosteroidsincasepatientsandcontrolpatients.Bothgroupshadidenticalobservationperiods(meanobservationperiodwas8.26years).Systemiccorticosteroidwasprescribedatleastoncemoreinthecasegroupthaninthecontrolgroup(71.8versus62.9%,P<.001).EvenwhenoralcorticosteroidsandIVcorticosteroidswerecompared,respectively,thenumberofcasesprescribedcorticosteroidsatleastoncewashigherinthepatientswhohadONFH(oralcorticosteroids:71.2versus62.4%,P<.001/IVcorticosteroids:10.7versus4.9%,P<.001).??Table3DifferenceinCorticosteroidUseBetweenCasesandMatchedControlsFrom2003UntilDiagnosis.TotalN=20,928(%)?????CasesN=3,488(%)ControlsN=17,440(%)?????PCorticosteroid(oralorhigh-doseIV)???????????????????????????Neveruse???????7,453(35.6)???983(28.2)??????6,470(37.1)?????<.001Everuse?13,475(64.4)?2,505(71.8)?10,970(62.9)???????Oralcorticosteroid????????????????????????Neveruse???????7,562(36.1)???1,004(18.8)???6,558(37.6)?????<.001Everuse?13,366(63.9)?2,484(71.2)?10,882(62.4)???????Neveruse???????7,562(36.1)???1,004(18.8)???6,558(37.6)?????<.001<180cDDDs??12,667(60.5)?2,192(62.8)???10,475(60.1)?????180to364cDDDs?397(1.9)146(4.2)251(1.4)365to729cDDDs?179(0.9)84(2.4)??95(0.5)??≥730cDDDs123(0.6)62(1.8)??61(0.4)??High-doseIVcorticosteroid??????????????????????????Neveruse???????19,703(94.2)?3,116(89.3)???16,587(95.1)?????<.001Everuse?1,225(5.8)?????372(10.7)??????853(4.9)Neveruse???????19,703(94.2)?3,116(89.3)???16,587(95.1)?????<.001<180cDDDs??988(4.7)266(7.6)722(4.1)180to364cDDDs?120(0.6)46(1.3)??74(0.4)??365to729cDDDs?77(0.4)??40(1.2)??37(0.2)??≥730cDDDs40(0.2)??20(0.6)??20(0.1)??cDDDs,cumulativedefineddailydoses(prednisolone10mg);IV,intravenous.??CumulativeCorticosteroidDoseandONFHDevelopmentConditionallogisticregressionanalysiswasperformedtoanalyzetheeffectofthecumulativedoseofsystemiccorticosteroidsfor1yearbeforediagnosisontheincidenceofONFH(Table4).SystemiccorticosteroidusewassignificantlyassociatedwithanincreasedriskofONFHincidencecomparedtothatofnonusers.Specifically,higherdosesoforalcorticosteroidwereassociatedwithincreasedriskofONFH(oddsratiosof1.61(95%CI1.47to1.78,P<.001),4.39(95%CI3.47to5.56,P<.001),6.42(95%CI4.65to8.87,P<.001),and5.44(95%CI3.65to8.13,P<.001)forpatientswhohavecorticosteroiduseof<180,180to365,365to720,and>720cDDDs(valuesconvertedtodailyprednisolone10mg),respectively.TheriskofONFHincreasedrapidlywhenthecDDDwas180ormore,thatis,whencumulativeprednisoloneusewas1,800mgormore.Inaddition,atrendtowardriskincreasewithcumulativedosesofIVcorticosteroidusewasshownwithadjustedoddsratio(AOR)of1.63(95%CI1.39to1.90,P<.001),2.34(95%CI1.57to3.49,P<.001),3.77(95%CI2.33to6.10,P<.001),and2.76(95%CI1.41to5.39,P=.003)forpatientswhohavecorticosteroiduseof<180,180to365,365to720,and>720cDDDs(valuesconvertedtodailyprednisolone10mg),respectively.??Table4AdjustedRiskofOsteonecrosisofFemoralHeadOccurrence.ConditionalLogisticRegressionAnalysisforONFHDevelopmentCrudeOR??????95%CI???P?????AdjustedOR??95%CI???????PHouseholdincome????????????????????????????????????????Low1.381.26to1.52???<.001?????1.381.25to1.51???????<.001Middle???1.131.03to1.23???.0071.131.03to1.23???????.008High???????1.00ref.?????????1.00ref.??Comorbidities???????????????????????????????????????Hypertension?1.471.35to1.60???<.001?????1.21???????1.06to1.37???.004Diabetesmellitus???1.381.26to1.51???<.001???????1.070.95to1.20???.289Dyslipidemia??1.471.35to1.60???<.001?????1.18???????1.04to1.34???.012Frequencyofdrinkingalcohol?????????????????????????????????????????????<1d/wk??1.00ref.?????????1.00ref.??1to2d/wk?????0.870.78to0.97???.0150.900.80to1.01.0713to7d/wk?????1.541.38to1.73???<.001?????1.54???????1.36to1.74???<.001Missing??1.080.97to1.20???.1801.120.59to2.14???????.731Smokingstatus?????????????????????????????????????????????Non–smoker??1.00ref.?????????1.00ref.??Ex–smoker?????1.010.89to1.15???.8670.930.82to1.07.314Currentsmoker??????1.131.01to1.26???.0321.01???????0.90to1.14???.855Missing??1.060.95to1.18???.2791.030.55to1.94???????.923BMI,kg/m2?????????????????????????????????????????<18·5?????1.130.91to1.41???.2621.150.92to1.44???????.23218·5to22·9???1.00ref.?????????1.00ref.??23·0to24·9???0.900.81to0.99???.0490.900.80to1.01.062≥25·0?1.020.93to1.13???.6280.990.89to1.09???????.784Missing??1.000.90to1.13???.9450.800.55to1.17???????.254HDL,mg/dL?????????????????????????????????????????<40?1.010.88to1.15???.9250.950.83to1.09???????.44740to59??1.00ref.?????????1.00ref.??≥60???????1.131.03to1.25???.0091.100.99to1.21???????.069Missing??1.121.01to1.23???.0312.910.14to60.46???????.490LDL,mg/dL??????????????????????????????????????????<100??????1.00ref.?????????1.00ref.??100to159?????0.790.72to0.86???<.001?????0.86???????0.78to0.94???.001≥160?????0.790.67to0.92???.0030.84071to0.98???????.031Missing??0.930.83to1.03???.1520.840.28to2.56???????.762TG,mg/dL????????????????????????????????????????????<150??????1.00ref.?????????1.00ref.??150to199?????1.010.89to1.14???.9170.990.88to1.13.970≥200?????1.261.13to1.40???<.001?????1.171.04to1.32.009Missing??1.121.01to1.23???.0250.460.03to7.70???????.585Medication????????????????????????????????????????????Steroid(oralorhigh–doseIV)?????????????????????????????????????????????Neveruse???????1.00ref.?????????1.00ref.??Everuse?1.751.59to1.92???<.001?????1.771.60to1.94<.001POsteroid?????????????????????????????????????????????Neveruse???????1.00ref.?????????1.00ref.??Everuse?1.731.57to1.90???<.001?????1.681.53to1.85<.001Neveruse???????1.00ref.?????????1.00ref.??<180cDDDs??1.631.49to1.79???<.001?????1.61???????1.47to1.78???<.001180to364cDDDs?4.983.96to6.25???<.001???????4.393.47to5.56???<.001365to729cDDDs?7.515.50to10.27?<.001???????6.424.65to8.87???<.001≥730cDDDs8.966.16to13.02?<.001?????5.44???????3.65to8.13???<.001High–doseIVsteroid????????????????????????????????????????????Neveruse???????1.00ref.?????????1.00ref.??Everuse?2.422.12to2.76???<.001?????2.201.92to2.51<.001Neveruse???????1.00ref.?????????1·00?????ref.??<180cDDDs??2.041.76to2.38???<.001?????1.63???????1.39to1.90???<.001180to364cDDDs?3.402.35to4.92???<.001???????2.341.57to3.49???<.001365to729cDDDs?5.863.74to9.18???<.001???????3.772.33to6.10???<.001≥730cDDDs5.232.81to9.73???<.001?????2.76???????1.41to5.39???.003BMI,bodymassindex;cDDDs,cumulativedefineddailydoses(prednisolone10mg);CI,confidenceinterval;HDL,highdensitylipoprotein;IV,intravenous;LDL,lowdensitylipoprotein;ONFH,osteonecrosisoffemoralhead;OR,oddsratio;PO,peroral;TG,triglyceride.??RiskFactorsforTHAinPatientswhoHaveONFHFortheONFHcasepatients,asubgroupanalysiswasperformedon1,175patientsintheTHAgroupand2,255patientsinthenon-THAgroupduringtheobservationperiod.Thefollow-updurationoftheTHAgroup(1,175patients)was1.03±2.25years,andthefollow-updurationofthenon-THAgroup(2,255patients)was7.93±5.15years.Table5showsthebaselinecharacteristicsofTHAcasesandnon-THAcases.IntheTHAgroup,therewasagreaterproportionofmen(63.9versus60.0%,P=.028),higherBMI(24.1versus23.8,P=.027),heavyalcoholuseofthosewhoconsumedalcoholmorethan3to7daysaweek(22.9versus15.2%,P<.001),currentsmokers(26.4versus20.8%,P<.001),andhigherTG(162.3mg/dLversus150.0,P≤.001).However,whentheeffectondiseaseprogressionwasanalyzedusingCoxproportionalhazardsmodelforsurvivalanalysisafterONFHdiagnosis,heavyalcoholuseandlongercorticosteroidusesweretheriskfactorsaffectingdiseaseprogression,anddiabeteswasafactorthatslowedprogression.Moreover,otherlipidprofilesaswellascorticosteroidsusedandcumulativedosesofcorticosteroidsdidnotaffecttheincidenceofTHA(Table6).Inaddition,whenthesurvivalanalysiswasperformedafterthediagnosisofONFHbydividingthepatientgroupintomalesandfemales,heavyalcoholuseinvolvingthosewhoconsumedalcoholmorethan3to7daysaweekincreasedtheriskofdiseaseprogressionafterONFHdiagnosisinmalesonly(aHR:1.38,95%CI1.16to1.65,P<.001),andaBMIof25orhigherinfemalesonlyincreasedtheriskofincidenceofTHAafterONFHdiagnosis(aHR:1.52,95%CI1.18to1.96,P<.001).??Table5Comparisonofthe2GroupsAccordingtoWhetherorNotTotalHipArthroplastywasPerformedDuringtheFollow-UpPeriodAfterOsteonecrosisofFemoralHeadDiagnosis.TotalN=3,430(%)??????THAafterDiagnosisN=1,175(%)?????NoTHAafterDiagnosisN=2,255(%)???????PSex????????????????????????Men2,104(61.3)???751(63.9)??????10,660(61.1)???????.028Women???1,326(38.7)???424(36.1)??????6,780(38.9)???????Birthyear??????????????????????????????<1930????141(4.1)16(1.4)??125(5.5)<.0011930to1939?492(14.3)??????153(13.0)??????339(15.0)?????1940to1949?665(19.4)??????246(20.9)??????419(18.6)?????1950to1959?837(24.4)??????344(29.3)??????493(21.9)?????1960to1969?621(18.1)??????229(19.5)??????392(17.4)?????1970to1979?359(10.5)??????118(10.0)??????241(10.4)?????1980to1989?180(5.3)56(4.8)??124(5.2)1990to1999?92(2.7)??13(1.1)??79(3.5)??2000to2009?35(1.0)??0(0.0)????35(1.6)??2010to2019?8(0.2)????0(0.0)????8(0.3)????Age(atindexdate)55.1±17.0????56.41±13.8???????54.6±18.4????.007Householdincome????????????????????????Low880(25.7)??????283(24.1)??????597(26.5)???????.008Middle???1,077(31.4)???409(34.8)??????668(29.6)???????High???????1,473(42.9)???483(41.1)??????990(43.9)???????Comorbidities????????????????????????Hypertension?1,269(37.0)???445(37.9)??????824(36.5)?????.466Diabetesmellitus???888(25.9)??????285(24.3)???????603(26.7)??????.125Dyslipidemia??1,095(31.9)???383(32.6)??????712(31.6)?????.568Frequencyofdrinkingalcohol??????????????????????????????<1d/wk??1,581(46.1)???504(42.9)??????1,077(47.8)???????<.0011to2d/wk?????549(16.0)??????207(17.6)??????342(15.2)?????3to7d/wk?????613(17.9)??????269(22.9)??????344(15.2)?????Missing??687(20.0)??????195(16.6)??????492(21.8)???????Smokingstatus?????????????????????????????Nonsmoker????1,507(43.9)???491(41.8)??????1,016(45.1)?????.199Ex-smoker?????454(13.2)??????180(15.3)??????274(12.2)?????Currentsmoker??????780(22.7)??????310(26.4)???????470(20.8)??????Missing??689(20.1)??????194(16.5)??????495(21.9)???????BMI,kg/m2???23.9±3.4??????24.1±3.4??????23.8±3.3??.027<18·5?????112(3.3)37(3.2)??75(3.3)??<.00118·5-22·9??????1,014(29.3)???355(30.2)??????659(29.2)?????23·0-24·9??????640(18.7)??????218(18.5)??????422(18.7)?????≥25·0?1,024(29.8)???388(33.0)??????636(28.2)???????Missing??640(18.7)??????177(15.1)??????463(20.5)???????HDL,mg/dL??55.3±22.9????55.7±16.0????55.1±26.1.015<40?331(9.6)110(9.4)221(9.8).03340-59?????1,379(40.2)???494(42.0)??????885(39.2)???????≥60???????822(24.0%)??322(27.4%)??500(22.2%)???????Missing??898(26.2%)??248(21.2%)??649(28.8%)???????LDL,mg/dL???110.6±57.1??111.4±80.9??110.1±37.0.668<100??????1,023(29.8%)378(32.2%)??645(28.6%)???????<.001100-159?1,277(37.2%)464(39.5%)??813(36.1%)???????≥160?????229(6.7%)????81(6.9%)??????148(6.5%)???????Missing??901(26.3%)??252(21.4%)??649(28.8%)???????TG,mg/dL?????154.5±125.1162.3±141.3150.0±114.5??????.024<150??????1,626(47.4%)576(19.0%)??1,050(46.6%)??<.001150-199?378(11.0%)???140(11.9%)???238(10.5%)???????≥200?????530(15.5%)??211(18.0%)???319(14.2%)???????Missing??896(26.1)??????248(21.1)??????648(28.7)???????Systemiccorticosteroid(Oralorhigh-doseIV)???????????????????????????Neveruse???????2,090(60.9)???710(60.4)??????1,380(61.2)?????.687Everuse?1,340(39.1)???465(39.6)??????875(38.8)???????Oralcorticosteroid????????????????????????Neveruse???????2,119(61.8)???718(61.1)??????1,401(62.1)?????.584Everuse?1,311(38.2)???457(38.9)??????854(37.9)???????.690Neveruse???????2,119(61.8)???718(61.1)??????1,401(62.1)?????<180cDDDs??1,240(36.1)???434(36.9)??????806(35.7)?????180-364cDDDs????47(1.4)??15(1.3)??32(1.4)??365-729cDDDs????21(0.6)??8(0.7)????13(0.6)??≥730cDDDs3(0.1)????0(0.0)????3(0.1)????High-doseIVcorticosteroid??????????????????????????Neveruse???????3,322(96.9)???1,142(97.2)???2,180(96.7)?????.471Everuse?108(3.1)33(2.8)??75(3.3)??.858Neveruse???????3,322(96.9)???1,142(97.2)???2,180(96.7)?????<180cDDDs??84(2.4)??26(2.2)??58(2.5)??180-364cDDDs????9(0.3)????2(0.2)????7(0.3)????365-729cDDDs????10(0.3)??4(0.3)????6(0.3)????≥730cDDDs5(0.1)????1(0.1)????4(0.2)????BMI,bodymassindex;cDDDs,cumulativedefineddailydoses(prednisolone10mg);CI,confidenceinterval;HDL,highdensitylipoprotein;IV,intravenous;LDL,lowdensitylipoprotein;ONFH,osteonecrosisoffemoralhead;OR,oddsratio;TG,triglyceride;THA,totalhiparthroplasty.??Table6AdjustedRiskofTotalHipArthroplastyofOsteonecrosisofFemoralHeadPatients.ConditionalLogisticRegressionAnalysisforONFHDevelopmentCrudeOR??????95%CI???P?????AdjustedOR??95%CI???????PSex????????????????????????????????????????Men1.00ref.?????????1.00ref.??Women???0.890.79to1.01???.0601.030.88to1.20???????.731Age?1.011.00to1.01???<.001?????1.011.01to1.02???????<.001Householdincome????????????????????????????????????????Low1.000.86to1.16???.9891.020.88to1.19???????.786Middle???1.201.05to1.37???.0081.211.06to1.38???????.006High???????1.00ref.?????????1.00ref.??Comorbidities???????????????????????????????????????Hypertension?1.120.99to1.26???.0581.100.91to1.32.340Diabetesmellitus???0.950.83to1.09???.4460.80???????0.68to0.96???.013Dyslipidemia??1.090.97to1.23???.1570.980.81to1.19.842Frequencyofdrinkingalcohol?????????????????????????????????????????????<1d/wk??1.00ref.?????????1.00ref.??1to2d/wk?????1.231.05to1.45???.0111.231.02to1.47.0263to7d/wk?????1.501.30to1.74???<.001?????1.38???????1.16to1.65???<.001Missing??0.900.76to1.06???.2043.120.80to12.23???????.103Smokingstatus?????????????????????????????????????????????Nonsmoker????1.00ref.?????????1.00ref.??Ex-smoker?????1.311.11to1.56???.0020.251.03to1.52.027Currentsmoker??????1.261.09to1.45???.0021.17???????0.98to1.41???.085Missing??0.860.73to1.02???.0850.400.10to1.64???????.203BMI,kg/m2?????????????????????????????????????????<18·5?????0.940.67to1.31???.6980.890.63to1.25???????.51018·5to22·9???1.00ref.?????????1.00ref.??23·0to24·9???0.940.80to1.12???.4940.950.80to1.12.519≥25·0?1.090.95to1.26???.2321.110.96to1.29???????.176Missing??0.770.65to0.93???.0051.040.61to1.77???????.880HDL,mg/dL?????????????????????????????????????????<40?0.930.76to1.15???.5170.910.74to1.12???????.37640to59??1.00ref.?????????1.00ref.??≥60???????1.130.98to1.30???.0941.161.01to1.34???????.043Missing??0.770.66to0.90???<.001?????0.320.03to3.11.325LDL,mg/dL??????????????????????????????????????????<100??????1.00ref.?????????1.00ref.??100to159?????0.970.84to1.11???.6140.990.86to1.13.844≥160?????0.930.73to1.18???.5610.960.75to1.23???????.728Missing??0.740.63to0.87???<.001?????5.091.59to16.28??????.006TG,mg/dL????????????????????????????????????????????<150??????1.00ref.?????????1.00ref.??150to199?????1.070.89to1.29???.4471.050.87to1.27.583≥200?????1.191.02to1.39???.0301.110.94to1.31???????.231Missing??0.780.67to0.91???.0010.490.07to3.60???????.485Medication????????????????????????????????????????????Steroid(oralorhigh–doseIV)?????????????????????????????????????????????Neveruse???????1.00ref.?????????1.00ref.??Everuse?1.090.97to1.22???.1721.070.95to1.21???????.268POsteroid?????????????????????????????????????????????Neveruse???????1.00ref.?????????1.00ref.??Everuse?1.090.97to1.23???.1341.070.95to1.21???????.268Neveruse???????1.00ref.?????????1.00ref.??<180cDDDs??1.090.97to1.23???.1421.080.95to1.21.247180to364cDDDs?1.100.66to1.83???.7161.22???????0.73to2.06???.449365to729cDDDs?1.280.64to2.58???.4821.62???????0.79to3.36???.191≥730cDDDs<0.001???<0.001to999.944<0.001???????<0.001to999.943High–doseIVsteroid????????????????????????????????????????????Neveruse???????1.00ref.?????????1.00ref.??Everuse?0.910.64to1.29???.5920.900.63to1.28???????.552Neveruse???????1.00ref.?????????1.00ref.??<180cDDDs??0.950.64to1.39???.7760.870.59to1.30.504180to364cDDDs?0.600.15to2.41???.4740.71???????0.17to2.87???.626365to729cDDDs?1.200.45to3.20???.7191.35???????0.50to3.64???.554≥730cDDDs0.480.07to3.38???.4580.540.07to4.01.545Steroiduseduration?????????????????????????????????????????????Neveruse???????1.00ref.?????????1.00ref.??<3mobeforediagnosis?1.601.45-1.76<.001???????1.621.47-1.78<.0013-6mobeforediagnosis3.863.22-4.63<.001???????3.913.25-4.70<.0016-12mobeforediagnosis??????5.284.16-6.71<.001???????5.234.10-6.67<.001>12mobeforediagnosis7.575.98-9.59<.001???????7.405.82-9.42<.001?查看原圖BMI,bodymassindex;cDDDs,cumulativedefineddailydoses(prednisolone10mg);CI,confidenceinterval;HDL,highdensitylipoprotein;IV,intravenous;LDL,lowdensitylipoprotein;ONFH,osteonecrosisoffemoralhead;OR,oddsratio;PO,peroral;TG,triglyceride;THA,totalhiparthroplasty.??DiscussionWeevaluated3,488ONFHcasesand17,440controlcaseswithmatchingvariablesincludingage,sex,andthetimeofthefollow-upata1:5ratiofromtheNHIS-NSC,includingthefollow-updatafrom2002to2019of1,137,861participantsinanationwidelongitudinalnestedcase-controlstudy.Wedemonstratedthatalowhouseholdincome,diabetes,hypertension,dyslipidemia,heavyalcoholicswhoconsumedalcoholmorethan3daysaweek,andserumTGlevelsof200mg/dLormorewereassociatedwiththedevelopmentofONFH.Inaddition,systemiccorticosteroidusewassignificantlyassociatedwithanincreasedriskofONFHincidencecomparedtothatofnonusers.Specifically,theriskofONFHincreasedrapidlywhenthecDDDswere180ormorecumulativedosesofcorticosteroiduse.WeanalyzedthefactorsaffectingtheprogressionofthediseasebycomparingpatientswhounderwentTHAwiththosewhodidnotundergoTHAduringthefollow-upperiodafterONFHdiagnosis.Men,whohadahigherBMI,heavyalcoholicswhoconsumedalcoholmorethan3daysaweek,currentsmokers,andserumTGlevelsof200mg/dLormorewereassociatedwithTHAafterONFHdiagnosis.However,afteradjustingforcompoundfactors,heavyalcoholicsweretheonlyfactoraffectingtheincidenceofTHAafterONFHdiagnosis,anditmaybeusedtocounselONFHpatients.Otherlipidprofiles,corticosteroidsused,andcumulativedosesofcorticosteroidsdidnotaffecttheincidenceofTHA.我們?cè)u(píng)估了3488例ONFH病例和17440例對(duì)照病例，匹配變量包括年齡、性別和隨訪時(shí)間，比例為1:5，來(lái)自NHIS-NSC，包括2002年至2019年全國(guó)縱向巢式病例對(duì)照研究中1137861名參與者的隨訪數(shù)據(jù)。研究表明，家庭收入低、糖尿病、高血壓、血脂異常、每周飲酒超過(guò)3天的重度酗酒者以及血清TG水平≥200mg/dL與ONFH的發(fā)生有關(guān)。此外，與不使用皮質(zhì)類固醇的患者相比，全身性使用皮質(zhì)類固醇與ONFH發(fā)生率增加顯著相關(guān)。特別是，當(dāng)皮質(zhì)類固醇的累積使用劑量達(dá)到180或更高時(shí)，ONFH的風(fēng)險(xiǎn)迅速增加。我們通過(guò)比較ONFH診斷后隨訪期間接受THA和未接受THA的患者來(lái)分析影響疾病進(jìn)展的因素。BMI較高的男性、每周飲酒超過(guò)3天的重度酗酒者、當(dāng)前吸煙者、血清TG水平≥200mg/dL的男性在ONFH診斷后與THA相關(guān)。然而，在調(diào)整復(fù)合因素后，重度酗酒者是ONFH診斷后唯一影響THA發(fā)生率的因素，可用于指導(dǎo)ONFH患者。其他脂質(zhì)特征、使用的皮質(zhì)類固醇和皮質(zhì)類固醇的累積劑量對(duì)THA的發(fā)生率沒(méi)有影響。TherelationshipbetweencorticosteroiduseandONFHdevelopmenthasbeenrevealedinseveralstudies[8,25,26],andtherearealsosomestudiesthathavesuggestedspecificdosesanddurationsofcorticosteroiduse,suchastheassociationwiththedevelopmentofdiseasewhenusingmorethan2gwithin3months[27]orthemeancorticosteroiduseofpatientswhohaveONFHdevelopmentof3,314mg[28].Inthecurrentlargecohortstudyofthegeneralpopulation,weanalyzedvariousfactorsthatcanaffectthedevelopmentofONFH.Asinpreviousstudies,thecaseofcorticosteroiduseatleastonceandadditionalcumulativecorticosteroiddosewereassociatedwiththeincreasedriskofONFHdevelopment,andwhencumulativeprednisoloneusewas1,800mg(180cDDDs)ormore,theriskofONFHdevelopmentincreasedrapidly.Surely,thedevelopmentofONFHrelatedtocorticosteroiduseisthoughttobecausedbyacombinationofnotonlycorticosteroidusebutalsoseveralfactorssuchascomorbidities,alcohol,smoking,andgeneticfactors.Sincecorticosteroidtreatmentisoftenessentialformanydiseases,itisnecessarytobeawareofthecumulativedoseatwhichtheriskofONFHincreasesrapidlywhencontinuouscorticosteroidtreatmentisrequired.?一些研究已經(jīng)揭示了皮質(zhì)類固醇的使用與ONFH發(fā)展之間的關(guān)系[8,25,26]，也有一些研究提出了皮質(zhì)類固醇使用的特定劑量和持續(xù)時(shí)間，如在3個(gè)月內(nèi)使用超過(guò)2g與疾病發(fā)展的關(guān)系[27]，或ONFH發(fā)展患者的平均皮質(zhì)類固醇使用量為3,314mg[28]。在目前針對(duì)普通人群的大型隊(duì)列研究中，我們分析了影響ONFH發(fā)展的各種因素。與之前的研究一樣，至少使用一次皮質(zhì)類固醇和額外的皮質(zhì)類固醇累積劑量與ONFH發(fā)展的風(fēng)險(xiǎn)增加有關(guān)，當(dāng)潑尼松龍累積使用1800毫克(180cDDDs)或更多時(shí)，ONFH發(fā)展的風(fēng)險(xiǎn)迅速增加。當(dāng)然，與皮質(zhì)類固醇使用相關(guān)的ONFH的發(fā)展被認(rèn)為不僅是由皮質(zhì)類固醇使用引起的，還包括合并癥、酒精、吸煙和遺傳因素等多種因素。由于皮質(zhì)類固醇治療通常對(duì)許多疾病至關(guān)重要，因此有必要了解在需要持續(xù)皮質(zhì)類固醇治療時(shí)ONFH風(fēng)險(xiǎn)迅速增加的累積劑量。Tothebestofourknowledge,nostudyhascomparedtheincidenceofONFHwithhigh-doseIVandoralcorticosteroidsatthesamecumulativedose.Inthepresentstudy,bothoralcorticosteroidandhigh-doseIVcorticosteroidsincreasedtheriskofdevelopingONFH,andwhencomparingtheoralandhigh-doseIVatthesamecumulativedose,oralcorticosteroidhadahigherrisk;totheAORsoforalcorticosteroidwere1.61(<180cDDDs),4.39(180to365cDDDs),6.42(365to720cDDDs),and5.44(>720cDDDs).TheAORsofhigh-doseIVcorticosteroidwere1.63(<180cDDDs),2.34(180to365cDDDs),3.77(365to720cDDDs),and2.76(>720cDDDs),respectively.Ingeneral,sincetheprednisolonepotencyoforalcorticosteroidsismuchlowerthanthatofhigh-doseIV,thedurationoforalcorticosteroidusewouldhavebeenlongerifthesamecumulativedosewasused.Montetal.reportedthatONFHoccurrencewasassociatedwithmeandailycorticosteroiddose,cumulativedose,andtreatmentduration[8].Ofcourse,ONFHoccurrenceswouldbeaffectedbygeneticsusceptibilityandexposuretovariousriskfactors,butinourstudy,weconfirmedthatmoreONFHoccurredinoralcorticosteroidswitharelativelysmalldailydoseatthesamecumulativedosecomparedtohigh-doseIVcorticosteroid,soitisassumedthatthelongertreatmentperiodofcorticosteroidisalsoassociatedwithdevelopingONFH.據(jù)我們所知，沒(méi)有研究比較相同累積劑量的高劑量靜脈注射和口服皮質(zhì)類固醇對(duì)ONFH的發(fā)生率。在本研究中，口服皮質(zhì)類固醇和高劑量靜脈注射皮質(zhì)類固醇都增加了發(fā)生ONFH的風(fēng)險(xiǎn)，并且在相同累積劑量下，口服皮質(zhì)類固醇與高劑量靜脈注射皮質(zhì)類固醇相比，風(fēng)險(xiǎn)更高;口服皮質(zhì)類固醇的AORs分別為1.61(<180cDDDs)、4.39(180~365cDDDs)、6.42(365~720cDDDs)和5.44(>720cDDDs)。高劑量靜脈注射皮質(zhì)類固醇的AORs分別為1.63(<180cDDDs)、2.34(180~365cDDDs)、3.77(365~720cDDDs)和2.76(>720cDDDs)。一般來(lái)說(shuō)，由于口服皮質(zhì)類固醇的強(qiáng)的松龍效力遠(yuǎn)低于高劑量靜脈注射，如果使用相同的累積劑量，口服皮質(zhì)類固醇的使用時(shí)間會(huì)更長(zhǎng)。Mont等人報(bào)道ONFH的發(fā)生與皮質(zhì)類固醇的平均每日劑量、累積劑量和治療時(shí)間有關(guān)[8]。當(dāng)然，ONFH的發(fā)生會(huì)受到遺傳易感性和暴露于各種危險(xiǎn)因素的影響，但在我們的研究中，我們證實(shí)在相同累積劑量下，相對(duì)于高劑量靜脈注射皮質(zhì)類固醇，日劑量相對(duì)較小的口服皮質(zhì)類固醇更易發(fā)生ONFH，因此我們假設(shè)皮質(zhì)類固醇治療時(shí)間越長(zhǎng)也與ONFH的發(fā)生有關(guān)。ItiswellknownthatahigherTGlevel,orLDLcholesterol,isanimportantriskfactorforischemicheartdiseaseandstrokebyinhibitingbloodflow,andONFHispresumedtoberelatedtoinhibitionofbloodflowtothefemoralheadinasimilarmechanism[29].Similartopreviousstudies[7,30],higherTGwasariskfactorforONFHinourstudy.Inaddition,itwasconfirmedthatLDLatlessthan100mg/dLhasaprotectiveeffectontheoccurrenceofONFH.眾所周知，較高的TG或LDL膽固醇水平通過(guò)抑制血流是缺血性心臟病和中風(fēng)的重要危險(xiǎn)因素，而ONFH被認(rèn)為與股骨頭血流的抑制有類似的機(jī)制[29]。與以往的研究相似[7,30]，在我們的研究中，高TG是ONFH的危險(xiǎn)因素。此外，還證實(shí)了低于100mg/dL的LDL對(duì)ONFH的發(fā)生有保護(hù)作用。SinceONFHoccurspredominantlyinyoungerpatientsandpreservationofthenativejointasmuchaspossibleistheprincipleoftreatment,thediseaseprogressionandprognosisareasimportantastheoccurrenceofthedisease.WeoftenseecasesofbilateralONFHdevelopmentwhereonesidehasfemoralcollapseandtheothersideremainsasymptomaticwithoutfemoralheadcollapse.Alternatively,somecaseswereasymptomaticwithoutfemoralheadcollapse,butreceivedTHA.ItisknownthattheprognosisafterONFHdevelopmentisinfluencedbyvariousfactors,anduntilnow,therehavebeenstudiesshowingthatradiologicfactorssuchasthesizeorlocationofnecrosisoracetabularanatomicalfactorshaveaneffect[1,19,31].Montetal.reportedthattheprevalenceoffemoralheadcollapsewas38%(106of282hips)inameta-analysisandvariedfrom17to73%dependingontheriskfactor[16].Inourstudy,34.3%ofpatientsunderwentTHA,anaverageof1.03±2.25yearsafterdiagnosis,similartothepreviousstudy.Althoughradiologicassessmentcouldnotbeperformed,casesthatmayhaveseengreaterphysicalloads,suchasmen,whohadahigherBMI,excessivedrinking,smoking,andahigherserumTGlevelover200mg/dL,wereassociatedwithdiseaseprogression.Inparticular,thefactorsthatincreasedtheriskofdiseaseprogressionweredifferentinmenandwomen.Wefoundthatcorticosteroidsprescribedornotandcumulativedosesofcorticosteroidswereunlikelytoaffectdiseaseprogression.由于ONFH主要發(fā)生在年輕患者中，治療原則是盡可能保留原有關(guān)節(jié)，因此疾病的進(jìn)展和預(yù)后與疾病的發(fā)生同樣重要。我們經(jīng)?？吹诫p側(cè)ONFH發(fā)展的病例，其中一側(cè)有股骨頭塌陷，另一側(cè)無(wú)股骨頭塌陷癥狀。另外，一些病例無(wú)股骨頭塌陷癥狀，但接受了THA。眾所周知，ONFH發(fā)生后的預(yù)后受多種因素影響，迄今已有研究表明，壞死的大小或位置等放射學(xué)因素或髖臼解剖因素對(duì)ONFH的預(yù)后有影響[1,19,31]。Mont等人在一項(xiàng)薈萃分析中報(bào)道，股骨頭塌陷的患病率為38%(282髖中的106髖)，根據(jù)危險(xiǎn)因素的不同，患病率從17%到73%不等[16]。在我們的研究中，34.3%的患者接受了THA，平均診斷后1.03±2.25年，與之前的研究相似。雖然無(wú)法進(jìn)行放射學(xué)評(píng)估，但可能出現(xiàn)較大身體負(fù)荷的病例，如男性，BMI較高，過(guò)度飲酒，吸煙，血清TG水平高于200mg/dL，與疾病進(jìn)展相關(guān)。特別是，增加疾病進(jìn)展風(fēng)險(xiǎn)的因素在男性和女性中是不同的。我們發(fā)現(xiàn)，開(kāi)具或不開(kāi)具皮質(zhì)類固醇以及皮質(zhì)類固醇的累積劑量不太可能影響疾病進(jìn)展。Ourstudyhasseveralpotentiallimitationsthatshouldbeaddressedinfurtherstudies.TheONFHwasassessedbyanoperationaldefinitionusingadiagnosiscode,notbyaradiologicevaluationsuchasanx-rayorMRI.However,theincidenceofONFHinthisstudywassimilartothatinapreviousAsiangeneralpopulationstudythatdefineditusinghipjointx-raysand/orMRI[32].BecauseanaccurateselectionofONFHpatientsmaynothavebeenmade,anestedcase-controlanalysisfromapopulation-basedcohortwasperformedtoincreasetheaccuracyoftheanalysis.Additionally,usingtheNHIS-NSCdatabase,prescriptionrecordsforcorticosteroidscouldbeaccessed.However,theactualintakeofcorticosteroidsinsubjectsmightbedifferentfromtheprescriptionrecords.Fortunately,severalstudieshaveshownagoodcorrelationbetweenprescriptionsandrealexposuretodrugs[33,34].Also,wecouldnotobtaininformationabouttraumaticONFH,whichmayhaveinfluencedtheresultsofthecurrentstudy.Inaddition,wecouldnotassessotherinterventionsthatcouldaffectdyslipidemia,microvascularbloodflow,andosteogenesis,suchastheuseoflipid-loweringmedication,aspirin,antiplatelets,andanticoagulantmedication.Thisshouldbeevaluatedinfuturestudies.Furthermore,ananalysisofmultiplecomorbiditiessuchasrheumaticdisease,sicklecelldisease,humanimmunodeficiencyvirus,organtransplantation,andsoonthatcouldaffecttheoccurrenceandprognosisofONFHwasnotperformed.Inparticular,sincetheprognosisofONFHisdifferentforeachdisease,subgroupanalysisaccordingtocomorbidityisabsolutelynecessaryforfuturestudies.Additionally,weanalyzedtheassociationbetweencumulativedoseofcorticosteroidanddiseaseprogressionafterONFHdiagnosisusingcDDD,andweconfirmedthatcumulativedoseofcorticosteroiddidnotaffectdiseaseprogression.However,sincethenumberofpatientswhohave180cDDDormorewassmall,additionalanalysiswithalargernumberofpatientsmaybeneededtoobtainmoreaccurateresults.我們的研究有幾個(gè)潛在的局限性，應(yīng)該在進(jìn)一步的研究中加以解決。ONFH通過(guò)使用診斷代碼的操作定義進(jìn)行評(píng)估，而不是通過(guò)x射線或MRI等放射學(xué)評(píng)估。然而，本研究中ONFH的發(fā)生率與先前的亞洲普通人群研究相似，該研究使用髖關(guān)節(jié)X光片和/或MRI來(lái)定義ONFH[32]。由于可能沒(méi)有對(duì)ONFH患者進(jìn)行準(zhǔn)確的選擇，因此進(jìn)行了基于人群的隊(duì)列嵌套病例對(duì)照分析，以提高分析的準(zhǔn)確性。此外，使用NHIS-NSC數(shù)據(jù)庫(kù)，可以訪問(wèn)皮質(zhì)類固醇的處方記錄。然而，受試者的實(shí)際皮質(zhì)類固醇攝入量可能與處方記錄不同。幸運(yùn)的是，有幾項(xiàng)研究表明，處方與實(shí)際接觸藥物之間存在良好的相關(guān)性[33,34]。此外，我們無(wú)法獲得有關(guān)創(chuàng)傷性O(shè)NFH的信息，這可能影響了當(dāng)前研究的結(jié)果。此外，我們無(wú)法評(píng)估其他可能影響血脂異常、微血管血流和成骨的干預(yù)措施，如使用降脂藥物、阿司匹林、抗血小板和抗凝藥物。這應(yīng)該在未來(lái)的研究中進(jìn)行評(píng)估。此外，對(duì)風(fēng)濕病、鐮狀細(xì)胞病、人類免疫缺陷病毒、器官移植等可能影響ONFH發(fā)生和預(yù)后的多重合并癥未進(jìn)行分析。特別是，由于每種疾病的預(yù)后不同，因此根據(jù)合并癥進(jìn)行亞組分析對(duì)于未來(lái)的研究是絕對(duì)必要的。此外，我們分析了使用cDDD診斷ONFH后皮質(zhì)類固醇累積劑量與疾病進(jìn)展之間的關(guān)系，我們證實(shí)皮質(zhì)類固醇累積劑量不影響疾病進(jìn)展。然而，由于cDDD≥180的患者數(shù)量較少，因此可能需要對(duì)更多患者進(jìn)行額外分析，以獲得更準(zhǔn)確的結(jié)果。?ConclusionLowhouseholdincome,diabetes,hypertension,dyslipidemia,heavyalcoholicswhoconsumedalcoholmorethan3daysaweek,serumTGlevelsof200mg/dLormore,andoralorhigh-doseIVcorticosteroiduseareassociatedwithONFHdevelopment.Specifically,theriskofONFHincreasedrapidlywhencumulativeprednisoloneusewas1,800mgormore.However,oralorhigh-doseIVcorticosteroiduseandcumulativedosedidnotaffecttheprognosisofONFH.SincethedevelopmentandprognosisofONFHarecomplexandmultifactorialprocesses,furtherstudyisneeded.低收入家庭、糖尿病、高血壓、血脂異常、每周飲酒超過(guò)3天的重度酗酒者、血清TG水平≥200mg/dL、口服或高劑量靜脈注射皮質(zhì)類固醇與ONFH的發(fā)生有關(guān)。具體來(lái)說(shuō)，當(dāng)累積使用強(qiáng)的松龍超過(guò)1800毫克時(shí)，ONFH的風(fēng)險(xiǎn)迅速增加。然而，口服或高劑量靜脈注射皮質(zhì)類固醇和累積劑量對(duì)ONFH的預(yù)后沒(méi)有影響。由于ONFH的發(fā)展和預(yù)后是一個(gè)復(fù)雜的多因素過(guò)程，需要進(jìn)一步研究。2024年09月27日
92
0
0
-
畢春強(qiáng)主任醫(yī)師 中國(guó)中醫(yī)科學(xué)院廣安門醫(yī)院南區(qū) 骨科 骨質(zhì)疏松癥在初期通常沒(méi)有明顯的臨床表現(xiàn)，但是隨著發(fā)展，可能會(huì)出現(xiàn)脊柱變形、疼痛、和輕微外力下的骨折。因此稱它為寂靜的疾病或者靜悄悄的疾病?！?骨質(zhì)疏松主要有以下4個(gè)表現(xiàn)：（1）疼痛。疼痛是原發(fā)性骨質(zhì)疏松癥最為常見(jiàn)的癥狀。患者表現(xiàn)為不明原因的腰背疼痛，沿著脊柱兩側(cè)彌漫性癥布，平臥休息以后，疼痛可以稍微緩解，直立后仰、久站久坐后疼痛會(huì)非常明顯。（2）變矮駝背。許多老年朋友感覺(jué)自己身高跟年輕時(shí)相比明顯“縮水”了，腰也伸不直了。骨質(zhì)疏松的脊柱椎體骨量明顯減少、骨強(qiáng)度差，容易壓縮變形，尤其是彎腰等動(dòng)作容易導(dǎo)致椎體前部分壓縮變扁，這種原因?qū)е碌纳砀叨炭s通常超過(guò)3厘米且有駝背的表現(xiàn)。（3）骨折。骨折是最嚴(yán)重的骨質(zhì)疏松并發(fā)癥，輕則影響機(jī)體功能，重則致殘甚至致死。嚴(yán)重骨質(zhì)疏松的患者，輕微受傷甚至日常做家務(wù)，如從沙發(fā)上坐地跌倒、彎腰拖地、崴腳就可導(dǎo)致相應(yīng)部位的骨折，常見(jiàn)的骨折部位是腰背部、髖部和手臂。（4）心肺功能受損。骨質(zhì)疏松的患者如發(fā)生胸、腰椎壓縮性骨折，可出現(xiàn)脊椎后凸畸形（駝背），胸腔容量變小且胸廓活動(dòng)范圍受限，導(dǎo)致肺活量和最大換氣量顯著減少，患者往往感覺(jué)心慌、憋氣、氣不夠用等，以爬樓、擰重物時(shí)較為明顯。為什么會(huì)出現(xiàn)骨質(zhì)疏松？老年人容易得骨質(zhì)疏松主要是由于性激素的減少、臟器功能的減弱，刺激了破骨細(xì)胞，同時(shí)也抑制了成骨細(xì)胞的增生，造成了骨量減少。在臨床上骨質(zhì)疏松是非常常見(jiàn)的一種疾病。有研究表明，六十歲以上的老年人得骨質(zhì)疏松的幾率可以達(dá)到百分之三十五以上，并且隨著年齡的增長(zhǎng)幾率逐漸增加。隨著老年人年齡的增長(zhǎng)，其臟器的功能會(huì)下降，吸收營(yíng)養(yǎng)的效率也會(huì)減退。導(dǎo)致維生素D的缺乏、鈣流失等，從而引起骨質(zhì)疏松。女性由于絕經(jīng)以后，雌激素水平降低，無(wú)法有效的抑制破骨細(xì)胞，導(dǎo)致破骨細(xì)胞過(guò)度的增生和活躍，也會(huì)導(dǎo)致骨的分解和吸收而形成骨質(zhì)疏松?？梢酝ㄟ^(guò)口服藥物以及在日常生活中增加鈣含量的食物來(lái)改善骨質(zhì)疏松。什么是腰間盤突出？骨質(zhì)疏松會(huì)導(dǎo)致骨頭強(qiáng)度下降，椎間盤承受壓力會(huì)過(guò)高，椎間盤纖維環(huán)發(fā)生破損的幾率就會(huì)變高。纖維環(huán)一旦破損就出現(xiàn)腰間盤突出，骨質(zhì)疏松跟腰間盤突出是有一定的關(guān)系的。骨質(zhì)疏松跟腰間盤突出是兩種不同的疾病，骨質(zhì)疏松使骨的強(qiáng)度下降，椎間盤突出是椎間盤破壞以后或椎間盤前塊損傷以后，導(dǎo)致神經(jīng)卡壓的一種表現(xiàn)。骨質(zhì)疏松如何引起股骨頭壞死？導(dǎo)致股骨頭壞死的常見(jiàn)因素，有長(zhǎng)期服用激素類藥物，外傷以及大量飲酒，強(qiáng)制性的脊柱炎，先天性的髖臼發(fā)育不良等。骨質(zhì)疏松是股骨頭壞死的病因之一。骨質(zhì)疏松的患者骨骼中，蛋白鈣、磷的比例減少，骨的脆性增加，容易發(fā)生骨折。如果骨折發(fā)生在股骨頭部位，就會(huì)引發(fā)股骨頭的血運(yùn)受到損害，造成股骨頭局部的血液循環(huán)障礙，進(jìn)而引發(fā)股骨頭壞死。此外，由于骨質(zhì)疏松造成骨吸收增加，疏松的股骨頭強(qiáng)度會(huì)降低，股骨頭局部會(huì)出現(xiàn)壓縮塌陷，導(dǎo)致流經(jīng)股骨頭部的骨流量減少，股骨頭的骨細(xì)胞和骨髓成分會(huì)引發(fā)股骨頭壞死。骨質(zhì)疏松應(yīng)該如何進(jìn)行治療？對(duì)于骨質(zhì)疏松首先要注意是骨質(zhì)疏松還是骨質(zhì)疏松癥，因?yàn)楣琴|(zhì)疏松是一個(gè)慢性的蛻變性信號(hào)。骨質(zhì)疏松治療方法：首先要強(qiáng)調(diào)非藥物的治療為主。比如采用平衡的飲食，適當(dāng)?shù)难a(bǔ)充鈣劑、維生素D，適當(dāng)?shù)幕顒?dòng)，戒煙，預(yù)防摔倒，這個(gè)是骨質(zhì)疏松一個(gè)基本的治療前提和方案。2024年05月13日242
0
1
-
唐浩副主任醫(yī)師 北京積水潭醫(yī)院 矯形骨科 股骨頭壞死（Avascularnecrosisofthefemoralhead.AVN）是一種常見(jiàn)的骨科疾病，指的是由于各種原因?qū)е鹿晒穷^的血液供應(yīng)不足，從而引起骨細(xì)胞和骨髓細(xì)胞的死亡，進(jìn)而導(dǎo)致股骨頭的結(jié)構(gòu)破壞和塌陷，最終形成髖關(guān)節(jié)炎。股骨頭壞死多發(fā)生在中青年人群，主要表現(xiàn)為髖關(guān)節(jié)疼痛和活動(dòng)受限，嚴(yán)重影響生活質(zhì)量和工作能力，被稱為“不死的癌癥”。股骨頭壞死的原因可以分為原發(fā)性和繼發(fā)性兩大類。原發(fā)性股骨頭壞死又稱為特發(fā)性股骨頭壞死：顧名思義，主要是指股骨頭壞死的原因不明確。對(duì)于有明確原因的股骨頭壞死，稱為繼發(fā)性股骨頭壞死，可分為創(chuàng)傷性和非創(chuàng)傷性兩大類。創(chuàng)傷性股骨頭壞死：是指由于髖部外傷，如股骨頸骨折、髖臼骨折、髖關(guān)節(jié)脫位等，導(dǎo)致股骨頭的血管受損或中斷，造成股骨頭的缺血壞死。非創(chuàng)傷性股骨頭壞死：是指由于其他原因，如長(zhǎng)期使用或?yàn)E用糖皮質(zhì)激素、長(zhǎng)期過(guò)量飲酒、減壓病、血液病、自身免疫病、感染、放射治療等，導(dǎo)致股骨頭的血管痙攣、狹窄、栓塞或閉塞，造成股骨頭的缺血壞死。我國(guó)非創(chuàng)傷性股骨頭壞死最常見(jiàn)的原因是飲酒和糖皮質(zhì)激素導(dǎo)致的壞死。因此，我們應(yīng)該避免長(zhǎng)期大量飲酒，在醫(yī)生指導(dǎo)下應(yīng)用糖皮質(zhì)激素，預(yù)防出現(xiàn)股骨頭壞死。股骨頭壞死的癥狀因病變的部位、范圍和程度不同而異。早期，股骨頭壞死可能沒(méi)有明顯的癥狀，或者只有輕微的髖關(guān)節(jié)不適，難以引起注意。隨著病情的發(fā)展，股骨頭壞死會(huì)出現(xiàn)以下的癥狀：?髖關(guān)節(jié)疼痛：這是股骨頭壞死的最常見(jiàn)和最主要的癥狀，通常表現(xiàn)為病變側(cè)的髖部、臀部或腹股溝部位的疼痛，有時(shí)也會(huì)放射到大腿內(nèi)側(cè)或膝關(guān)節(jié)。疼痛的性質(zhì)可以是鈍痛、隱痛、刺痛或劇痛，疼痛的程度可以是輕微、中等或嚴(yán)重，疼痛的時(shí)間可以是間歇性、持續(xù)性或加重性。一般來(lái)說(shuō)，疼痛會(huì)隨著活動(dòng)的增加而加重，隨著休息的延長(zhǎng)而減輕，但在病變嚴(yán)重時(shí)，即使在靜止或夜間也會(huì)出現(xiàn)疼痛。?髖關(guān)節(jié)活動(dòng)受限：這是股骨頭壞死的另一個(gè)常見(jiàn)的癥狀，通常表現(xiàn)為病變側(cè)的髖關(guān)節(jié)的活動(dòng)范圍減少，特別是內(nèi)旋、屈曲和外展等方向的活動(dòng)受限。髖關(guān)節(jié)活動(dòng)受限會(huì)影響患者的正常行走、下蹲、上下樓梯等日?；顒?dòng)，甚至導(dǎo)致跛行或需要使用輔助器具。?髖關(guān)節(jié)畸形：這是股骨頭壞死的晚期癥狀，通常表現(xiàn)為病變側(cè)的髖關(guān)節(jié)的外形發(fā)生改變，如股骨頭塌陷、髖關(guān)節(jié)間隙狹窄、下肢短縮等。髖關(guān)節(jié)畸形會(huì)進(jìn)一步加重髖關(guān)節(jié)的疼痛和活動(dòng)受限，甚至導(dǎo)致髖關(guān)節(jié)的功能喪失。股骨頭壞死的分型和分期有多種方法，常用的有以下幾種：?根據(jù)病變的程度，分為Ficat分期和ARCO分期。Ficat分期是最常用的分期方法，根據(jù)X線片的表現(xiàn)，分為0期、I期、II期、III期和IV期。0期：無(wú)疼痛，X線片正常，MRI或骨掃描出現(xiàn)異常；I期：有疼痛，X線片正常，MRI或骨掃描出現(xiàn)異常；II期：有疼痛，X線片出現(xiàn)囊性變或硬化，沒(méi)有軟骨下骨折；III期：有疼痛，X線片出現(xiàn)股骨頭塌陷，有新月征或臺(tái)階征；IV期：有疼痛，X線片出現(xiàn)髖臼病變，有關(guān)節(jié)間隙狹窄和骨關(guān)節(jié)炎。ARCO分型是在FICAT分期的基礎(chǔ)之上，根據(jù)X光片上股骨頭壞死的范圍，將每一期進(jìn)一步分為ABC三個(gè)亞型，并發(fā)現(xiàn)ARCO1/2C型的患者股骨頭塌陷率高達(dá)70-90%。這是因?yàn)镃型患者股骨頭壞死區(qū)域超出了髖臼邊緣以外，整個(gè)壞死區(qū)域都在髖臼應(yīng)力集中區(qū)域，因而更加容易發(fā)生塌陷。?A型：壞死區(qū)位于股骨頭的中心部，占據(jù)股骨頭的1/4至1/2。?B型：壞死區(qū)位于股骨頭的邊緣部，占據(jù)股骨頭的1/4至1/2，但仍在髖臼邊緣外側(cè)負(fù)重區(qū)以內(nèi)。?C型：壞死區(qū)位于股骨頭的整個(gè)部位，占據(jù)股骨頭的1/2以上，超過(guò)了髖臼邊緣外側(cè)負(fù)重區(qū)。ARCO分型的意義在于，由于不同類型患者的塌陷風(fēng)險(xiǎn)不同，該分型可以指導(dǎo)治療方案和預(yù)后：A型的患者可以采用保髖治療，如髓心減壓、骨移植等；B型的患者可以采用保髖或置換治療，如髖臼成形術(shù)、表面置換術(shù)等；C型的患者則需要采用置換治療，如全髖關(guān)節(jié)置換術(shù)。股骨頭壞死的治療方法主要有非手術(shù)治療和手術(shù)治療兩種。非手術(shù)治療適用于ARCO1/2A型患者，或者已塌陷患者置換前的對(duì)癥治療：?藥物治療：目前常用藥物包括降脂藥（如阿托伐他?。⑴c骨代謝藥物（如雙膦酸鹽）、抗凝藥（如阿司匹林）、血管擴(kuò)張劑（如尼可地爾）、抗炎藥（如非甾體抗炎藥）等，可以改善股骨頭的血液循環(huán)，減輕炎癥反應(yīng)，促進(jìn)骨組織修復(fù)。?物理治療：包括體外高能震波、高壓氧、電磁場(chǎng)、超聲波等，可以刺激股骨頭的血管生成，增加骨髓血流，抑制骨吸收，增強(qiáng)骨形成。非手術(shù)治療的優(yōu)點(diǎn)是無(wú)創(chuàng)、安全、經(jīng)濟(jì)，但缺點(diǎn)是效果不穩(wěn)定、不可預(yù)測(cè)，需要長(zhǎng)期堅(jiān)持，且不能根本解決股骨頭的壞死問(wèn)題，只能延緩病情的進(jìn)展。因此，非手術(shù)治療需要嚴(yán)格遵循醫(yī)囑，定期復(fù)查，及時(shí)評(píng)估療效，一旦發(fā)現(xiàn)股骨頭有塌陷的跡象，應(yīng)及時(shí)轉(zhuǎn)為手術(shù)治療。?保髖手術(shù)：保髖手術(shù)是指通過(guò)保留患者自身的股骨頭為主的修復(fù)重建術(shù)，來(lái)延緩或避免行人工髖關(guān)節(jié)置換術(shù)。保髖手術(shù)的種類很多，常用術(shù)式包括髓芯減壓術(shù)、截骨術(shù)、帶或不帶血運(yùn)的骨移植術(shù)、鉭棒植入手術(shù)、介入手術(shù)、股骨頭自體干細(xì)胞移植等。保髖手術(shù)適用于股骨頭壞死早期（FICATⅠ期和Ⅱ期），且壞死體積在15%以上者。保髖手術(shù)的優(yōu)點(diǎn)是可以最大限度地保留患者自身的骨組織和關(guān)節(jié)功能，避免人工關(guān)節(jié)置換術(shù)的并發(fā)癥和修復(fù)術(shù)。但缺點(diǎn)是有一定的失敗率和復(fù)發(fā)率，需要嚴(yán)格掌握適應(yīng)癥和手術(shù)時(shí)機(jī)。對(duì)塌陷前的ARCO1-2A/B型的患者，積水潭醫(yī)院矯形骨科周一新教授領(lǐng)銜研發(fā)了一種新的股骨頭壞死保髖治療術(shù)式——多孔AVNCage（3D打印籠形鈦金屬假體）支撐術(shù)，可避免既往鉭棒、人工骨、異體骨等植入材料的局限性（如導(dǎo)致后續(xù)治療困難和粗隆區(qū)骨折的并發(fā)癥、不能長(zhǎng)時(shí)間維持壞死區(qū)減壓、阻礙粗隆區(qū)向壞死區(qū)的修復(fù)通道、不能形成長(zhǎng)期有效力學(xué)支撐等）。自2018年開(kāi)始，我們采用AVNCAGE這一新型假體，并改良手術(shù)工具及手術(shù)方式，可避免牽引床手術(shù)，可有效避免術(shù)中股骨頭穿透等并發(fā)癥。該項(xiàng)創(chuàng)新術(shù)式將手術(shù)時(shí)間從1-2小時(shí)縮短為平均0.5小時(shí)，使2年股骨頭生存率從平均70-75%(髓心減壓術(shù)）提高至88%，使很多中青年病人避免了致殘及人工關(guān)節(jié)置換術(shù)，降低了醫(yī)療費(fèi)用，獲批多項(xiàng)專利，獲NMPA3類注冊(cè)證1項(xiàng)，目前已經(jīng)在國(guó)內(nèi)臨床應(yīng)用400余例。針對(duì)股骨頭壞死已經(jīng)塌陷，但仍未發(fā)生髖關(guān)節(jié)骨關(guān)節(jié)炎的FICAT3期患者，傳統(tǒng)保髖手術(shù)就無(wú)能為力了。針對(duì)這一部分患者的臨床需求，積水潭醫(yī)院矯形骨科周一新教授領(lǐng)銜研發(fā)了一種新型3D打印個(gè)性化定制部分髖關(guān)節(jié)假體，采用不損傷旋股動(dòng)脈的外科脫位入路，進(jìn)行塌陷區(qū)域股骨頭的部分置換，恢復(fù)關(guān)節(jié)面平滑度，延緩關(guān)節(jié)炎進(jìn)展，延后或避免全髖置換術(shù)。自2021年，我中心已開(kāi)始以定制化手術(shù)開(kāi)展3D打印定制部分髖關(guān)節(jié)置換術(shù)，適應(yīng)證為塌陷早期且壞死面積相對(duì)局限的股骨頭壞死病例，采用外科脫位入路，術(shù)中不切斷任何髖關(guān)節(jié)肌肉，保留髖臼側(cè)所有正常結(jié)構(gòu)，可極大保留髖關(guān)節(jié)功能，臨床隨訪使得傳統(tǒng)100需要髖關(guān)節(jié)置換的FICAT3期患者，有75%病例獲得明顯延緩甚至避免行全髖置換術(shù)。該手術(shù)填補(bǔ)了FICAT3期股骨頭壞死的手術(shù)治療空白，為因股骨頭塌陷致殘的中青年病人帶來(lái)了新的治療選擇。當(dāng)股骨頭壞死進(jìn)展為髖關(guān)節(jié)炎（FICAT4期），就失去了保髖治療機(jī)會(huì)了，需要進(jìn)行人工髖關(guān)節(jié)置換術(shù)。人工髖關(guān)節(jié)置換術(shù)的種類也很多，常用術(shù)式包括全髖關(guān)節(jié)置換術(shù)、表面置換術(shù)、半髖關(guān)節(jié)置換術(shù)等。人工髖關(guān)節(jié)置換術(shù)適用于股骨頭壞死晚期（FICAT3-4期）且癥狀嚴(yán)重、保髖手術(shù)失敗或不適合者。人工髖關(guān)節(jié)置換術(shù)的優(yōu)點(diǎn)是可以徹底解決股骨頭壞死引起的疼痛和功能障礙，療效顯著、穩(wěn)定，但缺點(diǎn)是有一定的手術(shù)風(fēng)險(xiǎn)和并發(fā)癥，如感染、血栓、脫位、松動(dòng)等，且人工關(guān)節(jié)有一定的使用壽命，對(duì)于年輕患者，存在可能需要進(jìn)行二次翻修的風(fēng)險(xiǎn)。2024年02月13日1378
0
3
-
2023年11月20日164
0
0
-
陶可主治醫(yī)師 北京大學(xué)人民醫(yī)院 骨關(guān)節(jié)科 股骨頭壞死：基礎(chǔ)知識(shí)2019年(致每一位曾經(jīng)或正在遭受股骨頭壞死折磨的病患，都需要了解的科學(xué)知識(shí))作者：MichelleJLespasio,NipunSodhi,MichaelAMont.作者單位:DepartmentofOrthopedicSurgery,BostonMedicalCenter,MA.譯者：陶可（北京大學(xué)人民醫(yī)院骨關(guān)節(jié)科）摘要在本報(bào)告中，我們對(duì)骨股骨頭壞死進(jìn)行了簡(jiǎn)明且最新的回顧，股骨頭骨壞死是一種病理性、疼痛性且常常致殘的疾病，據(jù)報(bào)道是由于受影響的骨骼區(qū)域的血液供應(yīng)暫時(shí)或永久中斷造成的。我們將討論髖關(guān)節(jié)股骨頭骨壞死的流行病學(xué)（疾病分布）、發(fā)病機(jī)制（發(fā)展機(jī)制）、病因（相關(guān)危險(xiǎn)因素、原因和疾?。?、臨床表現(xiàn)（報(bào)告的癥狀和查體結(jié)果）、診斷和分類以及治療方案。ConnectionsEveryactivityofthelivingorganismisconnectedwithaseparatepartofthebodywhenceitarises.Therefore,anactivityisnecessarilydamagedwhenthepartwhichproducesitisaffected.—GalenofPergamon,130AD-210AD,prominentGreekphysician,surgeon,andphilosopherintheRomanEmpire生物體的每項(xiàng)活動(dòng)都與其產(chǎn)生該活動(dòng)的身體的一個(gè)單獨(dú)部分相關(guān)。因此，當(dāng)產(chǎn)生某項(xiàng)活動(dòng)的部分受到影響時(shí)，該活動(dòng)必然會(huì)受到損害?！寮用傻纳w倫，公元130年至公元210年，羅馬帝國(guó)著名的希臘內(nèi)科醫(yī)生、外科醫(yī)生和哲學(xué)家Figure1Left,radiographofahealthyhipjoint.Right,radiographofahipjointwheretheosteonecrosishasprogressedtocollapseofthefemoralhead.圖1左圖是健康髖關(guān)節(jié)的X線片；右圖是髖關(guān)節(jié)股骨頭壞死已發(fā)展到塌陷階段的X線片。Figure2ProgressionofosteonecrosisusingtheFicat＆Arletclassificationsystem.Osteonecrosiscanprogressfromanormal,healthyhip(StageI)tothecollapseofthefemoralhead(StageIV).?圖2使用Ficat和Arlet分類系統(tǒng)的股骨頭骨壞死進(jìn)展情況。股骨頭骨壞死可以從正常、健康的髖關(guān)節(jié)（第一階段）發(fā)展到股骨頭塌陷(并骨關(guān)節(jié)炎)（第四階段）。介紹本文的目的是介紹影響股骨頭或髖關(guān)節(jié)的骨壞死(ON)的最新情況，以及如何在成年人群中最好地治療該病。具體來(lái)說(shuō)，本報(bào)告將涵蓋髖關(guān)節(jié)股骨頭壞死(ON)的流行病學(xué)、發(fā)病機(jī)制、病因、臨床表現(xiàn)、診斷和分類以及治療方案。股骨頭壞死(ON)，也稱為缺血性壞死、無(wú)菌性壞死或缺血性骨壞死，與許多導(dǎo)致成熟骨細(xì)胞死亡的疾病和危險(xiǎn)因素有關(guān)，從而導(dǎo)致骨破壞（例如塌陷）或終末期髖關(guān)節(jié)骨關(guān)節(jié)炎。這種情況可能發(fā)生在身體的任何骨骼（例如上肢、膝關(guān)節(jié)、肩關(guān)節(jié)和腳踝關(guān)節(jié)），或者在不同時(shí)間發(fā)生在超過(guò)1處骨骼，但最常見(jiàn)的是影響髖關(guān)節(jié)。當(dāng)最初在髖關(guān)節(jié)以外的區(qū)域進(jìn)行診斷時(shí)，應(yīng)同時(shí)對(duì)髖關(guān)節(jié)進(jìn)行臨床評(píng)估以及放射線和其他影像學(xué)研究。股骨頭壞死(ON)的原因分為外傷性（與損傷相關(guān)）或非外傷性（與損傷無(wú)關(guān)）。準(zhǔn)確診斷和分類股骨頭壞死(ON)對(duì)于幫助指導(dǎo)治療選擇非常重要。識(shí)別相關(guān)風(fēng)險(xiǎn)因素和患者教育對(duì)于成功治療股骨頭壞死(ON)非常重要。針對(duì)相關(guān)危險(xiǎn)因素、藥物管理和/或手術(shù)，包括關(guān)節(jié)保留手術(shù)和全髖關(guān)節(jié)置換術(shù)(THA)，在股骨頭壞死(ON)患者的臨床管理中也發(fā)揮著重要作用。髖關(guān)節(jié)股骨頭壞死的流行病學(xué)盡管股骨頭壞死(ON)的確切患病率尚不清楚，但據(jù)估計(jì)，美國(guó)每年有20,000至30,000名新診斷患者。在美國(guó)，約10%的THA患者的診斷是股骨頭壞死(ON)。股骨頭壞死(ON)影響所有年齡段的人，但最常見(jiàn)于30至65歲之間的患者。診斷時(shí)的平均年齡通常小于50歲。男女比例因相關(guān)合并癥而異。例如，與酒精相關(guān)的股骨頭壞死(ON)是在男性中更常見(jiàn)，而與系統(tǒng)性紅斑狼瘡(SLE)相關(guān)的股骨頭壞死(ON)是在女性中更常見(jiàn)。每年有超過(guò)20,000人因髖關(guān)節(jié)股骨頭壞死需要住院治療。在許多病例中，雙側(cè)髖關(guān)節(jié)都受到影響。通常，股骨頭壞死(ON)會(huì)影響股骨頭及頸部(近端骨骺)。髖關(guān)節(jié)股骨頭骨壞死的發(fā)病機(jī)制/假說(shuō)髖關(guān)節(jié)股骨頭壞死(ON)發(fā)生的機(jī)制仍不清楚。在大多數(shù)情況下，股骨頭壞死(ON)被認(rèn)為是遺傳傾向、代謝因素和影響血液供應(yīng)的局部因素（包括血管損傷、骨內(nèi)壓升高和機(jī)械應(yīng)力）綜合作用的結(jié)果。大多數(shù)專家都認(rèn)為產(chǎn)生干細(xì)胞和血小板的股骨頭和骨髓缺乏血液供應(yīng)，導(dǎo)致骨細(xì)胞（成熟骨內(nèi)的細(xì)胞）和/或間充質(zhì)細(xì)胞（形成軟骨、骨和脂肪的干細(xì)胞）死亡。結(jié)果是死亡組織脫礦質(zhì)或被新的但較弱的骨組織吸收（小梁變薄），隨后導(dǎo)致軟骨下骨折和股骨頭塌陷。其他提出的股骨頭壞死(ON)發(fā)病機(jī)制包括由過(guò)量糖皮質(zhì)激素影響骨和靜脈內(nèi)皮細(xì)胞的不利影響引起的血管收縮引起的變化，以及過(guò)量糖皮質(zhì)激素相關(guān)的股骨頭壞死(ON)涉及循環(huán)脂質(zhì)的變化，可能會(huì)在供應(yīng)骨的動(dòng)脈中引起微栓子。髖關(guān)節(jié)股骨頭骨壞死的病因創(chuàng)傷性和非創(chuàng)傷性因素的結(jié)合可直接導(dǎo)致股骨頭骨壞死。在縱向隊(duì)列研究和薈萃分析的基礎(chǔ)上，發(fā)現(xiàn)了在股骨頭壞死(ON)發(fā)展中起明確病因作用的直接危險(xiǎn)因素。然而，相關(guān)風(fēng)險(xiǎn)因素是與股骨頭壞死(ON)最終進(jìn)展(直接)相關(guān)的大部分因素。股骨頭壞死(ON)的外傷原因股骨頭壞死(ON)的創(chuàng)傷性原因包括股骨頸骨折或脫位以及骨髓成分的直接損傷（例如與放射損傷、氣壓失調(diào)或沉箱病相關(guān)）。股骨頸骨折或脫位的機(jī)制是骨外血管受損，導(dǎo)致髖關(guān)節(jié)受影響區(qū)域的血液供應(yīng)中斷。髖關(guān)節(jié)脫位是另一種類型的創(chuàng)傷性損傷，影響約20%的創(chuàng)傷相關(guān)股骨頭壞死(ON)患者。沉箱?。ɡ鐫撍疁p壓）會(huì)導(dǎo)致氮?dú)鈿馀莸男纬桑瑥亩枞?dòng)脈，導(dǎo)致股骨頭壞死(ON)。出現(xiàn)癥狀的患者可能會(huì)在經(jīng)歷此過(guò)程數(shù)年后出現(xiàn)髖關(guān)節(jié)股骨頭壞死(ON)。壓力的深度和持續(xù)時(shí)間以及暴露的次數(shù)是這種疾病進(jìn)展的重要因素。股骨頭壞死(ON)的非外傷原因許多研究報(bào)告稱，長(zhǎng)期使用皮質(zhì)類固醇激素與股骨頭壞死(ON)的發(fā)生相關(guān)，可能與藥物的持續(xù)時(shí)間和總劑量直接相關(guān)。長(zhǎng)期使用高劑量糖皮質(zhì)激素治療的患者似乎處于發(fā)生股骨頭壞死(ON)的最大風(fēng)險(xiǎn)；然而，這些患者通常有多種其他危險(xiǎn)因素。接受長(zhǎng)期治療的患者中有9%至40%會(huì)發(fā)生糖皮質(zhì)激素誘發(fā)的股骨頭壞死(ON)，而接受短期治療的患者則發(fā)生率要低得多。一項(xiàng)薈萃分析和系統(tǒng)評(píng)價(jià)發(fā)現(xiàn)，近7%的患者發(fā)生股骨頭壞死(ON)使用＜2g皮質(zhì)類固醇激素。根據(jù)這項(xiàng)薈萃分析，接受潑尼松劑量低于15mg/d至20mg/d治療的患者發(fā)生股骨頭壞死(ON)的風(fēng)險(xiǎn)較低。一項(xiàng)針對(duì)98,390名患者的基于人群的研究表明接受單次短期、低劑量甲強(qiáng)龍逐漸減量治療的患者股骨頭壞死(ON)的發(fā)生率為0.13%，而未接受甲強(qiáng)龍逐漸減量治療的患者的股骨頭壞死(ON)發(fā)生率為0.08%。約31%的股骨頭壞死(ON)患者與飲酒有關(guān)。與股骨頭壞死(ON)相關(guān)的過(guò)量飲酒被認(rèn)為是由于脂質(zhì)形成過(guò)多和細(xì)胞內(nèi)脂質(zhì)沉積增加導(dǎo)致骨生成減少所致，導(dǎo)致骨細(xì)胞死亡和股骨頭壞死(ON)。高劑量皮質(zhì)類固醇激素和過(guò)量飲酒共同構(gòu)成了髖關(guān)節(jié)股骨頭壞死(ON)發(fā)展的最高相關(guān)直接危險(xiǎn)因素，并且占與創(chuàng)傷無(wú)關(guān)的病例的80%以上。一項(xiàng)研究比較了112名患有特發(fā)性髖關(guān)節(jié)股骨頭壞死(ON)患者與168名對(duì)照者(沒(méi)有全身性皮質(zhì)類固醇激素使用史)，與對(duì)照者相比，經(jīng)常飲酒者的風(fēng)險(xiǎn)升高，并且與酒精存在明顯的劑量反應(yīng)關(guān)系。對(duì)于當(dāng)前飲酒量低于400毫升/周、400毫升/周至1000毫升/周和超過(guò)1000毫升/周的消費(fèi)者來(lái)說(shuō)，相對(duì)風(fēng)險(xiǎn)分別為3.3、9.8和17.9。股骨頭壞死(ON)在鐮狀細(xì)胞病患者中很常見(jiàn)，因?yàn)樗菀讓?dǎo)致紅細(xì)胞鐮狀化和骨髓增生。大約50%的受影響患者在35歲時(shí)出現(xiàn)股骨頭壞死(ON)。鐮狀細(xì)胞血紅蛋白病可直接導(dǎo)致血管阻塞和股骨頭壞死(ON)。據(jù)報(bào)道，3%至30%的系統(tǒng)性紅斑狼瘡SLE患者會(huì)發(fā)生股骨頭壞死(ON)，最危險(xiǎn)的是服用糖皮質(zhì)激素和常規(guī)劑量潑尼松劑量大于20mg/d的患者。據(jù)報(bào)道，高達(dá)60%的戈謝?。ㄒ环N遺傳性疾?。┗颊呋加泄晒穷^壞死(ON)，因?yàn)樗軌蛑苯幼璧K血管供應(yīng)。戈謝病是一種常染色體隱性遺傳代謝疾病，其中一種脂肪（脂質(zhì)）稱為葡萄糖腦苷脂不能被充分降解。通常情況下，身體會(huì)產(chǎn)生一種稱為葡萄糖腦苷脂酶（細(xì)胞膜的正常部分）的酶，它會(huì)分解并回收葡萄糖腦苷脂。其他不太常見(jiàn)但與股骨頭壞死(ON)明顯相關(guān)的患者包括抗磷脂抗體、庫(kù)欣病和系統(tǒng)性紅斑狼瘡SLE患者。急性淋巴細(xì)胞白血病、慢性粒細(xì)胞白血病和急性粒細(xì)胞淋巴瘤的發(fā)展，使患者因使用類固醇激素治療這些疾病而面臨更高的股骨頭壞死(ON)風(fēng)險(xiǎn)。胰腺炎（通常與使用皮質(zhì)類固醇激素有關(guān)）、懷孕、化療、吸煙、血管炎、胸膜炎和中樞神經(jīng)系統(tǒng)因素，例如導(dǎo)致交感神經(jīng)纖維數(shù)量減少的炎癥反應(yīng)（如類風(fēng)濕性關(guān)節(jié)炎、克羅恩病）、夏科足和炎癥性腸?。?，與股骨頭壞死(ON)相關(guān)。有一些證據(jù)表明股骨頭壞死(ON)可能具有相關(guān)風(fēng)險(xiǎn)因素的遺傳基礎(chǔ)。例如，當(dāng)過(guò)度飲酒是相關(guān)風(fēng)險(xiǎn)因素時(shí)，男性受到的影響是女性的3倍。然而，當(dāng)狼瘡或皮質(zhì)類固醇激素的使用成為相關(guān)危險(xiǎn)因素時(shí)，女性比男性更容易受到影響。系統(tǒng)性紅斑狼瘡SLE在女性中的發(fā)病率大約是男性的9倍。這種易感性增加是可能的，至少部分原因是與激素和性染色體有關(guān)的差異。血液透析、高尿酸患者的慢性腎衰竭或終末期腎病、貧血/痛風(fēng)、HIV感染、高脂血癥、器官移植和血管內(nèi)凝血也與股骨頭壞死(ON)的發(fā)生有關(guān)。盡管存在許多可能的關(guān)聯(lián)和聯(lián)系，但估計(jì)20%的股骨頭壞死(ON)病例被標(biāo)記為特發(fā)性或病因不明。髖關(guān)節(jié)股骨頭骨壞死的臨床表現(xiàn)髖關(guān)節(jié)疼痛是股骨頭壞死(ON)晚期最常見(jiàn)的癥狀，盡管一小部分患者可能沒(méi)有癥狀。腹股溝疼痛是最常見(jiàn)的癥狀，其次是大腿和臀部疼痛。疼痛可能因負(fù)重或關(guān)節(jié)運(yùn)動(dòng)而出現(xiàn)。大約三分之二的股骨頭壞死(ON)患者會(huì)出現(xiàn)休息時(shí)疼痛，大約三分之一的患者會(huì)出現(xiàn)夜間疼痛。身體多個(gè)部位的疼痛很少見(jiàn)，表明存在多灶性過(guò)程。髖關(guān)節(jié)股骨頭壞死(ON)的體格表現(xiàn)通常是非特異性的，但可能會(huì)導(dǎo)致受影響關(guān)節(jié)的活動(dòng)范圍減小、行走疼痛、Trendelenburg征和/或骨摩擦音。髖關(guān)節(jié)股骨頭骨壞死的臨床評(píng)估髖關(guān)節(jié)股骨頭壞死(ON)通常通過(guò)：1)回顧患者病史，2)獲得適當(dāng)?shù)姆派鋵W(xué)評(píng)估，3)確定病情階段，以及4)制定治療方案來(lái)解決。在評(píng)估患者是否患有股骨頭壞死(ON)，問(wèn)題應(yīng)針對(duì)評(píng)估疼痛史、藥物使用（尤其是皮質(zhì)類固醇）、手術(shù)、懷孕、創(chuàng)傷、慢性疾?。ㄓ绕涫晴牋罴?xì)胞病、戈謝病、自身免疫性疾病和白血?。?、吸煙和/或飲酒。當(dāng)詢問(wèn)受傷/疾病時(shí)，重要的是要仔細(xì)探討與髖部骨折、脫位或沉箱病相關(guān)的傷害，因?yàn)槌料洳∈欠莿?chuàng)傷性的。髖關(guān)節(jié)股骨頭骨壞死的診斷和分類在疾病的初始階段診斷髖關(guān)節(jié)股骨頭骨壞死對(duì)于治療很重要；在初始階段，疾病可能不會(huì)進(jìn)展。大多數(shù)情況下，早期股骨頭壞死(ON)患者一般沒(méi)有癥狀，是偶然發(fā)現(xiàn)的；不幸的是，大多數(shù)患者直到股骨頭壞死(ON)發(fā)展到后期才前來(lái)接受評(píng)估。盡管目前還沒(méi)有已知的明確治療方法可以永久阻止股骨頭壞死(ON)進(jìn)展到后期，但目前有一些治療方法用于此目的，例如降脂劑、抗凝劑和雙磷酸鹽。當(dāng)患者出現(xiàn)癥狀、影像學(xué)檢查結(jié)果一致、并且其他引起疼痛和骨異常的原因不太可能或已被排除時(shí)，就可以準(zhǔn)確地做出股骨頭壞死(ON)的診斷。除了臨床和體檢之外，放射線照片和磁共振成像（MRI）掃描等成像技術(shù)也用于診斷。首先，進(jìn)行普通放射線照相評(píng)估，然后進(jìn)行MRI。據(jù)報(bào)道，MRI對(duì)于檢測(cè)早期股骨頭壞死(ON)的特異性和敏感性＜99%。MRI圖像還可以通過(guò)對(duì)異常骨占據(jù)的股骨頭區(qū)域進(jìn)行數(shù)字化，定量評(píng)估病變的大小或受影響骨的受累程度。MRI變化包括T1加權(quán)圖像上界限分明且均勻的局灶性病變，具有分隔正常骨和缺血骨的單密度線，以及T2加權(quán)圖像上的第二條高強(qiáng)度線（特征性雙線征標(biāo)志）代表血管豐富的肉芽組織。這種級(jí)別的成像細(xì)節(jié)非常有用，因?yàn)槭苡绊懝趋啦∽兊拇笮『头秶苤匾?，可以幫助指?dǎo)治療。然而，對(duì)于終末期疾病，股骨頭壞死(ON)患者可能沒(méi)有必要使用MRI，因?yàn)榇穗A段的治療選擇可能有限。這些發(fā)現(xiàn)通常使用4個(gè)階段的Ficat和Arlet系統(tǒng)進(jìn)行分類，如此處和表1中所述。X線片可以在腹股溝疼痛等癥狀出現(xiàn)后數(shù)月內(nèi)保持正常（第一階段）。最早的放射學(xué)檢查結(jié)果通常是輕微的骨密度變化，然后是硬化和囊性變（第二階段）。然后，檢查結(jié)果會(huì)從軟骨下骨塌陷（第III期）發(fā)展到特征性新月征（在股骨頭近端前外側(cè)看到軟骨下射線可透性），并隨后出現(xiàn)股骨頭球形度喪失（測(cè)量圓度）或股骨頭最終關(guān)節(jié)塌陷，可見(jiàn)髖臼空間變窄和退行性變化（第四階段）。要尋找的關(guān)鍵放射學(xué)特征包括1)階段（塌陷前與塌陷后）、2)病變大小和3)股骨頭凹陷程度。右側(cè)股骨頭壞死的X線片表現(xiàn)：雙線征，承重區(qū)右側(cè)髖關(guān)節(jié)股骨頭壞死X線片（上圖）及MRI表現(xiàn)（下圖）生成骨骼三維圖像的計(jì)算機(jī)斷層掃描具有中等敏感性，但不具有特異性，可能會(huì)給患者帶來(lái)顯著的輻射負(fù)擔(dān)。如果股骨頭已經(jīng)塌陷，計(jì)算機(jī)斷層掃描可能具有一定的特異性。幸運(yùn)的是，大多數(shù)臨床醫(yī)生無(wú)需計(jì)算機(jī)斷層掃描即可診斷出股骨頭骨壞死，而計(jì)算機(jī)斷層掃描通常用于區(qū)分塌陷前和塌陷后疾病。髖關(guān)節(jié)股骨頭骨壞死的鑒別診斷由于有癥狀的髖關(guān)節(jié)股骨頭壞死(ON)患者可能會(huì)出現(xiàn)與許多其他髖關(guān)節(jié)病變類似的癥狀，因此在最終診斷之前應(yīng)充分排除這些癥狀。骨髓水腫綜合征和軟骨下骨折是也需要考慮的許多潛在診斷中的兩個(gè)。與骨壞死相關(guān)的病因創(chuàng)傷相關(guān)的危險(xiǎn)因素股骨頸骨折脫位或骨折脫位鐮狀細(xì)胞性貧血癥血紅蛋白病沉箱病（氣壓失調(diào)）戈謝病輻射非創(chuàng)傷相關(guān)的危險(xiǎn)因素皮質(zhì)類固醇激素飲酒系統(tǒng)性紅斑狼瘡庫(kù)欣病皮質(zhì)醇分泌過(guò)多（罕見(jiàn)）慢性腎功能衰竭/血液透析胰腺炎妊娠高脂血癥器官移植血管內(nèi)凝血血栓性靜脈炎吸煙高尿酸血癥/痛風(fēng)艾滋病病毒感染其他潛在風(fēng)險(xiǎn)因素特發(fā)性原因骨髓水腫綜合征，也稱為髖部暫時(shí)性骨質(zhì)減少，可能單獨(dú)發(fā)生或與損傷相關(guān)，特別是那些導(dǎo)致神經(jīng)損傷的創(chuàng)傷。在后一種情況下，慢性疼痛和短暫性骨質(zhì)減少是復(fù)雜區(qū)域疼痛綜合征（也稱為反射性交感神經(jīng)營(yíng)養(yǎng)不良、灼痛等術(shù)語(yǔ)）的特征。骨髓水腫綜合征可根據(jù)組織學(xué)和MRI與股骨頭壞死(ON)相鑒別。股骨頭軟骨下骨折通常發(fā)生在已有骨質(zhì)減少的患者中，通常被認(rèn)為代表不全骨折。這些骨折可能很難通過(guò)平片觀察到。早期病變有時(shí)會(huì)出現(xiàn)輕微的扁平化；股骨頭塌陷是進(jìn)行性的。髖關(guān)節(jié)股骨頭骨壞死的臨床治療在制定針對(duì)癥狀性髖關(guān)節(jié)骨關(guān)節(jié)炎的最佳治療方法時(shí)要考慮的因素應(yīng)旨在治療骨關(guān)節(jié)炎的分期和受累程度、骨受累的程度和位置、癥狀的存在（或不存在）以及患者的合并癥。治療的目標(biāo)是盡可能長(zhǎng)時(shí)間地保留天然髖關(guān)節(jié)，同時(shí)考慮患者年齡、活動(dòng)能力、職業(yè)和生活方式等生活質(zhì)量問(wèn)題。處理髖關(guān)節(jié)股骨頭壞死(ON)的三種主要治療選擇包括1)非手術(shù)治療、2)關(guān)節(jié)保留手術(shù)和3)全髖關(guān)節(jié)置換術(shù)THA。非創(chuàng)傷性原因引起的髖關(guān)節(jié)股骨頭壞死(ON)的影響引起了特別關(guān)注。對(duì)于受影響的患者，67%的人報(bào)告沒(méi)有任何癥狀，但最終可能會(huì)出現(xiàn)關(guān)節(jié)塌陷。無(wú)癥狀的中等、尤其是大面積股骨頭骨壞死的自然病程是病情惡化，最終發(fā)展為終末期疾病，許多患者出現(xiàn)股骨頭塌陷。對(duì)于有癥狀的患者，大約80%至85%的病例會(huì)在2年內(nèi)導(dǎo)致股骨頭塌陷。因此，早期診斷股骨頭壞死(ON)可能會(huì)提供早期治療的機(jī)會(huì)，這可以防止塌陷，并最終避免股骨頭塌陷而需要進(jìn)行的全髖關(guān)節(jié)置換的手術(shù)治療。然而，大多數(shù)患者在病程晚期就診，對(duì)于那些已知或可能存在危險(xiǎn)因素的患者，特別是使用大劑量皮質(zhì)類固醇激素的患者，必須高度懷疑（存在股骨頭壞死(ON)）。同樣，對(duì)于無(wú)癥狀的股骨頭壞死(ON)患者，應(yīng)考慮影響股骨頭壞死病變的大小、范圍和位置。一般來(lái)說(shuō)，影響股骨頭15%以下的病變最好采用非手術(shù)治療；15%至30%之間的病變應(yīng)進(jìn)行手術(shù)治療；盡管進(jìn)行了手術(shù)干預(yù)，但涉及超過(guò)30%股骨頭的病變?nèi)钥赡苓M(jìn)展至塌陷，并最終需要全髖關(guān)節(jié)置換術(shù)THA。髖關(guān)節(jié)股骨頭骨壞死的非手術(shù)治療選擇物理治療物理治療可以緩解和減輕一些癥狀，但通常不會(huì)阻止進(jìn)行性髖關(guān)節(jié)骨性關(guān)節(jié)炎進(jìn)展到后期。同樣，使用拐杖或手杖等輔助裝置限制負(fù)重可能有助于控制疼痛、虛弱和痛性步態(tài)等癥狀。如果治療的目標(biāo)是防止髖關(guān)節(jié)需要全髖關(guān)節(jié)置換，那么物理治療是不合適的，并且迄今為止沒(méi)有證據(jù)表明負(fù)重限制有助于防止進(jìn)行性骨關(guān)節(jié)炎疾病進(jìn)展為終末期疾病。藥物非甾體類抗炎藥和對(duì)乙酰氨基酚可以暫時(shí)緩解有癥狀患者的疼痛。當(dāng)其他藥物無(wú)法有效控制中度至重度疼痛時(shí)，在考慮手術(shù)選擇時(shí)，可以明智地短期使用阿片類藥物。目前正在使用但未經(jīng)證實(shí)或可靠地用于治療股骨頭壞死(ON)的研究藥物選擇包括1)抗凝劑、2)雙膦酸鹽抗吸收劑、3)降膽固醇他汀類藥物和4)高壓氧。早期股骨頭壞死(ON)的手術(shù)選擇髓心減壓髓心減壓是一種微創(chuàng)手術(shù)技術(shù)，用于控制病情早期（塌陷前）的癥狀（例如Ficat和ArletI期和II期）。該手術(shù)包括在股骨頭上鉆孔以緩解壓力并為新血管創(chuàng)造通道以滋養(yǎng)受影響的區(qū)域。已發(fā)表的髓心減壓成功率差異很大，從40%到100%不等，具體取決于患者群體。髓心減壓后的成功率在最早疾病階段的患者中可見(jiàn)。成功進(jìn)行髓心減壓手術(shù)的患者通常會(huì)在幾個(gè)月后恢復(fù)獨(dú)立行走，并且可以完全緩解疼痛。骨移植髓心減壓可以與骨移植相結(jié)合，幫助再生健康的骨骼并支撐髖關(guān)節(jié)的軟骨。骨移植物是移植到壞死或死骨區(qū)域的健康骨組織。一種標(biāo)準(zhǔn)技術(shù)使用自體移植，涉及從身體的一個(gè)部位取出骨頭并將其移動(dòng)到身體的另一部位。從捐贈(zèng)者或尸體上采集的骨移植物稱為同種異體移植物，通常通過(guò)骨庫(kù)獲取。骨髓抽吸濃縮物髓心減壓配合骨髓抽吸濃縮物注射是使用濃縮骨髓，將其注射到股骨頭壞死的死骨中。這項(xiàng)研究技術(shù)從患者的骨髓中采集干細(xì)胞并將其注射到股骨頭壞死(ON)區(qū)域。骨髓抽吸濃縮被認(rèn)為可以防止疾病進(jìn)一步發(fā)展并刺激新骨生長(zhǎng)。經(jīng)皮鉆孔另一種手術(shù)選擇是經(jīng)皮鉆孔。在此過(guò)程中，通過(guò)股骨頸經(jīng)皮鉆一個(gè)孔，到達(dá)股骨頭的受影響部位。一份對(duì)45個(gè)髖關(guān)節(jié)進(jìn)行平均隨訪24個(gè)月的報(bào)告顯示，30個(gè)患有Ficat和ArletI期疾病的髖關(guān)節(jié)中有24個(gè)（80%）取得了成功的結(jié)果（定義為Harris髖關(guān)節(jié)評(píng)分＜70）。一項(xiàng)最近的研究比較了多個(gè)鉆探與標(biāo)準(zhǔn)髓心減壓相比，顯示經(jīng)皮鉆探獲得更好的結(jié)果。晚期股骨頭壞死(ON)的手術(shù)選擇血管化骨移植血管化腓骨移植是一種更為復(fù)雜的外科手術(shù)，其中從腓骨及其血液供應(yīng)中取出一段骨。然后將移植物移植到股骨頸和股骨頭上形成的孔道中，并重新連接動(dòng)脈和靜脈以幫助愈合股骨頭壞死(ON)。截骨術(shù)髖關(guān)節(jié)截骨術(shù)可以將壞死骨從主要承重區(qū)域去除。盡管該手術(shù)可能會(huì)延遲THA手術(shù)，對(duì)于股骨頭輕度塌陷前或早期塌陷后的股骨頭壞死患者最有用。然而，截骨術(shù)的一個(gè)結(jié)果是使得未來(lái)可能的全髖關(guān)節(jié)置換術(shù)更具挑戰(zhàn)性，并且通常與骨不連的風(fēng)險(xiǎn)增加有關(guān)。非血管化骨移植非血管化骨移植手術(shù)有3種類型：1)活板門手術(shù)、2)燈泡技術(shù)和3)Phemister技術(shù)。活板門手術(shù)一種自體松質(zhì)骨和皮質(zhì)骨移植術(shù)，已成功用于Ficat和ArletIII期髖關(guān)節(jié)股骨頭壞死(ON)的中小型病變患者。對(duì)23名Ficat和ArletIII期或IV期股骨頭壞死(ON)患者進(jìn)行的30次（在股骨頭上制作的）活板門手術(shù)的結(jié)果顯示，根據(jù)Harris評(píng)分系統(tǒng)的判定，結(jié)果均良好或極好。燈泡技術(shù)燈泡技術(shù)使用股骨頸前部的皮質(zhì)窗口?？梢允褂迷摯翱谌コ龎乃拦?，隨后可以用非血管化骨移植物填充。Wang等對(duì)110名接受燈泡手術(shù)的患者（138髖）進(jìn)行了評(píng)估。在平均25個(gè)月的隨訪中，平均Harris髖關(guān)節(jié)評(píng)分從62分提高到79分。在最近的隨訪中，總共94個(gè)髖關(guān)節(jié)(68%)被認(rèn)為取得了成功。ARCO分期IIa期患者中100%、IIb期患者中77%、IIc和IIIa期患者中51%出現(xiàn)放射學(xué)改善。Phemister技術(shù)在Phemister技術(shù)中，通過(guò)股骨頸插入環(huán)鉆以形成通向病變部位的管道。然后插入第二個(gè)環(huán)鉆以形成通往病變部位的另一條管道。然后可以將皮質(zhì)支柱移植物放置在病變處。最近的一項(xiàng)評(píng)論報(bào)告稱，該手術(shù)的臨床成功率在36%至90%之間。全髖關(guān)節(jié)置換術(shù)（THA）一旦股骨頭發(fā)生嚴(yán)重塌陷，置換髖關(guān)節(jié)是唯一實(shí)用的手術(shù)選擇，并且可以在晚期股骨頭壞死中提供最可預(yù)測(cè)的疼痛緩解。全髖關(guān)節(jié)置換術(shù)（THA）成功地緩解了大多數(shù)患者的疼痛并恢復(fù)了功能。在全髖關(guān)節(jié)置換術(shù)（THA）中，構(gòu)成髖關(guān)節(jié)的患病軟骨和骨骼被由金屬和塑料制成的人工關(guān)節(jié)假體取代。人工髖關(guān)節(jié)置換術(shù)通?？梢允褂?5年，然后就會(huì)磨損并需要修復(fù)。對(duì)于較年輕的患者，由于可能存在活動(dòng)限制，全髖關(guān)節(jié)置換術(shù)（THA）可能不是最佳解決方案。此外，由于假肢有使用壽命限制（長(zhǎng)期使用后部件會(huì)磨損），這些患者可能需要在以后的生活中進(jìn)行全髖關(guān)節(jié)置換術(shù)（THA）翻修。必須仔細(xì)考慮全髖關(guān)節(jié)置換術(shù)并與生活質(zhì)量問(wèn)題進(jìn)行權(quán)衡，但年輕患者并非絕對(duì)禁忌。關(guān)于髖關(guān)節(jié)股骨頭壞死(ON)的患者教育預(yù)防股骨頭壞死(ON)對(duì)患者進(jìn)行有關(guān)危險(xiǎn)因素、治療和管理的教育對(duì)于患者對(duì)其病情做出更明智的決定至關(guān)重要。股骨頭壞死(ON)教育過(guò)程涉及識(shí)別個(gè)人的相關(guān)疾病和與股骨頭壞死(ON)相關(guān)的危險(xiǎn)因素。無(wú)癥狀股骨頭壞死的患者進(jìn)展為有癥狀疾病和股骨頭塌陷的可能性很高。對(duì)無(wú)癥狀疾病患者的教育是預(yù)防性的，也是必要的，以確保改變危險(xiǎn)因素和優(yōu)化護(hù)理。預(yù)防非創(chuàng)傷性股骨頭壞死(ON)需要：1)避免過(guò)量飲酒，定義為男性每周＜15杯飲酒，女性每周＜8杯飲酒，2)避免吸煙，以及3)將皮質(zhì)類固醇激素減少到盡可能低的治療劑量。告知患者皮質(zhì)類固醇激素的使用與股骨頭壞死(ON)潛在發(fā)展之間的相關(guān)性對(duì)于治療這種疾病至關(guān)重要。預(yù)防股骨頭壞死(ON)的進(jìn)展應(yīng)告知診斷為早期骨關(guān)節(jié)炎的患者采取上述預(yù)防措施，并應(yīng)避免對(duì)關(guān)節(jié)施加過(guò)度壓力，遵循健康飲食，并保持適當(dāng)?shù)捏w重以減緩骨關(guān)節(jié)炎的進(jìn)展。盡管健康飲食本身并不能直接減少患者關(guān)節(jié)的壓力，但減肥（如果超重/肥胖）會(huì)減少髖關(guān)節(jié)的軸向負(fù)荷，從而減少施加到股骨頭/頸（股骨頭和股骨頸）的壓力。結(jié)論股骨頭壞死(ON)是一種病理性的、經(jīng)常引起疼痛的病癥，涉及組織壞死區(qū)域，可影響身體的任何骨關(guān)節(jié)。髖關(guān)節(jié)是最常見(jiàn)的股骨頭壞死(ON)部位，當(dāng)最初診斷出股骨頭壞死(ON)發(fā)生在身體的其他部位時(shí)，應(yīng)始終利用放射線篩查和MRI掃描進(jìn)行正確評(píng)估。越早診斷股骨頭壞死，無(wú)需手術(shù)干預(yù)或采用微創(chuàng)手術(shù)技術(shù)來(lái)挽救髖關(guān)節(jié)的機(jī)會(huì)就越大。做出股骨頭壞死(ON)診斷后，將考慮病變的大小、范圍和位置以及分類階段，以制定最佳的治療計(jì)劃。在此過(guò)程中，癥狀的存在或不存在很重要。治療的目標(biāo)包括嘗試盡可能長(zhǎng)時(shí)間地保留天然髖關(guān)節(jié)，并考慮患者的生活方式和生活質(zhì)量問(wèn)題。迄今為止，治療股骨頭壞死(ON)的兩種主要治療選擇包括髖關(guān)節(jié)保留手術(shù)（保髖治療）和全髖關(guān)節(jié)置換術(shù)THA。對(duì)患者進(jìn)行有關(guān)潛在危險(xiǎn)因素和股骨頭壞死(ON)發(fā)展的教育，對(duì)于預(yù)防該病癥和/或潛在地預(yù)防或阻止早期疾病進(jìn)展為晚期疾病至關(guān)重要。OsteonecrosisoftheHip:APrimerAbstractInthisreport,wedeliveraconciseandup-to-datereviewofosteonecrosis,apathologic,painful,andoftendisablingconditionthatisbelievedtoresultfromthetemporaryorpermanentdisruptionofbloodsupplytoanaffectedareaofbone.Wewilldiscusstheepidemiology(diseasedistribution),pathogenesis(mechanismofdevelopment),etiology(associatedriskfactors,causes,anddisorders),clinicalmanifestations(reportedsymptomsandphysicalfindings),diagnosisandclassification,andtreatmentoptionsforhiposteonecrosis.文獻(xiàn)出處：MichelleJLespasio,NipunSodhi,MichaelAMont.OsteonecrosisoftheHip:APrimer.ReviewPermJ.2019;23:18-100.doi:10.7812/TPP/18-100.INTRODUCTIONTheintentofthisarticleistopresentanupdateonosteonecrosis(ON)affectingthefemoralheadorhipjointandhowitcanbestbemanagedintheadultpopulation.Specifically,thisreportwillencompasstheepidemiology,pathogenesis,etiology,clinicalmanifestations,diagnosisandclassification,andtreatmentoptionsforhipON.ON,alsoreferredtoasavascularnecrosis,asepticnecrosis,orischemicbonenecrosis,isassociatedwithmanydisordersandriskfactorsthatcausematurebonecellstodie,leadingtobonedestruction(eg,collapse)orend-stagearthritisofthefemoralhead.Theconditioncanoccurinanyboneinthebody(eg,upperextremity,knees,shoulders,andankles),orinmorethan1boneatdifferenttimes,butitmostcommonlyaffectsthehipjoint.Wheninitiallydiagnosedinanareaotherthanthehip,thehipshouldsimultaneouslybeevaluatedclinicallyandwithradiographicandotherimagingstudies.ThecausesofONareclassifiedaseithertraumatic(relatedtoaninjury)oratraumatic(notrelatedtoaninjury).AccuratelydiagnosingandclassifyingONareimportantinhelpingtodirecttreatmentoptions.IdentificationofassociatedriskfactorsandpatienteducationareimportantinsuccessfulmanagementofON.Targetingassociatedriskfactors,pharmacologicmanagement,and/orsurgery,includingjointpreservingproceduresandtotalhiparthroplasty(THA),alsoplaysignificantrolesintheclinicalcareofpatientswithON.EPIDEMIOLOGYOFHIPOSTEONECROSISAlthoughtheexactprevalenceofONisunknown,theincidenceisestimatedtobebetween20,000to30,000newlydiagnosedpatientseachyearintheUS.1ONistheunderlyingdiagnosisinapproximately10%ofallTHAintheUS.2,3ONaffectspeopleofallages,althoughitismostcommonlyseeninpatientsbetweentheagesof30and65years.4Themeanageatdiagnosisistypicallyyoungerthanage50years.3Themale-to-femaleratiovariesdependingontheassociatedcomorbidities.Forexample,alcohol-associatedONismorecommoninmen,whereasONassociatedwithsystemiclupuserythematosus(SLE)ismorecommoninwomen.3Morethan20,000peopleeachyearrequirehospitaltreatmentforhipON.4Inmanyofthesecases,bothhipsareaffectedbythecondition.Mostcommonly,ONaffectstheproximalend(epiphysis)ofthefemur(hipbone).PATHOGENESISOFHIPOSTEONECROSISThemechanism(s)bywhichhipONdevelopsremainsunclear.Forthemostpart,hipONisbelievedtoresultfromthecombinedeffectsofgeneticpredisposition,metabolicfactors,andlocalfactorsaffectingbloodsupplyincludingvasculardamage,increasedintraosseouspressure,andmechanicalstresses.2,5,6Mostexpertsagreethatalackofbloodsupplytothefemoralheadandbonemarrow,whichproducesstemcellsandplatelets,causesdeathoftheosteocytes(cellswithinmaturebone)and/ormesenchymalcells(stemcellsthatformcartilage,bone,andfat).7Theresultisdemineralizationorresorptionofthedeadtissuebynewbutweakerosseoustissue(trabecularthinning),subsequentlyleadingtosubchondralfractureandcollapseofthefemoralhead.OtherproposedmechanismsforthepathogenesisofONincludevasoconstriction-inducedchangescausedbytheadverseeffectsofexcessglucocorticosteroidsaffectingboneandvenousendothelialcells8,9andexcessglucocorticoid-associatedONinvolvingalterationsincirculatinglipidsbelievedtocausemicroemboliinthearteriesthatsupplybonewithblood.10ETIOLOGYOFHIPOSTEONECROSISAcombinationoftraumaticandatraumaticfactorscandirectlycontributetotheetiologyofON(seeSidebar:EtiologicFactorsAssociatedwithOsteonecrosis).Onthebasisoflongitudinalcohortstudiesandmeta-analyses,directriskfactorshavebeendiscoveredthatplayadefinitiveetiologicroleinthedevelopmentofON.Associatedriskfactors,however,accountformostofthelinkstotheeventualdevelopmentofON.11TraumaticCausesofHipOsteonecrosisTraumaticcausesofONincludefemoralneckfracturesordislocationsaswellasdirectinjuryofboneofmarrowelements(eg,relatedtoradiationinjury,dysbarism,orCaissondisease).Themechanisminvolvedinfemoralneckfracturesordislocationsisdamagetotheextraosseousbloodvessels,whichresultsindisruptedbloodsupplytotheaffectedregionofthehip.Hipdislocationisanothertypeoftraumaticinjury,whichaffectsapproximately20%oftrauma-relatedONpatients.12Caissondisease(eg,decompressioninscubadiving)causestheformationofnitrogenbubblesthatcanoccludearterioles,leadingtoON.PatientswhodevelopsymptomscandevelophipONyearsafterexposuretothisprocess.Thedepthanddurationofpressureandnumberofexposuresareimportantfactorsintheprogressionofthisdisorder.13AtraumaticCausesofHipOsteonecrosisNumerousstudiesreportprolongeduseofcorticosteroidsassociatedwiththedevelopmentofONcanbedirectlyrelatedtodurationandtotaldosageofthemedication.14–16PatientstreatedwithprolongedhighdosesofglucocorticoidsappeartobeatthegreatestriskofdevelopingON;however,thesepatientsoftenhavemultipleotherriskfactors.Glucocorticoid-inducedONdevelopsin9%to40%ofpatientsreceivinglong-termtherapy,anddevelopsmuchlessfrequentlyinpatientsreceivingshort-termtherapy.17Onemeta-analysisandsystematicreviewidentifiedanincidenceofONinnearly7%ofpatientswhoused＜2gofcorticosteroids.18Fromthismeta-analysis,alowerriskwasseeninpatientstreatedwithdosesofprednisonelessthan15mg/dto20mg/d.18Onepopulation-basedstudyof98,390patientsshowedtheincidenceofhipONamongpatientswhohadreceivedasingleshort-term,low-dosemethylprednisolonetaperpackwas0.13%,comparedwith0.08%inpatientswhowerenotprescribedamethylprednisolonetaperpack,thusindicatinganumberneededtoharmof2041patients.19Alcoholusehasbeenassociatedwithapproximately31%ofpatientswhodevelophipON.3,20–22ExcessivealcoholconsumptionrelatedtoONofthehipisbelievedtoresultfromthedecreasedbonegenesiscausedbyexcesslipidformationandincreasedintracellularlipiddeposits,leadingtoosteocytedeathandON.23HighdosesofcorticosteroidsandexcessivealcoholusetogetherpresentthehighestassociateddirectriskfactorsforthedevelopmentofhipON24andaccountformorethan80%ofcasesnotrelatedtotrauma.3,6Onestudycompared112patientswhohadidiopathichipONandnohistoryofsystemiccorticosteroidusewith168controls.3,20Anelevatedriskforregularalcoholdrinkersandacleardose-responserelationshipwithalcoholwerenoted,comparedwithcontrols.Therelativeriskswere3.3,9.8,and17.9forcurrentconsumersoflessthan400mL/wk,400mL/wkto1000mL/wk,andmorethan1000mL/wkofalcohol,respectively.9ONiscommoninpatientswithsicklecelldiseasebecauseofitspropensitytocauseredbloodcellsicklingandbonemarrowhyperplasia.Approximately50%ofaffectedpatientsdevelopONbytheageof35years.25SicklecellhemoglobinopathycandirectlycausevascularobstructionandON.ThedevelopmentofONhasbeenreportedin3%to30%ofpatientswithSLE,andthosemostatriskarepatientswhohavetakenglucocorticoidswithregulardosesofprednisonegreaterthan20mg/d.3,26–28ONhasbeenreportedinasmanyas60%ofpatientswithGaucherdisease(ahereditarydisorder)becauseofitsabilitytodirectlyobstructvascularsupply.3,29,30Gaucherdiseaseisanautosomalrecessiveinheriteddisorderofmetabolismwhereatypeoffat(lipid)calledglucocerebrosidecannotbeadequatelydegraded.Normally,thebodymakesanenzymecalledglucocerebrosidase(anormalpartofthecellmembrane)thatbreaksdownandrecyclesglucocerebroside.31OtherlesscommonbutapparentlinkstohipONincludepatientswithantiphospholipidantibodies,Cushingdisease,29andSLE.Thedevelopmentofacutelymphoblasticleukemia,chronicmyeloidleukemia,andacutemyeloidlymphoma3,32placespatientsatincreasedriskforONrelatedtothetreatmentwithsteroidsfortheseconditions.Pancreatitis(usuallyassociatedwithuseofcorticosteroids),pregnancy,chemotherapy,smoking,vasculitis,pleuritis,andcentralnervoussystemfactorssuchasaninflammatoryresponseresultinginareductioninthenumberofsympatheticnervefibers(asseeninrheumatoidarthritis,Crohndisease,Charcotfoot,andinflammatoryboweldisease),havebeenassociatedwithON.33ThereissomeevidencethathipONmayhaveageneticbasisunderlyingassociatedriskfactors.34Forexample,menareaffectedasmuchas3timesmorethanwomenwhenexcessivealcoholuseistheassociatedriskfactor.However,whenlupusorcorticosteroidusearetheassociatedriskfactors,womenareaffectedmoreoftenthanmen.26,27,32SLEisapproximately9timesmorecommoninwomenthaninmen.35Thisincreasedsusceptibilitymaybemadepossible,atleastinpart,owingtodifferencesrelatedtohormonesandsexchromosomes.35Chronicrenalfailureorend-stagerenaldiseaseinpatientsonhemodialysis,hyperuricemia/gout,HIVinfection,hyperlipidemia,organtransplantation,andintravascularcoagulationarealsolinkedtothedevelopmentofON.31,32,36–39Despitethemanypossibleassociationsandlinks,anestimated20%ofONcasesarelabeledasidiopathicorofunknownetiology.7CLINICALMANIFESTATIONSOFHIPOSTEONECROSISHippainisthemostcommonlyreportedsymptomoflater-stageON,althoughasmallproportionofpatientsmaynothavesymptoms.Paininthegroinisthemostcommonlyreportedsymptom,followedbypainreferredintothethighandbuttock.Paincanpresentwithweightbearingorjointmotion.Painatrestoccursinapproximatelytwo-thirdsofpatientswithON,andpainatnightoccursinapproximatelyone-thirdofpatients.33Paininmultiplelocationsofthebodyisrareandsuggestsamultifocalprocess.PhysicalfindingsofhipONaregenerallynonspecificbutmayentailreducedrangeofmotionoftheaffectedjoint,painfulambulation,Trendelenburgsign,and/orcrepitus.3,40,41ClinicalAssessmentofHipOsteonecrosisONofthehipisgenerallyaddressedby1)reviewofapatient’smedicalhistory,2)obtainingappropriateradiologicevaluation,3)determiningthestageofthecondition,and4)developingaplanfortreatmentoptions.42,43WhenevaluatingapatientforON,questionsshouldbedirectedatassessingahistoryofpain,useofmedications(especiallycorticosteroids),surgery,pregnancy,trauma,chronicmedicalconditions(especiallysicklecelldisease,Gaucherdisease,autoimmunedisease,andleukemia),smoking,and/oralcoholuse.Whenaskingaboutinjuries/illnesses,itisimportanttocarefullyexploreinjuriesrelatedtohipfractures,dislocations,orscubadivingbecauseCaissondiseaseisatraumatic.DIAGNOSISANDCLASSIFICATIONOFHIPOSTEONECROSISDiagnosinghipONintheinitialstagesofthedisorderisimportantformanagement43–46;atinitialstages,thediseasemaynotprogress.Inmostcases,patientswithearly-stageONaregenerallywithoutsymptomsandareidentifiedincidentally;unfortunately,mostpatientsdonotpresentforevaluationuntiltheONhasreachedlaterstages.AlthoughthereispresentlynodefinitivetreatmentknowntopermanentlyhaltONfromprogressingtolaterstages,therearetreatmentmethods,suchaslipidloweringagents,anticoagulants,andbisphosphonates,currentlybeingusedforthispurpose.36–38AdiagnosisofONcanaccuratelybemadewhenapatientissymptomatic,imagingfindingsarecompatible,andothercausesofpainandbonyabnormalitieseitherareunlikelyorhavebeenexcluded.Beyondtheclinicalandphysicalexamination,imagingtechniquessuchasradiographsandmagneticresonanceimaging(MRI)scanningarealsousedfordiagnosis.Plainradiographicevaluationisperformedfirst,followedbyMRI.MRIhasbeenreportedtobe＜99%specificandsensitivefordetectingearlyON.47,48MRIimagescanalsoquantitativelyassessthesizeofthelesionorinvolvementoftheaffectedbonebydigitizingtheareaofthefemoralheadoccupiedbybonewithabnormaltexture.49MRIchangesincludewell-demarcatedandhomogeneousfocallesionsonT1-weightedimageswithasingle-densitylineseparatingnormalandischemicbone,aswellasasecondhigh-intensitylineonT2-weightedimages(thepathognomonicdouble-linesign)representinghypervasculargranulationtissue.3Thislevelofimagingdetailisusefulbecausethesizeandextentofthelesionoftheaffectedboneisimportantandcanhelpdirecttreatment.Forend-stagedisease,however,useofMRIinpatientswithONmaybeunnecessarybecausetreatmentoptionsatthisstagecanbelimited.Thesefindingsareoftenclassifiedusingthe4-stageFicatandArletsystem,whichisdescribedhereandinTable1.Theplainradiographcanremainnormalformonthsaftertheonsetofsymptomssuchasgroinpain(StageI).Theearliestradiographicfindingsareusuallymilddensitychanges,followedbysclerosisandcysts(StageII).Findingsthenprogresstothepathognomoniccrescentsign(subchondralradiolucencyseenintheanterolateralaspectoftheproximalfemoralhead)fromsubchondralcollapse(StageIII),andsubsequentlossofsphericity(measurementoftheroundness)orcollapseofthefemoralheadwitheventualjoint-spacenarrowinganddegenerativechangesintheacetabulumthatarevisible(StageIV).Keyradiographicfeaturestolookforinclude1)stage(precollapsevspostcollapse),2)sizeoflesion,and3)amountofheaddepression.Table1Ficat＆ArletclassificationsystemofthefemoralheadClassificationClinicalRadiographsMRIStage0Nosymptoms;preclinicalNormalNormalStage1PossiblegroinpainNormalormildosteopeniaPossibleedemaStage2Groinpainandstiffness;painwithactivityOsteopeniaand/orsubchondralcysts;diffuseporosis;precollapseofjointspaceOutlinesareaofinvolvementofthefemoralheadStage3Groinpain,stiffness,radiationofpain;painwithactivityCrescentsignand/orsubchondralcollapse(flattening)ofjointwithsecondarydegenerativechanges;lossofsphericityoffemoralheadSameasradiographsStage4Groinpainandlimp;painatrestEnd-stagediseasewithcollapse;extensivedestructionofjoint;reducedjointspaceSameasradiographsOpeninaseparatewindowMRI=magneticresonanceimagingAcomputedtomographyscanproducinga3-dimensionalpictureofthebonehasmoderatesensitivitybutisnonspecificandcanposeasignificantradiationburdentopatients.Computedtomographycanhavesomespecificityifthereisalreadyfemoralheadcollapse.Fortunately,mostcliniciansareassuredwiththeirdiagnosisofONwithoutcomputedtomographyscanning,whichisgenerallyreservedfordistinguishingprecollapseandpostcollapsedisease.DifferentialDiagnosisofHipOsteonecrosisBecausepatientswithsymptomatichipONcanpresentwithsymptomssimilartomanyotherhippathologies,theseshouldbeadequatelyruledoutbeforefinaldiagnosis.Bonemarrowedemasyndromeandsubchondralfracturesaretwoofmanypotentialdiagnosesthatneedtoalsobeconsidered.EtiologicFactorsAssociatedwithOsteonecrosisTraumatic-associatedriskfactorsFemoralneckfractureDislocationorfracture-dislocationSicklecelldiseaseHemoglobinopathiesCaissondisease(dysbarism)GaucherdiseaseRadiationAtraumatic-associatedriskfactorsCorticosteroidadministrationAlcoholuseSystemiclupuserthyematosusCushingdiseaseHypersecretionofcortisol(rare)Chronicrenalfailure/hemodialysisPancreatitisPregnancyHyperlipidemiaOrgantransplantationIntravascularcoagulationThrombophlebitisCigarettesmokingHyperuricemia/goutHIVOtherpotentialriskfactorsIdiopathiccausesBonemarrowedemasyndrome,alsoknownastransientosteopeniaofthehip,mayoccurinisolationorinassociationwithinjuries,particularlythosethatresultinneurologicdamage.Inthelattersituation,chronicpainandtransientosteopeniaarefeaturesofthecomplexregionalpainsyndrome(alsoknownasreflexsympatheticdystrophy,causalgia,andotherterms).3BonemarrowedemasyndromecanbedifferentiatedfromONonthebasisofhistologicandMRIfindings.Subchondralfractureofthefemoralheadtypicallyoccursinpatientswithpreexistingosteopeniaandisgenerallythoughttorepresentaninsufficiencyfracture.50Thesefracturesmaybedifficulttovisualizewithplainradiographs.Subtleflatteningissometimespresentwithearlylesions;collapseofthefemoralheadisprogressive.CLINICALMANAGEMENTOFHIPOSTEONECROSISFactorstoconsiderwhendevelopinganoptimalmanagementapproachforsymptomaticONofthehipshouldbeaimedattreatingthestageanddegreeofinvolvementofON,theextentandlocationofbonyinvolvement,thepresence(orabsence)ofsymptoms,andthepatient’scomorbidities.Thegoaloftherapyistopreservethebiologicalhipjointforaslongaspossiblewhilealsotakingintoconsiderationqualityoflifeissuessuchaspatientage,mobility,occupation,andlifestyle.ThreemaintherapeuticoptionsformanagementofhipONinclude1)nonoperativemanagement,2)joint-preservingprocedures,and3)THA.TheeffectsofatraumaticcausesofhipONposespecialconcerns.Forthoseaffected,67%reportnosymptomsbutmayeventuallygoontohaveacollapsedjoint.51Thenaturalhistoryofasymptomaticmedium-sized,andespeciallylarge,osteonecroticlesionsisprogressiontoworseningoftheconditionandeventuallyend-stagediseaseandcollapseofthehipinasubstantialnumberofpatients.Forthosewithsymptoms,approximately80%to85%ofcaseswillresultincollapseofthefemoralheadwithin2years.6EarlydiagnosisofONmaythereforeprovidetheopportunityforearlytreatment,whichcanpreventcollapseand,ultimately,theneedfortotaljointarthroplasty.However,mostpatientspresentlateinthecourseofthedisease,andahighindexofsuspicionisnecessaryforthosewithknownorprobableriskfactors,particularlypatientswithhigh-dosecorticosteroiduse.3SimilarlyforpatientswithasymptomatichipON,thesize,extent,andlocationofthenecroticlesionaffectingthefemoralheadshouldbeconsidered.Generally,lesionsaffectinglessthan15%ofthefemoralheadarebestmanagednonoperatively;lesionsbetween15%to30%shouldbemanagedsurgically;andlesionsinvolvingmorethan30%ofthefemoralheadarelikelytoprogresstocollapse,despitesurgicalintervention,andeventuallyrequireTHA.3,52,53NonsurgicalTreatmentOptionsinHipOsteonecrosisPhysicalTherapyPhysicaltherapymayprovidereliefandalleviatesomesymptomsbutgenerallywillnotprecludeprogressivehipONfromadvancingtolaterstages.54Similarly,restrictingweight-bearingwiththeuseofassistivedevicessuchascrutchesoracanemaybeusefultocontrolsymptomsofpain,weakness,andantalgicgait.PhysicaltherapyisnotappropriateifthegoaloftreatmentistopreventthehipfromrequiringTHA,andtodatethereisnoevidencethatweight-bearingrestrictionsarehelpfulinpreventingprogressiveONdiseasefromadvancingtoend-stagedisease.MedicationsNonsteroidalanti-inflammatorydrugsandacetaminophenmayprovidetemporaryreliefofpaininsymptomaticpatients.Opioidmedicationsmaybeusedjudiciouslyandforshortperiodsoftimewhenotheragentsareineffectivetomanagemoderate-to-severepainwhilesurgicaloptionsarebeingconsidered.InvestigationalmedicationoptionscurrentlybeingusedbutthatarenotprovenorreliablyusedtotreatONinclude1)anticoagulants,2)bisphosphonateantiresorptiveagents,3)cholesterolloweringstatins,and4)hyperbaricoxygen.SurgicalOptionsinEarly-StageHipOsteonecrosisCoreDecompressionCoredecompressionisaminimallyinvasivesurgicaltechniqueperformedtomanagesymptomsinearlystages(precollapse)ofthecondition(eg,FicatandArletStagesIandII).Theprocedureinvolvesdrillingholesintothefemoralheadtorelievepressureandcreatechannelsfornewbloodvesselstonourishtheaffectedareas.Thepublishedsuccessratesofcoredecompressionvarygreatlyfrom40%to100%,dependingonpatientpopulation.35Highersuccessratesaftercoredecompressionareseeninpatientswiththeearliestdiseasestages.Patientswithsuccessfulcoredecompressionprocedurestypicallyreturntounassistedambulationafterseveralmonthsandcanhavecompletepainrelief.55BoneGraftingCoredecompressioncanbecombinedwithbonegraftingtohelpregeneratehealthyboneandsupportcartilageatthehipjoint.Abonegraftishealthybonetissuethatistransplantedtotheareaofnecroticordeadbone.Astandardtechniqueusesanautograftthatinvolvestakingbonefromonepartofthebodyandmovingittoanotherpartofthebody.Abonegraftthatisharvestedfromadonororcadaveriscalledanallograftandistypicallyacquiredthroughabonebank.BoneMarrowAspirateConcentrationThebonemarrowaspirateconcentrationinjectionprocedurewithcoredecompressioninvolvestheuseofconcentratedbonemarrowthatisinjectedintothedeadboneofthehip.Thisinvestigationaltechniqueharvestsstemcellsfromapatient’sbonemarrowandinjectsthemintotheareaofON.9Thebonemarrowaspirateconcentrationprocedureishypothesizedtopreventfurtherprogressionofthediseaseandtostimulatenewbonegrowth.56PercutaneousDrillingAnothersurgicaloptionispercutaneousdrilling.Inthisprocedure,aholeisdrilledpercutaneouslythroughthefemoralnecktotheaffectedsiteinthefemoralhead.Onereporton45hipswithameanfollow-upof24monthsreported24(80%)of30hipswithFicatandArletStageIdiseasehadsuccessfuloutcomes(definedasHarrisHipScore＜70).57Amorerecentstudycomparingmultipledrillingvsstandardcoredecompressionshowedfavorableresultsinfavorofpercutanteousdrilling.28SurgicalOptionsinAdvanced-StageHipOsteonecrosisVascularizedBoneGraftAvascularizedfibulagraftisamoreinvolvedsurgicalprocedureinwhichasegmentofboneistakenfromthefibulawithitsbloodsupply.Thegraftisthentransplantedintoaholecreatedinthefemoralneckandhead,andthearteryandveinarereattachedtohelphealtheareaofON.55OsteotomyOsteotomyinhipONcanbeperformedtoremovenecroticboneawayfromprimaryweight-bearingareas.AlthoughthisoperationmaydelayTHAsurgery,itismostusefulinpatientswithidiopathicONwhodemonstratesmallprecollapseorearlypostcollapseofthefemoralhead.Aconsequenceofosteotomies,however,isthattheymakesubsequentTHAmorechallengingandareoftenassociatedwithanincreasedriskofnonunionofthebone.NonvascularizedBoneGraftThereare3typesofnonvascularizedbonegraftingsurgeries:1)trapdoorprocedure,2)lightbulbtechnique,and3)Phemistertechnique.ThetrapdoorprocedureisoneinwhichautogenouscancellousandcorticalbonegraftinghavebeensuccessfulinFicatandArletStageIIIhipONinpatientswithsmall-tomedium-sizedlesions.Areviewoftheresultsof30trapdooroperationsperformedon23patientswithFicatandArletStageIIIorStageIVONofthefemoralheadperformedthroughaso-calledtrapdoormadeinthefemoralheadrevealedagoodorexcellentresultasdeterminedbytheHarrisHipScoresystem.11LightbulbTechniqueThelightbulbtechniqueusesacorticalwindowintheanterioraspectofthefemoralneck.Necroticbonecanberemovedusingthiswindow,whichcanbelaterpackedwithnonvascularizedbonegraft.Wangetal55evaluated110patients(138hips)whounderwentthelightbulbprocedure.Atmeanfollow-upof25months,meanHarrisHipScoresimprovedfrom62to79points.Atotalof94hips(68%)wereconsideredtohavesuccessfuloutcomesatlatestfollow-up.Radiographicimprovementswerenotedin100%ofAssociationResearchCirculationOsseousStageIIapatients,77%instageIIbpatients,and51%instageIIcandIIIapatients.55PhemisterTechniqueInthePhemistertechnique,atrephineisinsertedthroughthefemoralnecktocreateatracttothelesion.Asecondtrephineistheninsertedtocreateanothertracttothelesionsite.Acorticalstrutgraftcanthenbeplacedinthelesion.Arecentreviewreportsthisproceduretohaveaclinicalsuccessraterangingfrom36%to90%.25TotalHipArthroplastyOncethefemoralheadhasundergonemajorcollapse,replacingthehipjointistheonlypracticaloperativeoptionandoffersthemostpredictablepainreliefinadvancedON.THAissuccessfulinrelievingpainandrestoringfunctioninthemajorityofpatients.45–47InTHA,thediseasedcartilageandboneconstitutingthehipjointisreplacedwithartificialimplantsmadeofmetalandplastic.Aprosthetichipreplacementgenerallylasts15yearsbeforeitmightwearoutandneedtoberevised.Fortheyoungeragegroup,aTHAmaybeasuboptimalsolutionbecauseofpossibleactivityrestrictions.Additionally,becauseprostheseshavelongevityrestrictions—componentswearafterlong-termuse—thesepatientswilllikelyrequirearevisionTHAlaterinlife.THAmustbecarefullyconsideredandbalancedagainstqualityoflifeissues,butitisnotabsolutelycontraindicatedforyoungerpatients.PATIENTEDUCATIONABOUTHIPOSTEONECROSISPreventionofOsteonecrosisPatienteducationaboutriskfactors,therapies,andmanagementisessentialforpatientstomakebetter-informeddecisionsabouttheircondition.TheprocessofONeducationinvolvesidentificationofanindividual’sassociateddisordersandriskfactorsrelatedtoON.PatientswithasymptomaticONmayhaveahighprevalenceofprogressiontosymptomaticdiseaseandfemoralheadcollapse.Educationforpatientswithasymptomaticdiseaseisprecautionaryandimperativetoensuremodificationofriskfactorsandoptimizationofcare.PreventingatraumaticONrequires1)avoidingexcessiveuseofalcoholdefinedas＜15drinks/wkformenand＜8drinks/wkforwomen,102)avoidingsmoking,and3)reducingcorticosteroidstothelowestpossibletherapeuticdose.InformingpatientsaboutthecorrelationbetweencorticosteroiduseandpotentialdevelopmentofONiscriticalinmanagementofthiscondition.PreventionofProgressionofOsteonecrosisPatientsdiagnosedwithearly-stageONshouldbeadvisedoftheaforementionedprecautionsandshouldavoidplacingexcessivepressureontheirjoints,followahealthydiet,andmaintainanappropriateweighttomitigateprogressionofON.Althoughahealthydietinitselfdoesnotdirectlyreducepressureonapatient’sjoints,weightloss(ifoverweight/obese)willreduceaxialloadsonthehipjoint,whichinturndecreasesthestrainappliedtothefemoralhead/neck(toboththetensionandthecompressionsides).42CONCLUSIONONisapathologicandoftenpainfulconditioninvolvingnecroticareasoftissuethatcanaffectanybonyjointinthebody.ThehipjointisthemostcommonlocationforONandshouldalwaysbeproperlyevaluated,utilizingradiographicscreeningandMRIscanning,whenONisinitiallydiagnosedinanotherbodypart.TheearlieradiagnosisofONismade,thebettertheopportunitytosavethehipjointwithoutsurgicalinterventionorwithminimallyinvasivesurgicaltechniques.AfteradiagnosisofONismade,thesize,extent,andlocationofthelesionandtheclassificationstagesareconsideredtodevelopanoptimalplanofcare.Thepresenceorabsenceofsymptomsisimportantinthisprocess.Thegoalsoftreatmentinvolveattemptingtopreservethebiologicalhipjointforaslongaspossibleandconsiderationofapatient’slifestyleandqualityoflifeissues.Todate,the2maintherapeuticoptionsformanagementofhipONincludejoint-preservingproceduresandTHA.PatienteducationaboutpotentialriskfactorsanddevelopmentofONisessentialtopreventtheconditionand/ortopotentiallypreventorhaltprogressionofearly-stagediseasetolater-stagedisease.2023年07月10日1134
2
2
-
陶可主治醫(yī)師 北京大學(xué)人民醫(yī)院 骨關(guān)節(jié)科 股骨頭壞死：病因、診斷及治療方式：2019英國(guó)醫(yī)學(xué)雜志(BMJ)(醫(yī)學(xué)生及低年資住院醫(yī)師培訓(xùn)之)綜述作者：JonathanNLamb,ColinHolton,PhilipO'Connor,PeterVGiannoudis作者單位:LeedsInstituteofRheumaticandMusculoskeletalMedicine,SchoolofMedicine,UniversityofLeeds,Leeds,UK.譯者：陶可（北京大學(xué)人民醫(yī)院骨關(guān)節(jié)科）股骨頭壞死你需要了解什么？?股骨頭壞死(AVNFH)的常見(jiàn)危險(xiǎn)因素包括：酗酒、使用類固醇激素、化療和免疫抑制劑藥物以及鐮狀細(xì)胞性貧血。?如果患者髖部疼痛持續(xù)超過(guò)6周且X線片正常，請(qǐng)考慮對(duì)髖部進(jìn)行核磁共振MRI掃描，并轉(zhuǎn)診至骨科（保髖治療）團(tuán)隊(duì)。?早期治療可使髖關(guān)節(jié)7年后存活率提高至88%。Fig1Demonstrationofhiprotationtoelicithippainwiththepatientsitting(A)andsupine(B,C,D).圖1?演示通過(guò)患者坐位(A)和仰臥位(B、C、D)引起髖部疼痛的髖關(guān)節(jié)旋轉(zhuǎn)活動(dòng)(髖關(guān)節(jié)查體之內(nèi)外旋轉(zhuǎn)活動(dòng))。Fig2Typicalchangesseenonplainradiograph(top)andMRI(bottom)ofthehipinearlyandlateAVNFH.TheappearanceofearlyAVNFHisnotapparentonplainradiographbutisvisibleonMRI.圖2?早期和晚期股骨頭壞死(AVNFH)髖關(guān)節(jié)平片（上）和MRI（下）中看到的典型變化。早期股骨頭壞死(AVNFH)的在平片上表現(xiàn)不明顯，但在MRI上可見(jiàn)明顯信號(hào)的改變。Fig3ProposedpathwayformanagingAVNFHinaprimarycaresetting.圖3?在基層醫(yī)療機(jī)構(gòu)中管理股骨頭壞死(AVNFH)的建議診治流程。?典型病例：一名36歲的女性向她的全科醫(yī)生報(bào)告，有左側(cè)腹股溝疼痛放射到膝蓋的病史。疼痛很嚴(yán)重，走路時(shí)更嚴(yán)重，并伴有跛行。一年后，患者再次去看全科醫(yī)生，盡管進(jìn)行了鎮(zhèn)痛，但疼痛仍持續(xù)存在。髖關(guān)節(jié)和膝關(guān)節(jié)的平片顯示髖關(guān)節(jié)間隙輕微變窄，沒(méi)有其他特征，她被轉(zhuǎn)診到二級(jí)骨科診所。髖關(guān)節(jié)磁共振成像(MRI)掃描顯示股骨頭缺血性壞死(AVNFH)伴塌陷的典型特征。什么是股骨頭缺血性壞死？股骨頭壞死（AVNFH）由于微循環(huán)異常而導(dǎo)致軟骨下骨結(jié)構(gòu)完整性喪失。潛在的發(fā)病機(jī)制尚不清楚；風(fēng)險(xiǎn)因素可能會(huì)以某種方式影響微循環(huán)，但這尚未得到研究證實(shí)。共同的終點(diǎn)是微循環(huán)異常和壞死。軟骨下骨隨后塌陷，導(dǎo)致進(jìn)行性、繼發(fā)性髖關(guān)節(jié)骨關(guān)節(jié)炎。在英國(guó)，平均發(fā)病年齡為58.3歲，每10萬(wàn)名患者中有2人患病。平均而言，股骨頭壞死（AVNFH）比典型骨關(guān)節(jié)炎發(fā)生得更早。它在男性中更為常見(jiàn)，發(fā)病率最高的是25至44歲的男性和55至75.3歲的女性。在英國(guó)，它是50.4歲以下人群全髖關(guān)節(jié)置換術(shù)的第三大常見(jiàn)適應(yīng)癥。以下因素與股骨頭壞死（AVNFH）風(fēng)險(xiǎn)增加相關(guān)：?血液甘油三酯、總膽固醇、低密度脂蛋白膽固醇和非高密度脂蛋白膽固醇水平高；?男性；?城市居民；?股骨頭壞死（AVNFH）家族史；?大量吸煙；?濫用酒精；?超重；?凝血?。?血管病變；?艾滋病病毒；?大量接觸類固醇激素、化療和免疫抑制藥物。類固醇激素已被證明會(huì)使骨壞死（非部位特異性）的幾率增加3倍，而免疫抑制劑則增加6倍。Zhao報(bào)告稱，服用皮質(zhì)類固醇激素的患者發(fā)生股骨頭壞死（AVNFH）的幾率高出35倍，患有“酗酒”狀態(tài)的患者則高出6倍。為什么股骨頭壞死（AVNFH）會(huì)漏診呢？股骨頭壞死（AVNFH）很少見(jiàn)。患有這種疾病的患者可能同時(shí)患有慢性風(fēng)濕病和血液病。這可能會(huì)導(dǎo)致診斷的不確定性，特別是考慮到在這些情況下使用化療、免疫調(diào)節(jié)劑和類固醇激素時(shí)，這些都是股骨頭壞死（AVNFH）的危險(xiǎn)因素。查體可以幫助識(shí)別可能引起疼痛的解剖結(jié)構(gòu)，因?yàn)轶y關(guān)節(jié)疼痛可能源自髖關(guān)節(jié)和非髖關(guān)節(jié)的多個(gè)部位。臨床表現(xiàn)可能會(huì)被錯(cuò)過(guò)，因?yàn)橛捎跁r(shí)間和空間的限制，在基層醫(yī)療機(jī)構(gòu)中準(zhǔn)確確定單純由于髖關(guān)節(jié)運(yùn)動(dòng)時(shí)造成的腹股溝疼痛可能具有挑戰(zhàn)性(比較困難)。股骨頭壞死（AVNFH）早期階段的正常X線片可能會(huì)錯(cuò)誤地讓人放心并延遲適當(dāng)?shù)霓D(zhuǎn)診。如果X線片呈陰性并且患者繼續(xù)抱怨髖關(guān)節(jié)疼痛，醫(yī)生可能會(huì)診斷為非特異性髖關(guān)節(jié)疼痛（考慮到肌肉骨骼的原因）并建議患者接受物理治療。在新發(fā)病例中，18.75%只能通過(guò)MRI進(jìn)行診斷，并且在普通X線片上很容易被漏診。只有MRI掃描才具有診斷意義。為什么及早確診股骨頭壞死（AVNFH）很重要？早期診斷和轉(zhuǎn)診至關(guān)重要，因?yàn)楣琴|(zhì)破壞通常發(fā)生在發(fā)病后2年內(nèi)，因此不可能進(jìn)行保留髖關(guān)節(jié)的治療干預(yù)(保髖治療在股骨頭壞死發(fā)病2年內(nèi))。股骨頭壞死（AVNFH）的早期發(fā)現(xiàn)使多學(xué)科團(tuán)隊(duì)有時(shí)間改變可能引發(fā)股骨頭壞死（AVNFH）發(fā)作的治療方法。股骨頭髓心減壓術(shù)可降低中短期內(nèi)進(jìn)一步手術(shù)的需要，但僅適用于疾病的最早階段。一旦患者進(jìn)展為繼發(fā)性髖關(guān)節(jié)骨關(guān)節(jié)炎，關(guān)節(jié)置換通常是不可避免的。然而，考慮到股骨頭壞死（AVNFH）患者年齡較小，翻修手術(shù)和相關(guān)發(fā)病率的終生風(fēng)險(xiǎn)很大。如何診斷股骨頭壞死（AVNFH）？股骨頭壞死（AVNFH）診斷從仔細(xì)詢問(wèn)病史和檢查開(kāi)始，以確定髖關(guān)節(jié)疼痛的來(lái)源。最終需要MRI來(lái)診斷股骨頭壞死（AVNFH），并且還可以診斷髖關(guān)節(jié)疼痛的其他原因。仔細(xì)的詢問(wèn)病史病史顯示疼痛持續(xù)超過(guò)6周，通常位于腹股溝和大腿，負(fù)重和運(yùn)動(dòng)時(shí)疼痛更嚴(yán)重。通常沒(méi)有外傷史。詢問(wèn)危險(xiǎn)因素，如果患者有任何“危險(xiǎn)信號(hào)”，請(qǐng)進(jìn)行髖關(guān)節(jié)MRI檢查。股骨頭壞死（AVNFH）通常是雙側(cè)的，雙側(cè)股骨頭壞死（AVNFH）的風(fēng)險(xiǎn)通常是在單側(cè)確診后的2年內(nèi)?？?：需要轉(zhuǎn)介或進(jìn)一步評(píng)估的危險(xiǎn)信號(hào)：?髖關(guān)節(jié)X線檢查正常，髖關(guān)節(jié)疼痛超過(guò)6周；?患有髖關(guān)節(jié)疼痛和危險(xiǎn)因素的患者，包括：o既往單側(cè)股骨頭壞死（AVNFH），o酗酒，o大量接受類固醇激素治療，o免疫治療，?化療，o鐮狀細(xì)胞病和其他凝血病，?艾滋病毒，o新近妊娠。查體腹股溝、大腿和膝關(guān)節(jié)前側(cè)疼痛的再現(xiàn)并伴有單獨(dú)的大腿旋轉(zhuǎn)不能診斷股骨頭壞死（AVNFH），但有助于區(qū)分髖關(guān)節(jié)疼痛與脊柱和膝關(guān)節(jié)疼痛。這可以在患者坐位或仰臥時(shí)進(jìn)行（圖1）。影像學(xué)檢查早期股骨頭壞死（AVNFH）在X線片上并不明顯。如果患者持續(xù)感到疼痛，則需要進(jìn)一步檢查和轉(zhuǎn)診。股骨頭壞死（AVNFH）通過(guò)髖關(guān)節(jié)MRI進(jìn)行診斷，當(dāng)與臨床癥狀密切相關(guān)時(shí)，還可以診斷各種可治療的髖關(guān)節(jié)疼痛（例如風(fēng)濕病、肌腱疾病和骨病）（圖2）。僅當(dāng)有其他原因或高度懷疑風(fēng)濕病或感染時(shí)，才應(yīng)考慮進(jìn)行其他檢查，例如血液檢查。轉(zhuǎn)診如果患者的髖關(guān)節(jié)MRI顯示有股骨頭壞死（AVNFH）改變時(shí)，請(qǐng)就診于骨科醫(yī)生（圖3）。在二級(jí)醫(yī)療機(jī)構(gòu)就診時(shí)，股骨頭壞死（AVNFH）診斷應(yīng)與開(kāi)具類固醇激素、化療和免疫治療原發(fā)病的任何治療團(tuán)隊(duì)共享。藥物和手術(shù)治療取決于患者的特征和股骨頭壞死（AVNFH）的階段。使用前列環(huán)素類似物和雙膦酸鹽對(duì)塌陷前股骨頭壞死（AVNFH），可以減輕癥狀并防止關(guān)節(jié)形合度破壞，但其療效目前尚不清楚。手術(shù)治療仍存在爭(zhēng)議，但大多數(shù)塌陷前股骨頭壞死（AVNFH）患者均接受髓心減壓手術(shù)，并輔以或不輔以藥物治療，以減輕疼痛，并有可能在長(zhǎng)達(dá)7年的時(shí)間里避免88%的患者進(jìn)行全髖關(guān)節(jié)置換術(shù)治療。術(shù)后恢復(fù)包括12個(gè)月的非負(fù)重康復(fù)鍛煉，并在8周后逐漸恢復(fù)工作和駕駛。通常在術(shù)后12個(gè)月即可感受到完全的治療益處。專業(yè)的三級(jí)醫(yī)療機(jī)構(gòu)可以提供新的治療方法，例如骨移植和截骨術(shù)，以分別促進(jìn)血管再生和減輕受損髖關(guān)節(jié)表面的負(fù)荷。一旦發(fā)生塌陷，全髖關(guān)節(jié)置換術(shù)可以為患者提供快速、可靠的疼痛緩解和功能改善，但與未來(lái)有髖關(guān)節(jié)翻修的風(fēng)險(xiǎn)，特別是對(duì)于年輕患者。?AvascularnecrosisofthehipWhatyouneedtoknow?CommonriskfactorsforAVNFHarealcoholism,useofsteroids,chemotherapyandimmunosuppressantmedication,andsicklecellanaemia.?ConsiderMRIscanofthehipandreferraltoanorthopaedicteamifapatienthasapainfulhipforlongerthansixweekswithnormalradiographs.?Earlytreatmentimprovesthechancesofhipsurvivalbyupto88%atsevenyears.?A36yearoldwomanpresentstoherGPwithahistoryofleftgroinpainradiatingtotheknee.Thepainissevere,worseonwalking,andassociatedwithalimp.ThepatientrevisitstheGPayearlaterwithpersistentpaindespiteanalgesia.Plainradiographsofthehipandkneeshowslightnarrowingofthehipjointspacewithnootherfeaturesandsheisreferredtoasecondarycareorthopaedicclinic.Amagneticresonanceimaging(MRI)scanofthehipshowsclassicfeaturesofavascularnecrosisofthefemoralhead(AVNFH)withcollapse.Whatisavascularnecrosisofthefemoralhead?Osteonecrosisofthefemoralhead(AVNFH)causeslossofintegrityofsubchondralbonestructureduetoabnormalmicrocirculation.Theunderlyingpathogenesisisunclear1;riskfactorsarelikelytoaffectmicrocirculationinsomewaybutthishasnotbeenconfirmedbyresearch.Thecommonendpointisabnormalmicrocirculationandnecrosis.Subchondralbonesubsequentlycollapses,whichleadstoprogressivesecondaryarthritis.MeanageofpresentationintheUKis58.3years,withaprevalenceoftwoper100000patients.2Onaverage,AVNFHoccursearlierinlifethantypicalosteoarthritis.Itismorecommoninmenandthehighestprevalenceisinmenaged25to44andwomenaged55to75.3IntheUKitisthethirdmostcommonindicationfortotalhipreplacementinpeopleunder50.4ThefollowingfactorsareassociatedwithanincreasedriskofAVNFH35:?Highlevelsofbloodtriglycerides,totalcholesterol,lowdensitylipoproteincholesterol,andnon-highdensitylipoproteincholesterol?Malesex?Urbanresidence?FamilyhistoryofAVNFH?Heavysmoking?Alcoholabuse?Overweight?Coagulopathies?Vasculopathies?HIV?Highexposuretosteroids,chemotherapy,andimmunosuppressantmedication.Steroidshavebeenshowntoincreaseoddsofosteonecrosis(non-sitespecific)byafactorofthreeandimmunosuppressantsbyafactorofsix.ZhaoreportedthattheoddsofAVNFHwere35timesgreaterinpatientstakingcorticosteroidsandsixtimesgreaterinpatientswith“alcoholism”status.3Whyisitmissed?AVNFHisrare.Patientswiththeconditioncanhavecoexistingchronicrheumaticandhaematologicalproblems.Thismayleadtodiagnosticuncertainty,particularlygiventheuseofchemotherapy,immunomodulatoryagents,andsteroidsintheseconditions,whichareallriskfactorsforAVNFH.Aphysicalexaminationcanhelpidentifytheanatomicalstructuresthatmightbecausingthepain,sincehippaincanoriginatefrommultiplehipandnon-hipareas.Presentationsmaybemissedbecauseaccuratereproductionofgroinpainonisolatedhipmovementscanbechallengingtoelicitinaprimarycaresettingduetotimeandspaceconstraints.NormalplainradiographsintheearlystagesofAVNFHcanbefalselyreassuringanddelayappropriatereferral.Iftheplainradiographisnegativeandthepatientcontinuestocomplainofhippain,thedoctormaygiveadiagnosisofnon-specifichippain(giventhatmusculoskeletalpresentationsarecommoninprimarycare)andsendthepatientforphysiotherapy.Ofnewpresentations,18.75%arediagnosableonlywithMRIandareeasilymissedonnormalplainradiographs.3OnlytheMRIscanisdiagnostic.Whydoesitmatter?Earlydiagnosisandreferralareessentialsincebonedestructionnormallyoccurswithintwoyearsofdiseaseonset,makingjointpreservinginterventionimpossible.6EarlyidentificationofAVNFHgivesthemultidisciplinaryteamtimetochangemedicaltreatmentswhichmightbeprovokingonsetofAVNFH.Surgicaldecompressionofthefemoralheadreducestheneedforfurthersurgeryintheshorttomediumtermbutisonlysuitablefortheearlieststagesofdisease.5Oncepatientshaveprogressedtosecondaryhiparthritis,jointreplacementisusuallyinevitable.However,giventheyoungerageofpatientswithAVNFH,thelifetimeriskofrevisionsurgeryandassociatedmorbidityisgreat.HowisAVNFHdiagnosed?AVNFHdiagnosisstartswithacarefulhistoryandexaminationtodeterminethatthehipisthesourceofpain.UltimatelyanMRIisrequiredtodiagnoseAVNFHandmayalsodiagnoseothercausesofhippain.AcarefulhistoryAhistoryshowingpainlastinglongerthansixweeks,typicallylocatedinthegroinandthighandwhichisworseonweightbearingandmovementiskey.6Usuallythereisnohistoryoftrauma.AskaboutriskfactorsandreferforMRIofthehipifthepatienthasany“redflags”(box1).AVNFHisoftenbilateralandtheriskofbilateralAVNFHishighestwithintwoyearsofunilateraldiagnosis.6Box1:Redflagsrequiringreferralorfurtherassessment?Hippainformorethansixweekswithnormalhipradiograph?PatientspresentingwithhippainandriskfactorsincludingopreviousunilateralAVNFHoalcoholexcessohighexposuretosteroidtherapyoimmunologictherapyochemotherapyosicklecelldiseaseandothercoagulopathiesoHIVorecentpregnancyExaminationReproductionofpaininthegroin,thigh,andanterioraspectofkneewithisolatedthighrotationwillnotdiagnoseAVNFH,butwillhelptodifferentiatehippainfrompainoriginatingfromthespineandknee.Thiscanbeperformedwiththepatientsittingorsupine(fig1).RadiologicaltestsEarlyAVNFHisnotapparentonplainradiographs.Ifthepatientcontinuestobeinpain,furtherinvestigationandreferraliswarranted.AVNFHisdiagnosedonMRIofthehips,7whichmayalsodiagnoseabreadthoftreatablehippain(suchasrheumatologicaldisease,musculotendinousdisease,andbonydisease)whencarefullycorrelatedwithclinicalsymptoms8(fig2).Otherinvestigations,suchasbloodtests,shouldonlybeconsideredifindicatedforotherreasonsorifthereisahighsuspicionofrheumatologicaldiseaseorinfection.ReferralIfthepatienthassignsofAVNFHonMRIofthehip,refertoanorthopaedicsurgeonforconsultation(fig3).Insecondarycare,AVNFHdiagnosisshouldbesharedwithanycareteamsinvolvedintheadministrationofsteroids,chemotherapy,andimmunologictherapy.MedicalandsurgicaltreatmentdependonthepatientcharacteristicsandstageofAVNFH.Medicaltreatmentofpre-collapsediseasewithprostacyclinanaloguesandbisphosphonatesmayreducesymptomsandpreventlossofjointcongruitybuttheirefficacyisnotcurrentlywelldefined.6Surgically,treatmentremainscontroversial,butmostpatientswithpre-collapseAVNFHareofferedcoredecompressionsurgerywithorwithoutadjunctivepharmacologicaltherapytoreducepainandpotentiallypreventtheneedfortotalhipreplacementin88%ofpatientsforuptosevenyears.910Postoperativerecoveryinvolvesaperiodofnon-weightbearingfor12monthsandgradualreturntoworkanddrivingat8weeks.Fullbenefitisusuallyfeltat12monthsaftersurgery.Specialisttertiarycentresmayoffernoveltreatmentssuchasbonegraftingandosteotomiestoencouragevascularregrowthandunloaddamagedhiparticularsurface,respectively.Oncecollapsehasoccurred,totalhipreplacementcangivepatientsrapid,reliablepainreliefandimprovedfunctionbutisassociatedwiththeriskoffuturerevision,particularlyinyoungerpatients.Afulldescriptionofalltheoptionsisbeyondthescopeofthisarticleandpatientsshoulddiscussallavailableoptionswiththeirsurgeontoenableinformedshareddecisionmaking.文獻(xiàn)出處：JonathanNLamb,ColinHolton,PhilipO'Connor,PeterVGiannoudis.Avascularnecrosisofthehip.BMJ.2019May30;365:l2178.doi:10.1136/bmj.l2178.2023年07月09日526
1
1
-
陶可主治醫(yī)師 北京大學(xué)人民醫(yī)院 骨關(guān)節(jié)科 股骨頭壞死治療：2022年最新研究進(jìn)展作者：GaryGeorge,JosephMLane.作者單位:FromWeillCornellMedicine,NewYork,NewYork(Mr.George),andtheHospitalforSpecialSurgery,NewYork,NewYork(Dr.Lane).譯者：陶可（北京大學(xué)人民醫(yī)院骨關(guān)節(jié)科）摘要股骨頭壞死是一種進(jìn)展性、使人致殘的疾病，其病因多種多樣，包括外傷、使用激素(類固醇)和飲酒。診斷和分期基于影像學(xué)檢查，包括任何階段的MRI掃描和更晚期病變的X線片檢查。（疾病晚期）唯一確定的治療方法是全髖關(guān)節(jié)置換術(shù)，盡管，（目前臨床上）采用包括二磷酸鹽和核心減壓在內(nèi)的多種治療方法來(lái)延緩病情進(jìn)展。缺乏令人滿意的保守（治療）措施表明，需要對(duì)股骨頭壞死進(jìn)行進(jìn)一步研究，包括大型的患者登記，以進(jìn)一步了解（保守治療的）效果。股骨頭壞死是一種進(jìn)展性疾病，（股骨頭）缺乏足夠的血液供應(yīng)會(huì)導(dǎo)致受影響區(qū)域的細(xì)胞死亡、骨折和塌陷。這種情況通常與股骨頭有關(guān)，病情進(jìn)展可能會(huì)使人衰弱（殘疾），最終可能需要進(jìn)行全髖關(guān)節(jié)置換術(shù)(全髖關(guān)節(jié)置換術(shù)(THA))。股骨頭壞死的病因很復(fù)雜，有多種致病因素，其中最明顯的是外傷、使用激素和酒精。股骨頭壞死的治療是有爭(zhēng)議的，因?yàn)闆](méi)有任何一種治療方式是被廣泛接受的，而且很少有研究比較（各種）治療方法（之間的優(yōu)劣）。研究人員估計(jì)，美國(guó)每年診斷出20,000例新發(fā)的股骨頭壞死病例。股骨頭壞死發(fā)病率的增加和使人致殘的進(jìn)展表明需要對(duì)有效和新穎的治療方法進(jìn)行深入的研究，以及需要更清楚地了解現(xiàn)有的治療方法。這篇綜述描述了目前關(guān)于股骨頭壞死的病因?qū)W、病理生理學(xué)、流行病學(xué)和臨床治療的知識(shí)，重點(diǎn)介紹了最新進(jìn)展。流行病學(xué)據(jù)估計(jì)，美國(guó)每年股骨頭壞死的發(fā)病率約為20000至30000例，主要影響20至40歲之間的年輕人。最近的分析表明，盡管因股骨頭壞死而進(jìn)行的全髖關(guān)節(jié)置換術(shù)(THA)數(shù)量有所增加，2001年和2010年（從每100,000名住院患者54.2例到每100,000名住院患者60.6例），因股骨頭壞死而進(jìn)行全髖關(guān)節(jié)置換術(shù)(THA)的比例從9.7%下降到8.3%，可能是因?yàn)樾枰M(jìn)行全髖關(guān)節(jié)置換術(shù)(THA)的骨關(guān)節(jié)炎迅速增加。病理生理學(xué)和發(fā)病機(jī)制一般發(fā)病機(jī)制盡管臨床表現(xiàn)是修復(fù)過(guò)程的結(jié)果，而不是最初的缺血，但股骨頭壞死的發(fā)生是由于骨骼的血流或氧氣輸送受損。在股骨頭壞死中，成骨細(xì)胞的骨形成無(wú)法與破骨細(xì)胞的骨吸收相匹配。這種重塑不平衡并不能充分替代壞死骨，從而留下了結(jié)構(gòu)不健全的骨組織區(qū)域。創(chuàng)傷創(chuàng)傷是股骨頭壞死的最常見(jiàn)原因，會(huì)擾亂血流并導(dǎo)致骨細(xì)胞死亡。發(fā)生股骨頭外傷性股骨頭壞死的估計(jì)因損傷類型而異；然而，在創(chuàng)傷性股骨頭壞死的薈萃分析中，發(fā)現(xiàn)其發(fā)生率高達(dá)14.3%。Garden分類對(duì)股骨頸骨折進(jìn)行了分類，可用于估計(jì)股股骨頭壞死的風(fēng)險(xiǎn)。GardenI（不完全骨折）和GardenII（完全且無(wú)移位）被認(rèn)為是穩(wěn)定且風(fēng)險(xiǎn)低的，可以通過(guò)內(nèi)固定修復(fù)。GardenIII（完全骨折和部分移位）和GardenIV（完全骨折和完全移位）內(nèi)固定的股骨頭壞死發(fā)生率要高得多（16%），應(yīng)考慮髖關(guān)節(jié)置換術(shù)。另外，有文獻(xiàn)報(bào)道，股骨轉(zhuǎn)子間骨折導(dǎo)致股骨頭壞死的風(fēng)險(xiǎn)較低，一年隨訪時(shí)的股骨頭壞死結(jié)果為0.95%。非外傷性股骨頭壞死非外傷性股骨頭壞死有多種原因。值得注意的是，在非創(chuàng)傷性股骨頭壞死中，由于系統(tǒng)性危險(xiǎn)因素，疾病常常是雙側(cè)的，一些估計(jì)表明，高達(dá)70%的單側(cè)股骨頭壞死患者的對(duì)側(cè)髖部會(huì)發(fā)生疾病。在存在系統(tǒng)性危險(xiǎn)因素的情況下，一側(cè)髖關(guān)節(jié)的磨損尚未得到充分研究，可能是由于亞臨床表現(xiàn)、髖關(guān)節(jié)之間磨損模式的差異、對(duì)癥狀的調(diào)查不足或缺乏協(xié)調(diào)的隨訪。糖皮質(zhì)激素類固醇的使用是股骨頭壞死的第二個(gè)最常見(jiàn)原因。已經(jīng)提出了這種關(guān)聯(lián)的幾種潛在機(jī)制，包括骨基質(zhì)和軟骨變性、誘導(dǎo)干細(xì)胞異常、脂質(zhì)代謝的變化、脂肪栓塞的產(chǎn)生、凝血改變。薈萃分析發(fā)現(xiàn)，服用大劑量皮質(zhì)類固醇的患者風(fēng)險(xiǎn)增加多達(dá)10倍；當(dāng)累積劑量超過(guò)10g時(shí)，股骨頭壞死的風(fēng)險(xiǎn)增加一倍；而使用大劑量皮質(zhì)類固醇患者每日劑量每增加10毫克股骨頭壞死風(fēng)險(xiǎn)就會(huì)增加3.6%。皮質(zhì)類固醇也與成骨細(xì)胞死亡和成骨細(xì)胞增殖減少有關(guān)，損害修復(fù)和替換骨壞死病變的能力。酒精據(jù)推測(cè)，酒精會(huì)通過(guò)改變脂質(zhì)代謝和增加脂肪生成來(lái)發(fā)揮（導(dǎo)致股骨頭壞死的）作用。據(jù)推測(cè)，脂質(zhì)生成的增加會(huì)增加脂肪栓塞導(dǎo)致血管閉塞的風(fēng)險(xiǎn)。此外，血脂升高會(huì)導(dǎo)致骨髓堵塞、骨內(nèi)壓升高和血流量減少。酒精也可能導(dǎo)致骨細(xì)胞死亡。一項(xiàng)研究還表明，與酒精性股骨頭壞死患者相比，酒精性股骨頭壞死患者的皮質(zhì)醇水平升高。特發(fā)性股骨頭壞死對(duì)照受試者，表明酒精引起的股骨頭壞死可能通過(guò)類固醇途徑起作用。之前有研究指出，每天飲酒超過(guò)400mL的患者發(fā)生股骨頭壞死的風(fēng)險(xiǎn)高出11倍。高脂血癥高脂血癥被認(rèn)為會(huì)增加骨內(nèi)壓并產(chǎn)生脂肪栓塞，從而減少受影響區(qū)域的血液供應(yīng)。一項(xiàng)針對(duì)老年人低能量股骨頸骨折的研究發(fā)現(xiàn)，發(fā)生股骨頭壞死的患者血脂異常率高于未發(fā)生股骨頭壞死的患者。一項(xiàng)針對(duì)急性淋巴細(xì)胞白血病(ALL)患者的研究發(fā)現(xiàn)，高脂血癥是發(fā)生股骨頭壞死的危險(xiǎn)因素。一項(xiàng)類似的研究發(fā)現(xiàn)，高脂血癥和系統(tǒng)性紅斑狼瘡(SLE)患者與股骨頭壞死的發(fā)生有關(guān)。系統(tǒng)性紅斑狼瘡SLE與股骨頭壞死的關(guān)聯(lián)與頻繁的皮質(zhì)類固醇治療有關(guān)；然而，最近的分析顯示，患有SLE的皮質(zhì)類固醇使用者的股骨頭壞死發(fā)生率高于未患SLE的皮質(zhì)類固醇使用者，這表明存在協(xié)同效應(yīng)。SLE研究的薈萃分析已發(fā)現(xiàn)SLE中的許多非皮質(zhì)類固醇危險(xiǎn)因素，特別是腎臟受累和中樞神經(jīng)系統(tǒng)（CNS）疾病?；旌蠑?shù)據(jù)表明，抗磷脂抗體的促血栓作用在SLE股骨頭壞死的發(fā)展中發(fā)揮作用。最近對(duì)兒童期發(fā)病的SLE的薈萃分析發(fā)現(xiàn)了顯著的股骨頭壞死關(guān)聯(lián)，估計(jì)6%至8.4%的兒童期發(fā)病的SLE患者會(huì)發(fā)生股骨頭壞死，盡管大多數(shù)患者直到青春期后才發(fā)現(xiàn)（并確診）股骨頭壞死。鐮狀細(xì)胞性貧血癥對(duì)鐮狀細(xì)胞病與股骨頭壞死之間關(guān)系的研究發(fā)現(xiàn)，每100名鐮狀細(xì)胞病患者中就有2至4.5例發(fā)生股骨頭壞死。低氧環(huán)境中血紅蛋白S的沉淀可能會(huì)導(dǎo)致血管閉塞和骨骼缺血，從而導(dǎo)致股骨頭壞死。與鐮狀細(xì)胞病中其他血管閉塞性損傷的發(fā)展類似。最近的一項(xiàng)研究支持這一理論，指出血紅蛋白水平升高是鐮狀細(xì)胞病患者股骨頭壞死的危險(xiǎn)因素，并表明血管閉塞、高血液粘度、缺氧和并發(fā)的α地中海貧血會(huì)導(dǎo)致股骨頭壞死。戈謝病最近對(duì)戈謝登記處的一項(xiàng)評(píng)估估計(jì)，股骨頭壞死的發(fā)生率為30%。戈謝病可能通過(guò)與鐮狀細(xì)胞病類似的途徑發(fā)揮作用，受戈謝影響的細(xì)胞會(huì)阻礙血流或通過(guò)增加骨內(nèi)壓，因?yàn)樗鼈冊(cè)隗w內(nèi)積聚。此外，戈謝細(xì)胞可以釋放破骨細(xì)胞激活細(xì)胞因子，破壞骨形成和吸收的平衡。酶替代可以減輕或延遲股骨頭壞死的癥狀；然而，一項(xiàng)研究表明，骨髓可能是戈謝細(xì)胞的“避難所”，導(dǎo)致部分患者盡管接受治療，仍容易發(fā)生股骨頭壞死。減壓病減壓病相關(guān)的股骨頭壞死或氣壓異常性股骨頭壞死是由于長(zhǎng)時(shí)間處于高壓環(huán)境后快速減壓而發(fā)生的。快速減壓會(huì)在血液中形成氣泡，因?yàn)槿芙獾牡獨(dú)鈺?huì)從溶液中逸出。氮?dú)庠谥窘M織中的高溶解度使得骨髓特別容易受到影響。已經(jīng)提出了多種機(jī)制，包括直接阻塞骨髓血流和骨內(nèi)壓升高減少有效血流。最近一項(xiàng)針對(duì)患有肌肉骨骼減壓病的潛水員的研究發(fā)現(xiàn)，26%的病例存在氣壓不足性股骨頭壞死的證據(jù)，盡管研究受到這種情況相對(duì)罕見(jiàn)的限制。急性淋巴細(xì)胞白血病ALL患者發(fā)生股骨頭壞死的風(fēng)險(xiǎn)增加，前瞻性研究中影像學(xué)發(fā)生率達(dá)到71.8%。ALL患者發(fā)生股骨頭壞死的最大單一因素是青春期，這表明ALL或其治療對(duì)骨骼的生長(zhǎng)和發(fā)育、重塑有影響。也有可能是代謝和生長(zhǎng)時(shí)期的變化放大了易感性。老年人占股骨頭壞死診斷患者的一小部分，他們經(jīng)常接受改良的治療方案，與年輕人相比，總體結(jié)果更差。最近的一項(xiàng)兒童白血病研究發(fā)現(xiàn)與單純化療相比，接受造血干細(xì)胞移植(HSCT)治療的患者股骨頭壞死發(fā)生率更高（6.8%比1.4%），這表明治療方法會(huì)影響股骨頭壞死的發(fā)展。此外，對(duì)治療方案的審查發(fā)現(xiàn)，患有任何血液系統(tǒng)惡性腫瘤兒童的激素累積劑量的增加發(fā)生股骨頭壞死的危險(xiǎn)因素。對(duì)治療策略的回顧表明，使用不連續(xù)的激素治療方案可能會(huì)降低股骨頭壞死的風(fēng)險(xiǎn)，而甲氨蝶呤和天冬酰胺酶等非激素化療藥物可能會(huì)導(dǎo)致股骨頭壞死的發(fā)生。一項(xiàng)隔周地塞米松試驗(yàn)與持續(xù)治療高危ALL兒童相比，降低了股骨頭壞死的風(fēng)險(xiǎn)。移植最近的一項(xiàng)研究表明，移植患者中的股骨頭壞死是由激素介導(dǎo)的，發(fā)現(xiàn)發(fā)生股骨頭壞死的腎移植患者的累積激素劑量高于未發(fā)生股骨頭壞死的腎移植患者。研究還發(fā)現(xiàn)，隨著環(huán)孢素的引入和激素使用的減少，癥狀性股骨頭壞死的發(fā)生率從20%下降到5%以下。艾滋病病毒多項(xiàng)研究表明，艾滋病毒患者股骨頭壞死的發(fā)病率不斷上升，其風(fēng)險(xiǎn)幾乎是普通人群的三倍。最近的一項(xiàng)研究表明，高活性抗逆轉(zhuǎn)錄病毒治療與股骨頭壞死的發(fā)生之間存在密切關(guān)聯(lián)，盡管作者警告說(shuō)，這種關(guān)聯(lián)并不意味著病理作用。其他研究發(fā)現(xiàn)股骨頭壞死與抗逆轉(zhuǎn)錄病毒治療(ART)之間沒(méi)有關(guān)聯(lián)，而與酒精、高脂血癥或低最低CD4計(jì)數(shù)有關(guān)，盡管其機(jī)制尚不清楚。遺傳參與盡管已經(jīng)發(fā)現(xiàn)了股骨頭壞死的家族變異和一些相關(guān)基因，但尚未確定單一的相關(guān)基因。一個(gè)候選基因是II型膠原蛋白的突變，盡管尚未確定明確的因果關(guān)系。與健康骨骼相比，壞死區(qū)域中發(fā)現(xiàn)骨保護(hù)素水平升高，RANK/RANK配體表達(dá)降低，這表明破骨細(xì)胞的潛在作用。在多項(xiàng)研究中，因子VLeiden突變和凝血酶原突變與股骨頭壞死患者相關(guān)，表明凝血功能改變的潛在作用。對(duì)選定人群的全基因組關(guān)聯(lián)研究已經(jīng)確定了幾個(gè)感興趣的位點(diǎn)，包括ALL、皮質(zhì)類固醇誘導(dǎo)的股骨頭壞死患者中谷氨酸受體基因附近的變異簇，以及幾個(gè)意義不明的位點(diǎn)，這些位點(diǎn)可能與凝血途徑有關(guān)，脂質(zhì)代謝，或飲酒行為。特發(fā)性股骨頭壞死值得注意的是，估計(jì)20%至40%的股骨頭壞死病例是特發(fā)性的（無(wú)明確病因）。原因不明的高比例可能是由于非特異性早期癥狀和非快速進(jìn)展的病程，（因而會(huì)）妨礙早期診斷，以及缺乏標(biāo)準(zhǔn)化報(bào)告和數(shù)據(jù)收集，這可能有助于揭示少見(jiàn)的病因和聯(lián)系。臨床表現(xiàn)和診斷診斷股骨頭壞死的早期階段通常無(wú)癥狀，但查體時(shí)也可能出現(xiàn)髖部或腹股溝的放射痛以及髖關(guān)節(jié)活動(dòng)范圍有限。股骨頭壞死的診斷主要基于影像學(xué)，盡管查體和病史（采集）對(duì)于收集髖關(guān)節(jié)周圍（其他病變）和潛在病因很重要。X線片是識(shí)別股骨頭壞死病例的合適的一線方法，其優(yōu)點(diǎn)包括低成本、高可用性以及對(duì)中期和晚期疾病足夠的敏感性。為了準(zhǔn)確起見(jiàn)，建議采用正位和“蛙式位”側(cè)視圖。在疾病早期的情況下，放射線檢查可能不足以識(shí)別早期或微小的變化。MRI是診斷股骨頭壞死的標(biāo)準(zhǔn)，因?yàn)樗鼘?duì)發(fā)病早期病變具有很高的敏感性。補(bǔ)充成像，包括彌散加權(quán)MRI和釓增強(qiáng)灌注MRI可能會(huì)進(jìn)一步提高M(jìn)RI的診斷能力。灌注MRI可能有助于區(qū)分影像學(xué)和癥狀相似的情況，例如骨髓水腫和軟骨下功能不全骨折。在患有髖關(guān)節(jié)發(fā)育不良的兒科患者中，灌注MRI有助于識(shí)別閉合復(fù)位/人字形石膏脫外固定后有股骨頭壞死風(fēng)險(xiǎn)的患者。此外，全身骨掃描患有多灶性股骨頭壞死風(fēng)險(xiǎn)的患者提供了一種選擇，如接受全身性皮質(zhì)類固醇或免疫抑制劑的患者。鑒別診斷骨髓水腫綜合征骨髓水腫綜合征(BMES)表現(xiàn)為突發(fā)疼痛，沒(méi)有明顯的誘發(fā)事件。影像學(xué)顯示，與股骨頭壞死的局部區(qū)域相比，BMES顯示彌漫性水腫。一些研究表明BMES可能先于股骨頭壞死發(fā)生。軟骨下不全骨折軟骨下不全骨折的表現(xiàn)（與股骨頭壞死）類似，但發(fā)生在受傷后。盡管這兩種情況都呈現(xiàn)低信號(hào)軟骨下帶，但股骨頭壞死成像呈現(xiàn)平滑的凹線，而骨折則呈現(xiàn)鋸齒狀、不連續(xù)的凸面。保守治療不太可能改善骨折癥狀，并且這兩種情況都可能發(fā)展到需要進(jìn)行全髖關(guān)節(jié)置換術(shù)(THA)。（股骨頭）腫瘤雖然罕見(jiàn)，但透明細(xì)胞軟骨肉瘤和軟骨母細(xì)胞瘤可在股骨頭中出現(xiàn)射線可透的病變。這些病癥不伴有股骨頭壞死或其他類似病癥（例如BMES）中出現(xiàn)的水腫。分類系統(tǒng)和分期最流行的股骨頭壞死分期系統(tǒng)是Ficat分期。Ficat系統(tǒng)于1964年開(kāi)發(fā)，后來(lái)進(jìn)行了修改，包括使用MRI，根據(jù)平片上的表現(xiàn)將股骨頭壞死患者分為0至4期。盡管該系統(tǒng)被廣泛接受并經(jīng)常使用，但批評(píng)者認(rèn)為其局限性在于使用臨床癥狀、觀察者間一致性較低和缺乏預(yù)測(cè)（效力）。賓夕法尼亞大學(xué)開(kāi)發(fā)該系統(tǒng)的目的是為了更清楚地描述股骨頭壞死的進(jìn)展，并通過(guò)為放射學(xué)前疾病添加0期，根據(jù)新月征的不存在(II)或存在(III)將FicatII期分為兩個(gè)階段，并將FicatIV期分為兩個(gè)階段：扁平化，關(guān)節(jié)間隙變窄，從而促進(jìn)各階段之間的區(qū)別僅(V)以及關(guān)節(jié)畸形和關(guān)節(jié)間隙閉塞(VI)。骨循環(huán)研究協(xié)會(huì)(ARCO)系統(tǒng)與Ficat密切相關(guān)，但將MRI結(jié)果納入I期并根據(jù)關(guān)節(jié)間隙的程度劃分II期。股骨頭變平（如果＜2毫米則為IIIA，如果＞2毫米則為IIIB）。ARCO系統(tǒng)最近根據(jù)國(guó)際專家工作組進(jìn)行了修訂，以更好地結(jié)合MRI和X線片的結(jié)果。對(duì)不同分期系統(tǒng)的系統(tǒng)分析發(fā)現(xiàn)，任何分類系統(tǒng)對(duì)于股骨頭壞死分期都是有價(jià)值且充分的，只要收集必要的數(shù)據(jù)以允許轉(zhuǎn)換為另一個(gè)指標(biāo)。為了患者評(píng)估和治療的目的，最重要的分類是塌陷前與塌陷前股骨頭碎裂，因?yàn)檫@是指導(dǎo)保守治療與髖關(guān)節(jié)置換術(shù)(THA)的依據(jù)。出于研究目的（特別是收集注冊(cè)數(shù)據(jù)），我們建議使用更新的ARCO指南，因?yàn)樗鼈冇行У厥褂枚喾N成像模式并描繪階段之間較小的變化。這可以更詳細(xì)地跟蹤疾病進(jìn)展，并且可能有助于提供更清晰的答案，因?yàn)樾炉煼ǖ挠行缘玫搅嗽u(píng)估。治療方案進(jìn)展風(fēng)險(xiǎn)評(píng)估進(jìn)展風(fēng)險(xiǎn)對(duì)于確定適當(dāng)?shù)闹委熯x擇很重要。盡管對(duì)于明確預(yù)測(cè)塌陷的系統(tǒng)尚未達(dá)成共識(shí)，但對(duì)嘗試策略的審查發(fā)現(xiàn)，病變體積增加、壞死＞40%的承重表面以及壞死弧度＞200至250度提示未來(lái)的塌陷。觀察最保守的治療方法——觀察——被認(rèn)為是治療股骨頭壞死的一種可能方法。有一些證據(jù)表明小的早期股骨頭壞死病變可自行消退。與觀察相結(jié)合，通常建議限制負(fù)重，盡管這尚未顯示出作為主要治療方式的實(shí)用性。一項(xiàng)將觀察作為策略的研究發(fā)現(xiàn)，股骨頭壞死四年內(nèi)的失敗率超過(guò)80%，不建議作為晚期病變的獨(dú)立治療方法。非手術(shù)治療藥物一直是股骨頭壞死治療的主要手段，但最近其有效性受到質(zhì)疑。二磷酸鹽是藥物治療的熱門選擇，通過(guò)抑制破骨細(xì)胞活性發(fā)揮作用。關(guān)于二磷酸鹽使用的研究顯示了不同的結(jié)果。盡管一些早期研究表明二磷酸鹽具有積極作用，但最近的一項(xiàng)大型多中心隨機(jī)對(duì)照試驗(yàn)發(fā)現(xiàn)阿侖膦酸鈉和安慰劑之間沒(méi)有差異。此外，對(duì)5項(xiàng)隨機(jī)對(duì)照試驗(yàn)的薈萃分析顯示，類似的發(fā)現(xiàn)，幾乎沒(méi)有證據(jù)支持二磷酸鹽的功效。二磷酸鹽的主要用途是在疾病的早期階段，隨著股骨頭壞死的進(jìn)展，二磷酸鹽并不優(yōu)于手術(shù)。研究已確定他汀類藥物在延緩股骨頭壞死方面發(fā)揮有益作用的多種潛在機(jī)制，包括降脂作用、增加自噬、抑制過(guò)氧化物酶體增殖物激活受體γ以及激活Wnt信號(hào)通路。他汀類藥物與多種藥物聯(lián)合使用可有效發(fā)揮作用。髓心減壓（CD）手術(shù)，可以改善股骨頭壞死的臨床和放射學(xué)進(jìn)展。其他非手術(shù)方式已經(jīng)提出了其他幾種治療股骨頭壞死的方式，并取得了不同程度的成功。飲食改變或硫辛酸補(bǔ)充劑等脂質(zhì)調(diào)節(jié)劑在試驗(yàn)中顯示出一些積極的結(jié)果，但沒(méi)有足夠的證據(jù)推薦它們作為主要治療策略。高壓氧治療、脈沖電磁場(chǎng)和體外沖擊波療法已獲得一些積極的成果，但對(duì)其有效性的分歧使得它們難以推薦。保髖手術(shù)治療髓心減壓CD用于治療股骨頭壞死，以降低骨內(nèi)壓，促進(jìn)血流增加和骨生成。Ficat在他對(duì)股骨頭壞死和髓心減壓CD手術(shù)的早期描述中指出，髓內(nèi)壓力增加，髓心減壓CD釋放髓內(nèi)壓力，如果在病變進(jìn)展早期得到治療，可以緩解疼痛并最終恢復(fù)血流。盡管早期的髓心減壓CD研究對(duì)其有效性尚不明確，但最近的研究顯示出顯著的益處。對(duì)短期和長(zhǎng)期結(jié)果的研究表明，與更保守的治療方案相比，接受髓心減壓CD治療的患者有所改善，并且延遲了全髖關(guān)節(jié)置換術(shù)(THA)時(shí)間。與許多治療一樣，在疾病早期階段使用時(shí)，這些結(jié)果更為積極。高達(dá)100%的髖關(guān)節(jié)存活3年，高達(dá)96%的早期疾病存活10年。更準(zhǔn)確地說(shuō)，髓心減壓CD在股骨頭壞死方面顯示出積極的結(jié)果，顯示無(wú)塌陷、中央病變和小尺寸（合并壞死）角度＜250°。當(dāng)與移植物和細(xì)胞治療相結(jié)合時(shí)，這些結(jié)果可能會(huì)更加有益。血管化和非血管化骨移植非血管化骨移植涉及放置骨移植材料以提供結(jié)構(gòu)支撐，目的是降低骨內(nèi)壓力并防止股骨頭壞死早期階段的塌陷。血管化骨移植（VBG）還尋求增加血液供應(yīng)。通過(guò)將來(lái)自髂骨、脛骨或腓骨的非血管化同種異體皮質(zhì)移植物或來(lái)自髂嵴、腓骨或大轉(zhuǎn)子的血管化移植物放置到為手術(shù)或髓心減壓CD手術(shù)創(chuàng)建的髓心空間中來(lái)完成移植。無(wú)血管化骨移植已顯示出一定的成功率，特別是對(duì)于較小的病變，在多項(xiàng)研究中，經(jīng)過(guò)2至9年的隨訪，成功率為55%至87%。血管化骨移植（VBG）顯示（在塌陷前病變中）5年髖關(guān)節(jié)存活率為80%或14年后類似患者中的60%，需要全髖關(guān)節(jié)置換術(shù)(THA)的比例較低。然而，血管化骨移植（VBG）的益處主要在沒(méi)有明顯塌陷的較小病變中實(shí)現(xiàn)。正在進(jìn)行的研究評(píng)估了使用或不使用生物因子的合成支架增強(qiáng)整合和骨骼生長(zhǎng)。盡管尚未找到明確的解決方案，但許多有機(jī)、無(wú)機(jī)和生物材料的開(kāi)發(fā)前景廣闊。輔助治療由于股骨頭壞死被認(rèn)為是由骨再生缺陷引起的，因此有人建議使用干細(xì)胞治療來(lái)阻止或逆轉(zhuǎn)其發(fā)病機(jī)制。研究表明，接受自體干細(xì)胞移植治療的患者放射學(xué)進(jìn)展率較低，全髖關(guān)節(jié)置換術(shù)(THA)需求也較低。在早期研究中，自體干細(xì)胞移植與髓心減壓CD相結(jié)合顯示，股骨頭塌陷時(shí)間平均延遲了10年（最多17年）。此外，細(xì)胞療法可以與髓心減壓CD等其他療法相結(jié)合。一項(xiàng)研究表明，除了同種異體移植物和/或骨移植物之外，骨形態(tài)發(fā)生蛋白(BMP)在改善骨形成和限制股骨頭壞死進(jìn)展方面也有益處。保髖截骨術(shù)截骨術(shù)是通過(guò)減輕壞死或壞死前區(qū)域的負(fù)重來(lái)延緩股骨頭壞死的進(jìn)展，以防止塌陷。為此，將承重的股骨頭壞死區(qū)域傾斜或旋轉(zhuǎn)，以將主要壓力施加在股骨頭非壞死區(qū)域上。股骨頭旋轉(zhuǎn)截骨術(shù)（3至15年期間的成功率為82%至100%）和（內(nèi)外翻、前伸后屈）成角截骨術(shù)（6至18年期間的成功率為82%至98%）顯示出極高的成功率。然而，如果有必要的話，未來(lái)的全髖關(guān)節(jié)置換術(shù)(THA)可能會(huì)在截骨術(shù)后變得困難。帳篷植入和改變的解剖結(jié)構(gòu).69髖關(guān)節(jié)置換術(shù)髖關(guān)節(jié)表面置換術(shù)對(duì)于晚期股骨頭壞死來(lái)說(shuō)，髖關(guān)節(jié)表面置換是最簡(jiǎn)單的選擇，涉及用人造材料替換關(guān)節(jié)表面以保留自然解剖結(jié)構(gòu)。然而，由于材料引起的并發(fā)癥以及可能導(dǎo)致股骨頭壞死進(jìn)展，表面置換不再用作股骨頭壞死的治療方法。全髖關(guān)節(jié)置換術(shù)全髖關(guān)節(jié)置換術(shù)是目前治療股骨頭壞死的唯一有效方法。然而，潛在的缺點(diǎn)需要仔細(xì)考慮。全髖關(guān)節(jié)置換術(shù)并不是永久的解決方案，盡管它們可能有利于老年患者盡早減少累積手術(shù)，但大多數(shù)股骨頭壞死患者相對(duì)年輕。鑒于這一人群，如果在診斷時(shí)更換關(guān)節(jié)，患者在以后的生活中可能需要再次進(jìn)行髖關(guān)節(jié)置換術(shù)或翻修術(shù)。髖關(guān)節(jié)置換術(shù)的建議包括晚期疾病、持續(xù)進(jìn)展和持續(xù)的誘發(fā)因素。盡管因股骨頭壞死而接受全髖關(guān)節(jié)置換術(shù)(THA)的患者比因骨關(guān)節(jié)炎接受全髖關(guān)節(jié)置換術(shù)(THA)的患者有更多的合并癥和更復(fù)雜的住院時(shí)間，但長(zhǎng)期隨訪顯示出相似的結(jié)果：兩組之間的假體存活率、骨長(zhǎng)入和無(wú)菌性松動(dòng)等并發(fā)癥無(wú)明顯差異。然而，其他研究表明，與髖骨關(guān)節(jié)炎OA患者相比，接受全髖關(guān)節(jié)置換術(shù)(THA)的股骨頭壞死患者敗血癥、輸血需求和再入院率增加。最近的分析顯示，結(jié)果有所改善，超過(guò)90%的股骨頭壞死全髖關(guān)節(jié)置換術(shù)(THA)存活4至7年，而1990年之前的存活率為8%至37%，這可能是由于手術(shù)中使用的植入物和材料的改進(jìn)。文獻(xiàn)在檢查病因方面有限。值得注意的是，對(duì)需要進(jìn)行全髖關(guān)節(jié)置換術(shù)(THA)的股骨頭壞死患者的研究發(fā)現(xiàn)，46.6%的患者將繼續(xù)接受全髖關(guān)節(jié)置換術(shù)(THA)治療。需要對(duì)側(cè)全髖關(guān)節(jié)置換術(shù)(THA)，特別是如果對(duì)側(cè)髖關(guān)節(jié)在第一次全髖關(guān)節(jié)置換術(shù)(THA)時(shí)有股骨頭壞死的影像學(xué)證據(jù)，表明需要密切隨訪。總結(jié)股骨頭壞死仍然是一種病因、治療和發(fā)育特征存在廣泛差異的疾病。由于發(fā)病率持續(xù)上升，因此有必要加強(qiáng)對(duì)病理生理學(xué)的了解，以促進(jìn)新療法和正確治療方案的發(fā)展。盡管骨移植和干細(xì)胞治療等領(lǐng)域正在取得有希望的發(fā)展，但該領(lǐng)域仍然缺乏一致意見(jiàn)的治療方案，來(lái)為股骨頭壞死患者提供最高的生活質(zhì)量并延緩他們發(fā)展為衰弱性損傷、股骨頭塌陷或髖關(guān)節(jié)置換術(shù)。為了更有效地了解這種疾病過(guò)程，需要更多數(shù)據(jù)。國(guó)家登記處將是確定診斷和治療方向的最完整的系統(tǒng)。在缺乏這種協(xié)調(diào)努力的情況下，機(jī)構(gòu)登記和大型隊(duì)列研究將有助于在這一領(lǐng)域取得進(jìn)展。在治療領(lǐng)域，有許多潛在的改進(jìn)途徑。骨修復(fù)方面的有前景的進(jìn)步（例如合成代謝藥物）可能在促進(jìn)愈合中發(fā)揮作用。此外，針對(duì)同時(shí)發(fā)生的情況進(jìn)行更有針對(duì)性的治療可能會(huì)減少類固醇和化療引起的股骨頭壞死的繼發(fā)性發(fā)展。隨著對(duì)病因、預(yù)防和治療的廣泛研究，我們有理由期望在減輕這種疾病的負(fù)擔(dān)方面取得進(jìn)展。OsteonecrosisoftheFemoralHeadAbstractOsteonecrosisofthefemoralheadisaprogressiveanddebilitatingconditionwithawidevarietyofetiologiesincludingtrauma,steroiduse,andalcoholintake.DiagnosisandstagingarebasedonimagingincludingMRIatanystageandplainradiographyinmoreadvancedlesions.Theonlydefinitivetreatmentistotalhiparthroplasty,althoughnumeroustreatmentsincludingdisphosphonatesandcoredecompressionareusedtodelaytheprogression.Lackofsatisfactoryconservativemeasuressuggeststheneedforadditionalresearchofosteonecrosisincludinglargepatientregistriestofurtherunderstandthiscondition.Osteonecrosisisaprogressivedisorderinwhichlackofsufficientbloodsupplyleadstocelldeath,fracture,andcollapseoftheaffectedarea.Theconditionisfrequentlyassociatedwiththefemoralhead,whereprogressioncanbedebilitatingandcanultimatelynecessitatetotalhiparthroplasty(THA).Theetiologyofosteonecrosisiscomplexwithnumerouscontributingagents,mostmarkedlytrauma,steroiduse,andalcohol.Treatmentofosteonecrosisiscontroversialbecausenooptionhasbeenoverwhelminglyembraced,andlittleresearchhascomparedtreatments.Researchersestimatetotalhiparthroplasty(THA)t20,000newcasesofosteonecrosisarediagnosedintheUnitedStateseachyear.1Theincreasingincidenceanddebilitatingprogressionofosteonecrosissuggesttheneedforadditionalinvestigationofeffectiveandnoveltreatments,aswellastheneedforclearerunderstandingofavailabletreatments.Thisreviewcharacterizesthecurrentknowledgeonetiology,pathophysiology,epidemiology,andclinicalmanagementofosteonecrosis,withanemphasisonrecentdevelopments.EpidemiologyTheincidenceofosteonecrosisintheUnitedStateshasbeenestimatedat～20000to30000casesperyear,affectingprimarilyyoungadultsbetweentheagesof20to40years.1Recentanalysishasshowntotalhiparthroplasty(THA)talthoughthenumberoftotalhiparthroplasty(THA)sdoneforosteonecrosishasincreasedbetween2001and2010(from54.2per100,000hospitaladmissionto60.6per100,000hospitaladmission),thepercentageoftotalhiparthroplasty(THA)sdoneforosteonecrosishasdecreasedfrom9.7%to8.3%,likelybecauseoftherapidincreaseinosteoarthritisnecessitatingtotalhiparthroplasty(THA).2PathophysiologyandPathogenesisGeneralPathogenesisOsteonecrosisoccursbecauseofcompromisedbloodfloworoxygendeliverytothebone,althoughtheclinicalpresentationisaresultoftherepairprocess,rathertotalhiparthroplasty(THA)ninitialischemia.Inosteonecrosis,boneformationbyosteoblastsisunabletomatchboneresorptionbyosteoclasts.Thisremodelingimbalancedoesnotadequatelyreplacethenecroticbone,leavingaregionofstructurallyunsoundbonetissues.3TraumaTraumaisthemostcommoncauseofosteonecrosis,4disruptingbloodflowandleadingtoosteocytedeath.Estimatesofoccurrenceoftraumaticosteonecrosisofthefemoralheadvarydependingontheinjurytype5;however,inmeta-analysisoftraumaticosteonecrosis,incidencehasbeenfoundtobeashighas14.3%.6TheGardenclassificationcategorizesfemoralneckfracturesandcanbeusedtoestimatetheriskofosteonecrosis.GardenI(incompletefracture)andGardenII(completeandnondisplaced)areconsideredstableandlowrisk,andcanberepairedwithinternalfixation.GardenIII(completeandpartiallydisplaced)andGardenIV(completeandcompletelydisplaced)havemuchhigherratesofosteonecrosiswithinternalfixation(16%),andarthroplastyshouldbeconsidered.7Intertrochanterichipfracturesresultinalowriskofosteonecrosis,notedat0.95%aftera1-yearfollow-up.8AtraumaticOsteonecrosisAtraumaticosteonecrosisencompassesadiversearrayofcauses.Itisimportanttonotetotalhiparthroplasty(THA)tinatraumaticosteonecrosis,diseaseisfrequentlybilateralowingtosystemicriskfactors,withsomeestimatessuggestingashighas70%ofthepatientswithunilateralosteonecrosisdevelopingdiseaseinthecontralateralhip.9,10Thereasonsforthesparingofonehipinthepresenceofasystemicriskfactorarenotwellstudiedandmaybebecauseofsubclinicalpresentation,differencesinwearpatternsbetweenhips,underinvestigationofsymptoms,orlackofcoordinatedfollow-up.GlucocorticoidsSteroiduseisthesecondmostcommoncauseofosteonecrosis.11,12Severalpotentialmechanismshavebeenproposedforthisassociation,includingbonematrixandcartilagedegeneration,inducedstemcellabnormalities,changesinlipidmetabolism,creationoffatemboli,alteredcoagulation,andchangesinbloodsupply.11,12Meta-analysisfoundupto10timesincreasedriskofpatientsonhigh-dosecorticosteroids,adoublingofriskforosteonecrosiswhenthecumulativedoseexceeds10g,anda0%increaseinriskwitheach10mgincreaseofdailydose.13Corticosteroidshavealsobeenimplicatedinosteoblastdeathanddecreasedosteoblastproliferation,impairingtheabilitytorepairandreplacenecroticlesions.11AlcoholAlcoholishypothesizedtoactthroughalteredlipidmetabolismandincreasedadipogenesis.14Itishypothesizedtotalhiparthroplasty(THA)tincreasedgenerationoflipidsincreasestheriskforfatembolileadingtovascularocclusion.Inaddition,increasedserumlipidscancausepackingofthemarrow,increasingintraosseouspressureanddecreasingbloodflow.5,12Alcoholmayalsocontributetoosteocytedeath.5Astudyhasalsoshownincreasedcortisollevelsinpatientswithalcohol-inducedosteonecrosiscomparedwithidiopathicosteonecrosiscontrolsubjects,suggestingtotalhiparthroplasty(THA)talcohol-inducedosteonecrosismayactthroughthesteroidpathway.15Previousestimatesnotedan11timeshigherriskofosteonecrosisinconsumersof＞400mLofalcoholdaily.16HyperlipidemiaHyperlipidemiaisthoughttodecreasethebloodsupplytoaffectedregionsbyincreasingintraosseouspressureandproducingfatemboli.4Onestudyoflow-energyfemoralneckfracturesintheelderlyfoundhigherbloodlipidabnormalitiesinthosewhodevelopedosteonecrosistotalhiparthroplasty(THA)nthosewhodidnot.17Astudyofpatientswithacutelymphoblasticleukemia(ALL)identifiedhyperlipidemiaasariskfactorfordevelopingosteonecrosis.18Asimilarstudyfoundassociationwithosteonecrosisdevelopmentinpatientswithhyperlipidemiaandsystemiclupuserythematosus(SLE).19SystemicLupusErythematosusTheassociationofSLEwithosteonecrosisisrelatedtofrequentcorticosteroidtreatment;however,recentanalysishasshownhigherincidenceofosteonecrosisincorticosteroiduserswithSLEtotalhiparthroplasty(THA)nincorticosteroiduserswithoutSLE,suggestingsynergisticeffects.20Meta-analysisofSLEstudieshasidentifiednumerousnoncorticosteroidriskfactorsinSLE,notablyrenalinvolvementandcentralnervoussystem(CNS)disease.21,22Mixeddatasuggesttotalhiparthroplasty(THA)ttheprothromboticeffectsofantiphospholipidantibodiesplayaroleinosteonecrosisdevelopmentinSLE.Recentmeta-analysisofchildhood-onsetSLEfoundnotableosteonecrosisassociation,withestimatestotalhiparthroplasty(THA)t6to8.4%ofthepatientswithchildhood-onsetSLEdeveloposteonecrosis,23althoughmostdidnotdeveloposteonecrosisuntilafterpuberty.21SickleCellDiseaseStudiesoftheassociationbetweensicklecelldiseaseandosteonecrosishaveidentified2to4.5casesofosteonecrosisper100patientswithsicklecelldisease.24PrecipitationofhemoglobinSinlow-oxygenenvironmentsmayleadtovaso-occlusionandischemiaofthebone,whichissimilartothedevelopmentofothervaso-occlusiveinjuryinsicklecelldisease.5Arecentstudysupportsthistheory,citingelevatedhemoglobinlevelsasariskfactorforosteonecrosisinpatientswithsicklecelldiseaseandsuggestingtotalhiparthroplasty(THA)tvaso-occlusion,highbloodviscosity,hypoxia,andconcurrentalpha-totalhiparthroplasty(THA)lassemiacontributetoosteonecrosis.25GaucherDiseaseArecentevaluationoftheGaucherRegistryestimatedtheincidenceofosteonecrosisat30%.26Gaucherdiseasemayactthroughasimilarpathtototalhiparthroplasty(THA)tofsicklecelldisease,withGaucher-affectedcellsobstructingthebloodflow27orbyincreasingintraosseouspressurebecausetheyaccumulateinthefattymarrow.3Inaddition,Gauchercellscanreleaseosteoclast-activatingcytokineswhichdisruptthebalanceofboneformationandresorption.26Enzymereplacementcanreduceordelaythesymptomsofosteonecrosis28;however,astudyhassuggestedtotalhiparthroplasty(THA)tthebonemarrowmayserveasa“sanctuarysite”forGauchercells,leavingasubsetofpatientsvulnerabletoosteonecrosisdespitetreatment.29DecompressionSicknessDecompressionsickness–relatedosteonecrosisordysbaricosteonecrosisoccursbecauseofrapiddecompressionafteranextendedperiodinahyperbaricenvironment.Rapiddecompressionformsbubblesinthebloodstreambecausedissolvednitrogencomesoutofthesolution.Thehighsolubilityofnitrogeninfattytissuesmakesthemarrowparticularlysusceptible.Multiplemechanismshavebeenproposed,includingdirectocclusionofbloodflowtothemarrowandtheincreaseinintraosseouspressurereducingeffectivebloodflow.30Arecentstudyofdiverswithmusculoskeletaldecompressionsicknessfoundevidenceofdysbaricosteonecrosisin26%ofthecases,althoughthestudywaslimitedbytherelativerarityofthiscondition.31AcuteLymphoblasticLeukemiaPatientswithALLshowanincreasedriskofosteonecrosis,withradiographicincidencereaching71.8%inprospectivestudies.32ThesinglelargestfactoridentifiedinthedevelopmentofosteonecrosisinpatientswithALLisadolescence,suggestinganeffectofALLoritstreatmentonthegrowthandremodelingofthebone.Itisalsopossibletotalhiparthroplasty(THA)ttheoccurrenceofthistimeofchangingmetabolismandgrowthmagnifiessusceptibilitytoosteonecrosis-causingdamagefromotherfactors.33Olderadults,whomakeupasmallportionofthosediagnosedwithosteonecrosis,oftenundergomodifiedtreatmentregimensandhaveworseoveralloutcomescomparedwiththeiryoungercounterparts.34Arecentstudyofchildhoodleukemiasfoundhigherincidenceofosteonecrosisinpatientstreatedwithhematopoieticstemcelltransplant(HSCT)versuschemotherapyalone(6.8%versus1.4%),suggestingtotalhiparthroplasty(THA)ttreatmentmethodsinfluenceosteonecrosisdevelopment.35Inaddition,areviewoftreatmentregimensidentifiedincreasedcumulativedoseofsteroidsasariskfactorfordevelopingosteonecrosisinchildrenwithanyhematologicmalignancy.36Areviewoftreatmentstrategiessuggestedtotalhiparthroplasty(THA)ttheuseofdiscontinuoussteroidregimensmaydecreasetheriskofosteonecrosisandnonsteroidchemotherapeuticagentssuchasmethotrexateandasparaginasemaycontributetothedevelopmentofosteonecrosis.37Onetrialofalternateweekdexametotalhiparthroplasty(THA)sonereducedtheriskofosteonecrosiscomparedwithcontinuoustreatmentinchildrenwithhigh-riskALL.38TransplantationArecentstudysuggestssteroid-mediateddevelopmentofosteonecrosisintransplantpatients,findingcumulativesteroiddosestobehigherinrenaltransplantpatientswhodevelopedosteonecrosistotalhiparthroplasty(THA)ninthosewhodidnot.Thestudyalsofoundtotalhiparthroplasty(THA)ttheincidenceofsymptomaticosteonecrosisdecreasedfrom20%tolesstotalhiparthroplasty(THA)n5%withtheintroductionofcyclosporineandadecreaseinsteroidusage.39HIVMultiplestudiesshowagrowingincidenceofosteonecrosisinpatientswithHIV,showingnearlythreetimestheriskofthegeneralpopulation.40Onerecentstudyrevealedastrongassociationbetweenhigh-activityantiretroviraltherapyanddevelopmentofosteonecrosis,althoughtheauthorscautiontotalhiparthroplasty(THA)ttheassociationdoesnotimplyapathologicrole.40Otherstudieshavefoundnoassociationbetweenosteonecrosisandantiretroviraltherapy(ART),citinginsteadassociationwithalcohol,hyperlipidemia,41orlownadirCD4counts,42althoughthemechanismisnotwellunderstood.GeneticInvolvementAlthoughfamilialvariantsofosteonecrosisandsomeassociatedgeneshavebeenfound,nosingleresponsiblegenehasbeenidentified.OnegenecandidateisamutationintypeIIcollagen,althoughnodefinitivecausalityhasbeenestablished.43ElevatedlevelsofosteoprotegerinanddecreasedexpressionofRANK/RANKligandhavebeenfoundinnecroticregionscomparedwithhealthybone,suggestingapotentialroleofosteoclast-regulatinggenes.44FactorVLeidenmutationsandprothrombinmutationshavebeenassociatedwithpatientswithosteonecrosisinmultiplestudies,43invokingapotentialroleofalteredcoagulation.Genome-wideassociationstudiesofselectedpopulationshaveidentifiedseverallociofinterest,includingclustersofvariantsnearglutamatereceptorgenesinpatientswithALL,45corticosteroid-inducedosteonecrosis,33andseverallociofunknownsignificance,whichmayberelatedtocoagulationpathways,lipidmetabolism,oralcoholdrinkingbehavior.46IdiopathicOsteonecrosisItisimportanttonotetotalhiparthroplasty(THA)tanestimated20%to40%ofosteonecrosiscasesareidiopathic.47Thishighrateofanunknowncausemaybeduetononspecificearlysymptomsandindolentcourse,whichpreventearlydiagnosis,9aswellaslackofstandardizedreportinganddatacollection,whichmayhelptoreveallittleunderstoodcausesandconnections.ClinicalManifestationsandDiagnosisDiagnosisTheearlystagesofosteonecrosisofthefemoralheadarefrequentlyasymptomaticbutmayalsopresentwithradiatingpainfromthehiporgroinandlimitedrangeofmotionofthejointonphysicalexamination.47Diagnosisofosteonecrosisisprimarilybasedonimaging,althoughexaminationandhistoryareimportanttogathersurroundingcontextandpotentialetiology.5Aplainradiographisanappropriatefirst-linemodalityforidentifyingcasesofosteonecrosis,withbenefitsincludinglowcost,highavailability,andadequatesensitivityformid-stageandlate-stagedisease.48Frontalandlateral“frog-leg”viewsarerecommendedforaccuracy.Inthecaseofearly-stagedisease,radiographymaybeinsufficienttoidentifyearlyorminimalchanges.MRIisthebenchmarkfordiagnosisofosteonecrosisbecauseofitshighsensitivityforearlysignsofonset.Supplementalimaging,includingdiffusion-weightedMRI49andgadolinium-enhancedperfusionMRI,50,51mayfurtheradvancethediagnosticcapabilitiesofMRI.PerfusionMRImayassistindistinguishingbetweenradiographicallyandsymptomaticallysimilarconditionssuchasbonemarrowedemaandsubchondralinsufficiencyfractures.52Inpediatricpatientswithdevelopmentaldysplasiaofthehip,perfusionMRIwashelpfulinidentifyingthoseatriskforosteonecrosisafterclosedreduction/spicacasting.53Inaddition,awhole-bodybonescanprovidesanoptionforpatientsatriskformultifocalosteonecrosis,suchasthosereceivingsystemiccorticosteroidsorimmunosuppressants.54DifferentialDiagnosisBoneMarrowEdemaSyndromeBonemarrowedemasyndrome(BMES)presentsassuddenpainwithoutaclearprecipitatingevent.Onimaging,BMESshowsdiffuseedemacomparedwithmorelocalizedareasinosteonecrosis.Somestudieshavesuggestedtotalhiparthroplasty(THA)tBMESmayprecedeosteonecrosis.5SubchondralInsufficiencyFractureAsubchondralinsufficiencyfracturepresentssimilarlybutoccursafteraninjury.Althoughbothconditionspresentwithlow-signalsubchondralbands,osteonecrosisimagingpresentswithasmooth,concavelinewhilethefracturepresentswithajagged,discontinuous,convexfinding.Conservativetreatmentisunlikelytoimprovefracturesymptoms,andbothconditionscanprogresstotheneedforatotalhiparthroplasty(THA).5NeoplasmAlthoughrare,clearcellchondrosarcomaandchondroblastomacanpresentwithradiolucentlesionsinthefemoralhead.TheseconditionsarenotaccompaniedbytheedemapresentinosteonecrosisorothersimilarconditionssuchasBMES.5ClassificationSystemsandStagingThemostpopularstagingsystemforosteonecrosisofthefemoralheadistheFicatclassification(Table?(Table1).1).Developedin1964andlatermodifiedtoincludetheuseofMRI,theFicatsystemclassifiespatientswithosteonecrosisasstage0to4basedontheappearanceonaplainradiograph.Althoughthissystemiswidelyacceptedandfrequentlyused,detractorscitetheuseofclinicalsymptoms,lowinterobserverconsensus,andlackofprognosticationaslimitations.55TheUniversityofPennsylvaniasystemwasdevelopedinanattempttomoreclearlydelineatetheprogressionofosteonecrosisandtopromotedistinctionsbetweenthestagesbyaddingstage0forpreradiographicdisease,dividingFicatstageIIintotwostagesbasedontheabsence(II)orpresence(III)ofacrescentsign,anddividingFicatIVintotwostages:flatteningwithjointspacenarrowingonly(V)andjointdeformityandjointspaceobliteration(VI).56TheAssociationResearchCirculationOsseous(ARCO)systemcloselyfollowsFicatwiththeexceptionoftheinclusionofMRIfindingsinstageIanddivisionofstageIIbasedontheextentoffemoralheadflattening(IIIAif＜2mmandIIIBif＞2mm).TheARCOsystemwasrecentlyrevisedbasedonaninternationalexperttaskforcetobetterincorporateresultsofbothMRIandplainradiography.57ThesestagingsystemsaresummarizedinTable?Table11.Systematicanalysisofdifferentstagingsystemsfoundtotalhiparthroplasty(THA)tanyclassificationsystemisvaluableandsufficientforthestagingofosteonecrosis,providednecessarydataarecollectedtoallowconversiontoanothermetric.58Forthepurposesofpatientevaluationandtreatment,themostimportantclassificationisprecollapseversuscollapsebecausethisguidesdiscussionofconservativetreatmentversustotalhiparthroplasty(THA).Forresearchpurposes(especiallyforthecollectionofregistrydata),werecommendusingtheupdatedARCOguidelinesbecausetheyeffectivelyusemultipleimagingmodalitiesanddelineatesmallerchangesbetweenstages.Thisallowsforahigherlevelofdetailintrackingdiseaseprogressionandmayhelptoprovidecleareranswersbecausetheeffectivenessofnewtherapiesisevaluated.TreatmentOptionsRiskofProgressionEvaluatingriskofprogressionisimportantindetermininganappropriatetreatmentchoice(Table?(Table2).2).Althoughthereisnoconsensusonasystemtodefinitivelypredictcollapse,areviewofattemptedstrategieshasfoundincreasedlesionvolume,necrosis＞40%oftheweight-bearingsurface,andnecrosisradian＞200to250tobesuggestiveoffuturecollapse.59ObservationThemostconservativemanagement,observation,hasbeenconsideredasapossibleapproachtoosteonecrosis.Therehasbeensomeevidenceforspontaneousresolutionofsmallearly-stageosteonecrosislesions.60Incombinationwithobservation,restrictedweight-bearingisusuallyadvised,althoughthishasnotshownutilityasaprimarytreatmentmodality.61Astudyofobservationasastrategyinosteonecrosisofthehiphasfoundafailurerateofover80%byfouryearsandisnotrecommendedasastandalonetreatmentinadvancedlesions.62NonsurgicalTreatmentPharmacologicAgentsMedicationshavebeenamainstayofosteonecrosistreatment,butrecently,theireffectivenesshasbeenquestioned.Disphosphonatesareapopularchoiceforpharmacologictreatmentandworkbyinhibitingosteoclastactivity.Studiesoftheuseofdisphosphonateshaveshownmixedresults.63Althoughsomeearlystudiesshowedpositiveeffectsofdisphosphonates,arecentlargemulticenterrandomizedcontrolledtrialfoundnodifferencebetweenalendronateandplacebo.64Furthermore,ameta-analysisoffiverandomizedcontrolledtrialshadsimilarfindings,withlittletonoevidencesupportingtheefficacyofdisphosphonatesinthenontraumaticosteonecrosisofthefemoralhead.65Theprimaryutilityofdisphosphonatesisintheearlystagesofdisease,andtheyarenotpreferredtosurgeryasosteonecrosisprogresses.61Studieshaveidentifiedmultiplepotentialmechanismsforbeneficialeffectsofstatinsindelayingosteonecrosisincludinglipid-loweringeffects,47increasedautophagy,66suppressionofPeroxisomeproliferator-activatedreceptorγ,andactivationoftheWntsignalingpathway.67Statinshavebeeneffectiveincombinationwithmultiplecoredecompression(CD)procedures,improvingbothclinicalandradiographicprogressionofosteonecrosis.68OtherNonsurgicalModalitiesSeveralothermodalitieshavebeenproposedforthetreatmentofosteonecrosiswithvaryingsuccess.Lipidmodifierssuchasdietarychangesorlipoicacidsupplementshaveshownsomepositiveresultsintrials,butthereisinsufficientevidencetorecommendthemasprimarytreatmentstrategies.61,63Hyperbaricoxygentreatments,pulsedelectromagneticfields,andextracorporealshockwavetherapyhavebeenproposedshowingsomepositiveoutcomes,butdisagreementabouttheireffectivenessmakesthemdifficulttorecommend.47,61,69JointPreservingProceduresCoreDecompressionCDisdoneforosteonecrosisofthefemoralheadtoreduceintraosseouspressureandpromoteincreasedbloodflowandbonegenesis.Ficat,70inhisearlydescriptionsofosteonecrosisandtheCDprocedure,notedincreasedintramedullarypressures,whicharereleasedwithCDleadingtoareliefofpainandeventualrestorationofbloodflowifthelesionistreatedearlyinitsprogression.AlthougholderstudiesofCDwereequivocalaboutitseffectiveness,studyofmorerecentprocedureshasshownnotablebenefits.Studiesofbothshort-termandlong-termoutcomeshaveshownimprovementinpatientstreatedwithCDanddelayedtimetototalhiparthroplasty(THA)comparedwithmoreconservativetreatmentoptions.71Aswithmanytreatments,theseoutcomesaremorepositivewhenusedintheearlystagesofdisease,withupto100%ofhipssurviving3years69andupto96%surviving10yearsinearly-stagedisease.71Moreprecisely,CDhasshownpositiveresultsinosteonecrosisshowingnocollapse,acentrallesion,andsmallsize(combinednecroticangle＜250°).72Theseoutcomesmayproveevenmorebeneficialwhenpairedwithgraftsandcell-basedtherapy.VascularizedandNonvascularizedBoneGraftingNonvascularizedbonegraftinginvolvestheplacementofbonegraftmaterialtoprovidestructuralsupportwiththeintentofreducingintraosseouspressureandpreventingcollapseinearlystagesofosteonecrosis.Vascularizedbonegrafting(VBG)alsoseekstointroduceincreasedbloodsupply.Thegraftisdonebyplacinganonvascularizedcorticalallograftfromtheilium,tibia,orfibula,73oravascularizedgraftfromtheiliaccrest,fibula,orgreatertrochanter74intoacorespacecreatedfortheprocedureorfromaCDprocedure.Nonvascularizedbonegraftinghasshownmoderatesuccess,especiallywithsmallerlesions,havinga55%to87%successratewitha2-to9-yearfollow-upacrossseveralstudies.69VBGhasshowna5-yearhipsurvivalof80%inprecollapselesionor60%after14yearsinsimilarpatients,69withlowconversiontototalhiparthroplasty(THA).75However,thebenefitsofVBGareprimarilyrealizedinsmallerlesionswithoutnotablecollapse.76Ongoingresearchhasevaluatedsyntheticscaffoldsusedwithorwithoutbiofactorstoenhanceintegrationandbonegrowth.Numerousorganic,inorganic,andbiologicmaterialshavebeendevelopedwithpromise,althoughnodefinitivesolutionhasbeenidentified.77AdjunctiveTherapyBecauseosteonecrosisisthoughttoresultfromadeficiencyofboneregeneration,useofstemcelltreatmentshasbeenproposedtohaltorreverseitspathogenesis.Studieshaveshownlowerratesofradiographicprogressionandlowerneedfortotalhiparthroplasty(THA)inpatientstreatedwithautologousstemcelltransplants.Inearlystudies,thecombinationofautologousstemcelltransplantwithCDshowedanotabledelayofanaverageof10years(upto17years)intimetocollapse.78Inaddition,celltherapycanbecombinedwithothertherapiessuchasCDand/orbonegraftsandcanpotentiallyimproveoutcomes.69Astudyhasshownbenefitsofbonemorphogeneticprotein(BMP)inadditiontoallograftand/orCDinimprovingboneformationandlimitingtheprogressiononosteonecrosis.79OsteotomyOsteotomyattemptstodelaytheprogressofosteonecrosisbyrelievingweight-bearingonnecroticorprenecroticareastopreventcollapse.Todothis,weight-bearingosteonecroticregionisangledorrotatedtoplaceprimarypressureonanon-necroticareaofthebone.Rotational(82%to100%from3to15years)andangular(82%to98%between6and18years)osteotomiesofthefemoralheadhaveshownexcellentsuccessrates.However,futuretotalhiparthroplasty(THA)canbecomedifficultifnecessarybecauseofpersistentimplantandalteredanatomy.69ArthroplastyResurfacingResurfacingofthejointsinquestionisthemostminimaloptionforadvancedosteonecrosisandinvolvesreplacingthearticularsurfacewithartificialmaterialstopreservenaturalanatomy.However,becauseofthecomplicationsfrommaterialsandpossiblecontributiontoosteonecrosisprogression,resurfacingisnolongerusedasosteonecrosistreatmentofthefemoralhead.69TotalJointArthroplastyJointarthroplastyistheonlydefinitivecureforosteonecrosisavailableatthistime;however,potentialdownsidesrequirecarefulconsideration.totalhiparthroplasty(THA)sarenotapermanentsolution,andalthoughtheymaybebeneficialearlyinolderpatientstoreducecumulativeprocedures,mostpatientswithosteonecrosisarerelativelyyoung.Giventhispopulation,ifthejointisreplacedatdiagnosis,thepatientwilllikelyneedanotherarthroplastyorrevisionlaterinlife.Recommendationsforjointarthroplastyincludeadvanceddisease,continuingprogression,andcontinuingprovocativefactors.77Althoughpatientswhohaveatotalhiparthroplasty(THA)forosteonecrosishavemorecomorbiditiesandmorecomplicatedhospitalstaystotalhiparthroplasty(THA)nthosehavingtotalhiparthroplasty(THA)forosteoarthritis,long-termfollow-uphasshownsimilaroutcomebetweenthetwogroupsforimplantsurvival,osseointegration,andcomplicationssuchasasepticloosening.80Otherstudies,however,haveshownincreasedratesofsepsis,81transfusionrequirement,andhospitalreadmissioninpatientswithosteonecrosiswhounderwenttotalhiparthroplasty(THA)comparedwithOApatients.Recentanalysishasshownimprovedoutcomes,with＞90%ofosteonecrosistotalhiparthroplasty(THA)ssurviving4to7yearscomparedwith8to37%survivalratesbefore1990,possiblybecauseofimprovedimplantsandmaterialsusedintheprocedures.69Theliteratureislimitedinexaminingetiology-basedimplantsurvival,butastudyofpatientswithosteonecrosissecondarytoalcoholconsumptionshowedexcellentlong-termoutcomes.82Itisalsoimportanttonotetotalhiparthroplasty(THA)tthestudyofpatientswithosteonecrosisrequiringtotalhiparthroplasty(THA)foundtotalhiparthroplasty(THA)t46.6%ofthepatientswouldgoontorequirecontralateraltotalhiparthroplasty(THA),especiallyifthecontralateralhiphadradiographicevidenceofosteonecrosisatthetimeofthefirsttotalhiparthroplasty(THA),suggestingtheneedforaclosefollow-up.83SummaryOsteonecrosiscontinuestobeaconditionofwidelyvariantetiologies,treatments,anddevelopmentalprofiles.Becauseincidencecontinuestorise,increasedunderstandingofthepathophysiologyisnecessarytopromotedevelopmentsofnewtreatmentsandcorrectiveprocedures.Althoughpromisingdevelopmentsarebeingmadeinareassuchasbonegraftingandstemcelltherapy,thefieldcontinuestolackanagreed-uponregimentoprovidepatientswithosteonecrosisthegreatestqualityoflifeanddelaytheirprogressiontodebilitatinginjury,collapse,orjointarthroplasty.Tomoreeffectivelyunderstandthisdiseaseprocess,moredataareneeded.Anationalregistrywouldbethemostcompletesystemtodeterminediagnosticandtreatmentdirections.Intheabsenceofsuchacoordinatedeffort,institutionalregistriesandlargecohortstudieswouldhelptomakeadvancesinthisrealm.Intheareaoftreatment,therearemanypotentialavenuesforimprovement.Promisingadvancementsinbonerepairsuchasanabolicagentsmayplayaroleinpromotinghealing.Inaddition,moredirectedtherapiesforcoincidentconditionsmayreducethesecondarydevelopmentofosteonecrosisfromsteroidsandchemotherapy.Withanexpandedstudyofetiologies,prevention,andtherapy,thereisareasontohopeforadvancementsinreducingtheburdenofthisdisease.文獻(xiàn)出處：GaryGeorge,JosephMLane.OsteonecrosisoftheFemoralHead.JAmAcadOrthopSurgGlobResRev.2022May1;6(5):e21.00176.doi:10.5435/JAAOSGlobal-D-21-00176.2023年06月18日642
0
2
-
劉寧主任醫(yī)師 哈醫(yī)大一院 骨科 各位患者朋友們周末好，今天的最后一名手術(shù)呢，是一個(gè)酒精性股骨頭壞死的患者，那么現(xiàn)在正在等待麻醉，這個(gè)患者呢也比較年輕，嗯，只有50幾歲，但是啊股骨頭的壞死啊非常嚴(yán)重，那么病人右側(cè)股骨頭啊是好的，而左側(cè)的股骨頭啊已經(jīng)出現(xiàn)了明顯的塌陷變形，病人呢有長(zhǎng)期的飲酒，那么呢，尤其是酒精的慢性的中毒也會(huì)導(dǎo)致股骨頭壞死的發(fā)生，而一旦發(fā)生股骨頭壞死呢，隨著你酒精攝入量的增加，那么呢，它的壞死就會(huì)逐漸的加重，也有的朋友啊問(wèn)為什么病人一直在喝酒，右側(cè)的股骨頭卻沒(méi)有什么事，而左側(cè)的股骨頭呢，會(huì)出現(xiàn)一個(gè)壞死的表現(xiàn)呢？呃，這個(gè)呢，在醫(yī)學(xué)上現(xiàn)在還沒(méi)辦法完全的解釋，只因?yàn)槟?，酒精啊，可能是?duì)于左側(cè)股骨頭的一些血管的問(wèn)題啊導(dǎo)致。 這個(gè)它的缺血的表現(xiàn)呢，更加嚴(yán)重，而右側(cè)的股骨頭的血管的供應(yīng)呢，恰巧沒(méi)有被這個(gè)酒精所完全的破壞，所以右側(cè)的股骨頭得以保證了一個(gè)正常的一個(gè)血液循環(huán)，當(dāng)然了，隨著科學(xué)的進(jìn)步，那么總有一天也會(huì)明確，為什么有些股骨頭壞死呢是單發(fā)，而有些股骨頭壞死呢是多發(fā)。2023年02月17日121
0
2
-
劉萬(wàn)軍主任醫(yī)師 上海市第六人民醫(yī)院 骨科-關(guān)節(jié)外科 專家介紹：劉萬(wàn)軍，主任醫(yī)師，醫(yī)學(xué)博士，研究生導(dǎo)師；上海交通大學(xué)醫(yī)學(xué)院附屬第六人民醫(yī)院；骨科-關(guān)節(jié)外科主任醫(yī)師，東院關(guān)節(jié)外科負(fù)責(zé)人，擅長(zhǎng)疾?。?、髖關(guān)節(jié)置換、膝關(guān)節(jié)置換手術(shù)（股骨頭壞死、嚴(yán)重骨折手術(shù)后髖關(guān)節(jié)炎、嚴(yán)重髖關(guān)節(jié)發(fā)育不良、嚴(yán)重類風(fēng)濕性髖關(guān)節(jié)炎、髖關(guān)節(jié)僵直、嚴(yán)重老年骨質(zhì)增生性膝關(guān)節(jié)炎引起的關(guān)節(jié)痛）；2、髖膝關(guān)節(jié)翻劉萬(wàn)軍+住院后可以立刻做髖關(guān)節(jié)手術(shù)嗎？修術(shù)；3、早期股骨頭壞死的保髖手術(shù)；4、早期膝關(guān)節(jié)骨性關(guān)節(jié)炎的保膝手術(shù)；5、關(guān)節(jié)置換術(shù)后假體感染及術(shù)后骨折；6、各類骨關(guān)節(jié)疼痛疾病的微創(chuàng)治療。2023年01月25日416
0
0
-
劉寧主任醫(yī)師 哈醫(yī)大一院 骨科 各位患者朋友啊，大家好，呃，我是任醫(yī)生，那么今天呢，繼續(xù)和大家來(lái)分享我們臨床上的常見(jiàn)病例，呃，今天呢，又是一個(gè)雙側(cè)股骨頭缺血性壞死的患者，那么呢，這個(gè)老人家呢，是女性患者，今年呢，64歲，呃，指素呢，就是雙側(cè)的髖關(guān)節(jié)的疼痛和活動(dòng)受限，那么病人呢，有激素的使用病史，所以呢，出現(xiàn)了一個(gè)明顯的股骨頭壞死，表現(xiàn)為雙側(cè)的股骨頭呢，失去了圓形的外觀，同時(shí)呢，疼痛伴有活動(dòng)受限，那么對(duì)于這樣的情況呢，我們?nèi)匀豢紤]呢，給病人做這個(gè)人工髖關(guān)節(jié)的置換手術(shù)，因?yàn)榧に匦缘墓晒穷^壞死，一旦呢，時(shí)間比較長(zhǎng)的話呢，股骨頭內(nèi)部的血運(yùn)呢，將很難重建，所以呢，只能采用人工關(guān)節(jié)置換的方法，來(lái)恢復(fù)呢，病人的髖關(guān)節(jié)功能。2022年11月21日56
0
1
股骨頭壞死相關(guān)科普號(hào)
楊文成醫(yī)生的科普號(hào)
楊文成 副主任醫(yī)師
鄭州大學(xué)附屬鄭州中心醫(yī)院
骨科
727粉絲11.4萬(wàn)閱讀
王衛(wèi)國(guó)醫(yī)生的科普號(hào)
王衛(wèi)國(guó) 主任醫(yī)師
中日友好醫(yī)院
骨科·關(guān)節(jié)外科
265粉絲11.4萬(wàn)閱讀
車旭醫(yī)生的科普號(hào)
車旭 主任醫(yī)師
中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院深圳醫(yī)院
肝膽外科
3662粉絲43.8萬(wàn)閱讀